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Abstract
The regulatory effects of adenosine are dependent upon its ability to bind four 
distinct adenosine receptor (AR) subtypes termed Ai, A2A, A2B and A3 (Ralevic and 
Bumstock, 1998). Despite coupling to the same class of inhibitory guanine 
nucleotide-binding regulatory protein (G-protein) and binding the same physiological 
ligand, the Ai and A3ARS are subject to distinct regulatory events following agonist 
exposure. Rapid termination of G protein-coupled receptor (GPCR) signalling is 
typically regulated by their phosphorylation by second messenger-activated and/or G 
protein-coupled receptor kinases (GRKs). Upon phosphorylation by G protein- 
coupled receptor kinases (GRKs), many GPCRs bind arrestin proteins that serve to 
uncouple activated receptors from G-proteins leading to a functional desensitisation 
of G protein-linked signalling, cluster activated receptors to clathrin-coated vesicles 
(CCVs) and recruit and activate Src family tyrosine kinases ultimately resulting in 
the activation of the mitogen activated protein kinase (MAPK) cascade. It is thought 
that receptors proceed from CCVs to endosomes where they may be 
dephosphorylated and recycled back to the plasma membrane or degraded and down- 
regulated.
In this study, by employing the use of epitope and fluorescently tagged 
receptors, we show that agonist activation is required for A3AR phosphorylation and 
internalisation and that this process can be blocked by an AgAR-selective antagonist 
MRS 1523. We have characterised rates of A3AR internalisation and recycling and 
shown that it is dynamically controlled by three phosphorylation sites Thr 307, 318 
and 319 and two presumed palmitoylation sites Cys 302 and 305 in its carboxyl- 
terminal (C) tail. Mutation of the Thr sites renders the receptor resistant to 
phosphorylation by GRKs, ultimately resulting in a loss of receptor sequestration 
compared to WT A3AR. In contrast, mutation of the Cys residues produces an 
increase in the rate of receptor internalisation compared to wild type (WT), a 
phenomenon not observed by the introduction of a similar mutation in the WT Ai AR 
(Cys^^^Ala, data not shown).
By the use of confocal microscopy, we reveal that despite their differences in 
trafficking rates, both WT and (C-A)A3ARs co-localise with transferrin (Tfn) 
receptor-positive early endosomes. We also demonstrate that this accumulation is 
dependent upon receptor phosphorylation as the non-intemalising AiAR can be 
directed through this endosomal pathway by replacing the C-terminal tail with the
XX
GRK-phosphorylatable 14 amino acids of the A3AR (AiCT3AR). The process of 
receptor phosphorylation also dictates the pattern of arrestin distribution following 
agonist stimulation. A%AR activation caused a re-distribution of arrestin3 to distinct 
spots at the plasma membrane whereas WT A3AR, (C-A)A3AR and AiCT3 produced 
an accumulation of arrestinS at both the plasma membrane and diffusely within the 
cytoplasm
This study also demonstrates that long-term agonist exposure causes a down- 
regulation in total A3AR number via an as yet undefined pathway and may be 
directed by the C-terminal region of the receptor (Tsao and von Zastrow 2000b). 
Consequently, we have presented initial confocal images to suggest that recovery 
from down-regulation requires newly synthesised receptor to be transported from the 
Golgi apparatus to the plasma membrane.
XXI
Chapter 1 
Introduction
1.1 Adenosine History
The first documentation of the physiological effects of adenosine and 
adenosine monophosphate (AMP) was in 1929, when Drury and Szent-Gyorgyi 
showed that extracts from heart muscle, brain, kidney and spleen had pronounced 
biological effects including arterial dilation, lowering of blood pressure and 
inhibition of intestinal contraction. Early investigation (Gillespie, 1934) drew 
attention to the structure-activity relationships of adenosine compounds showing that 
de-amination and removal of phosphate groups influenced not only the potency of 
the compound but also the type of response illustrated. Diverse responses to 
extracellular purines have now been documented for a wide range of biological 
systems including smooth muscle contraction, neurotransmission, inflammation and 
modulation of cardiac function.
1.1.1 Adenosine: Structure, Synthesis and Metabolism
Nucleotides consist of three distinct functional groups: (1) a heterocyclic 
nitrogenous base; (2) a pentose sugar and (3) a phosphoryl group, of which the 
nucleotide bases belong to two groups, purines and pyrimidines. The heterocyclic 
nitrogenous bases of purines are a 6 -membered pyrimidine ring fused to a 5- 
membered imidazole ring and are termed adenine, guanine and hypoxanthine (Fig. 
1.1). Purine nucleotides can be synthesised in three ways: de novo synthesis, 
reconstruction from purine bases through the addition of the ribose phosphate 
moiety, or phosphorylation of nucleosides, with the first two being the most 
important quantitatively (Zubay, 1998). A schematic representation of the pathways 
by which cells synthesise, interconvert and catabolise various purine nucleotides can 
be found in Fig. 1.2.
Adenosine is a by-product of adenosine triphosphate (ATP) metabolism that 
is released from cells into the surrounding tissue when oxygen demand exceeds 
supply (Bardenheur, 1986). Ischaemia, defined as the scenario whereby inadequate 
blood flow leads to tissue hypoxia, is one of the most potent stimuli that trigger the 
degradation of adenine nucleotides and the consequent formation of adenosine. 
Adenosine metabolism involves at least four different enzymes that can form 
adenosine (cytosolic 5’-nucleotidase, ecto 5’-nucleotidase, alkaline phosphatase and
S-adenosylhomocysteinehydrolase) and another two enzymes (adenosine kinase,
Figure 1.1 Chemical structure of adenosine
Shown opposite is a schematic representation of the purine nucleoside adenosine. 
The purine bases consist of a 6 -membered pyrimidine ring fused to a 5-membered 
imidazole ring, the fused system containing four nitrogen atoms. In purine 
nucleotides the glycosidic linkage is between N-9 of the purine and C-1 of the 
pentose sugar.
1HOHjC
5 '
8
adenosine
Figure 1.2 Pathways of adenosine metabolism
Shown opposite is a representation of the pathways undertaken by cells to synthesise, 
interconvert and catabolise various purine nucleotides. Double-headed arrows 
indicate reversible enzymatic reactions and separate arrows in opposite directions 
between metabolites indicate a different enzyme is required in each direction. The 
diagram is arranged in tiers with purines, nucleosides and nucleoside mono-, di- and 
tri-phosphates in ascending order.
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adenosine deaminase (ADA)) which lead to its metabolism to inosine and finally uric 
acid (Fig. 1.3). The biological effects documented by Drury and Szent- Gyorgyi are 
produced via a specific transport step which carries adenosine across the cell 
membrane. Various types of receptors have been cloned, although the most common 
and best characterised are those known as GPCRs.
1.2 G-protein coupled Receptors
Transduction of extracellular signals across the plasma membrane to the 
intracellular environment is achieved by the interaction of regulatory molecules with 
specific membrane-spanning cell-surface receptors. Structural and functional criteria 
has led to the definition of three broad categories of cell surface receptors: (1 ) 
receptors involved in cellular adhesion processes; (2 ) receptors which capture and 
convey ligands to appropriate intracellular destinations and (3) receptors which 
initiate a sequence of intracellular transducing signals when activated by their ligand. 
Examples of receptors that are components of the third class of receptors include 
cytokine receptors, ligand-gated ion channels and GPCRs. GPCRs can be divided 
into three distinct classes distinguishable by their amino acid (aa) sequences. Class I 
GPCRs can be further subdivided into a, b and c subtypes and includes odorants, 
rhodopsin and beta-adrenergic receptors (PAdRs) that are activated by ligand binding 
to the amino-terminal (N) domain and extracellular loops. Class II GPCRs comprise 
receptors for hormones such as glucagons and secretin. They share a similar 
morphology to Class Ic receptors but show no sequence homology. They have been 
shown to bind ligand via their long N-terminal domain. The third class of GPCRs 
includes the metabotropic glutamate receptors (mGlu), Ca^^-sensing and y-amino 
butyric acid (GABA) receptors. These receptors also possess a large extracellular 
domain (Bockaert and Pin, 1999).
G-protein coupled receptors (GPCRs) are integral membrane proteins that 
comprise the largest protein superfamily, consisting of greater than 1 0 0 0  members. 
All members of the GPCR superfamily comprise a single polypeptide chain typically 
comprising seven stretches of hydrophobic transmembrane-spanning (TM) a-helices 
linked by hydrophilic extracellular N- and intracellular C-terminal domains of 
varying lengths (Ji et al., 1998; Fig. 1.4). The organisation of the membrane- 
spanning domains is such that they form a central pore accessible to the extracellular
Figure 1.3 Schematic representation of adenosine metabolism
Pathway of adenosine and homocysteine production from the transmethylation 
pathway. This involves the transfer of a methyl group of adenosyl methionine 
(SAM) to a variety of methyl acceptors. In a metabolic steady state, the S- 
adenosylhomocysteine (SAH) formed by this pathway is continuously removed by 
SAH-hydrolase such that adenosine formation via this pathway is equivalent to the 
transmethylation rate from SAM to SAH. The transmethylation pathway is 
essentially oxygen insensitive, while degradation of adenine nucleotides to adenosine 
is critically dependent on tissue oxygenation. Therefore when adenosine formation 
is accelerated by hypoxia, the net flux of adenosine from the transmethylation 
pathway back into adenine nucleotides is reversed.
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Figure 1.4 Schematic representation of a G-protein coupled
receptor
G-protein coupled receptors (GPCRs) are integral membrane proteins that display a 
similar topography across differing species. They comprise a single polypeptide 
chain with an extracellular N- and intracellular C-terminus (black) linked by seven 
hydrophobic transmembrane (TM) spanning domains (blue). The TM domains 
display a relatively uniform size with the greatest variation in the receptors found 
within the extracellular and intracellular tails. GPCRs also contain several sites of 
lipid modification involved in receptor expression, ligand binding activity and G- 
protein interaction. Shown opposite is a schematic representation of a typical GPCR 
embedded within the plasma membrane.
NH
COOH
surface that can bind the appropriate ligand. Signal transduction via GPCRs is 
initiated by the interaction of the receptor with an extracellular ligand. These 
compounds initiate an intracellular response by causing a conformational change 
within the cytoplasmic loops of the receptor which are responsible for coupling and 
activation of G-proteins that in turn, act upon effector molecules (Gilman, 1987). 
The structure of these receptors was originally deduced by studies of bovine 
rhodopsin and beta2-adrenergic receptors (P2AdR) (Henderson et al., 1990; Dixon et 
al., 1986) with further studies identifying key features that appear to be conserved 
throughout all GPCRs
1.2.1 Structural Features of GPCRs
The TM domains of GPCRs display a relatively constant length with 
variation in the members of this superfamily seen primarily in the N- and C-terminal 
domains. The N-terminal domain has been shown to range from between 340-450 
residues in mature glycoprotein hormone receptors (Dias et al., 1992) to less than 10 
residues in the A%A (Furlong et al., 1992) and AzsARs (Pierce et al., 1992). The C- 
terminal domain comprises 359aa in the metabotropic glutamate receptor la 
(mGluRla, Masu et al., 1991) compared to as little as 2aa in the gonadotrophin 
releasing hormone receptor (GnRHR, Brooks et al., 1993). Size variability is also 
seen in the third intracellular loop that ranges from 239aa in the m3 mucarinic 
acetylcholine receptor (mAchR, Peralta et al., 1987) to approximately 15aa in the 
human complement C5a receptor (Gerard and Gerard, 1991).
In most receptors, the N-terminal domain contains potential sites of Asp- 
linked (N-linked) glycosylation, represented by the sequence Asn-X-Ser/Thr 
(Hubbard and Ivatt, 1981). It has not been established whether all potential N-linked 
glycosylation sites are functional, but there is evidence of their requirement for 
receptor expression and ligand binding activity of GPCRs (Segaloff and Ascoli, 
1993; Liu et al, 1993). Class II GPCRs such as receptors for endothelin A, B (ETa, 
ETb) and thrombin also contain an N-terminal hydrophobic leader sequence or signal 
peptide (Haendler et al., 1992; Zhong et al., 1992). This sequence directs newly 
synthesised receptor to the plasma membrane from the endoplasmic reticulum and is 
cleaved off to generate the mature receptor (Von Heijne, 1990). Almost all GPCRs 
contain Cys residues in the first and second extracellular loops that form di sulphide 
bonds between each other. These bonds are critical for maintaining the tertiary
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structure of the receptor as mutations of these residues in the rhodopsin (Kamik, 
1998), P^Ad (Dixon, 1987) and mAch receptors (Hulme, 1990) resulted in reduced 
expression levels, aberrant ligand binding properties and altered receptor functional 
activation in response to agonist. In addition, Dohlman and co-workers (1990) 
showed that mutation of these Cys residues in other receptor families, resulted in low 
levels of radioligand binding.
Both the C-terminal domain and third intracellular loop of GPCRs contain 
numerous Ser and Thr residues which are potential sites of receptor regulation via 
phosphorylation by kinases such as G-protein-coupled receptor kinases (GRK), 
protein kinase A (PKA) and protein kinase C isoforms (PKC) (Dohlman, 1991; 
Kobilka, 1992). These residues have significance in receptor desensitisation and 
initiation of internalisation (see section 1.4.1). Most GPCRs also contain a 
conserved Cys residue at the N-terminal region of the cytoplasmic tail. This has 
been shown in the PzAd (O’Dowd, 1989) and the rhodopsin receptor (Ovchinnikov et 
al., 1998) to be the site of palmitoylation. Palmitate is a 16-carbon fatty acid chain 
that can attach to Cys residues through a labile, reversible thioester linkage, 
regulation of which can be determined by the activation state of the receptor 
(Wedegaertner et al., 1995). Frequently, sites of palmitoylation are found to be close 
to other lipid modifications such as myristate or prenyl groups or to stretches of 
hydrophobic amino acids such as those found in the transmembrane domains of 
GPCRs (Mumby, 1997). This anchorage introduces an additional intracellular loop to 
the molecular structure of the receptor that may affect the interaction of the receptor 
with the G-protein (Milligan et al., 1995). Chemical removal of the palmitate from 
rhodopsin has been reported to enhance coupling of the receptor to the G-protein 
transducin (Morrison, 1991), whereas mutation of Cys 322 or 323 to Ser has no 
effect on activation of transducin (Kamik et al., 1993). In contrast, a (3 2 AdR with 
mutation of Cys 341 to Ala or Gly (Glycine) resulted in a receptor displaying a 
dramatic impairment in functional coupling to Gg (O’Dowd et al., 1989; Moffett et 
al., 1993). Cys '^^^Gly was also observed to have an increased phosphorylation level 
in the absence of agonist and displayed no increase in either phosphorylation levels 
or uncoupling from Gg (stimulatory) upon agonist stimulation. The properties of the 
mutant P2AdR resembled those of WT receptors that had undergone agonist-induced 
desensitisation (see Section 1.4.1), suggesting a role for palmitoylation in regulating
the accessibility of the C-terminal region to the action of protein kinases. This data 
implies that a universal role for palmitoylcysteines is unlikely. However, it is 
possible that these Cys residues have varying functions in receptor regulation from 
interaction with G-proteins to receptor turnover, expression and subcellular 
localisation (Kennedy and Limbird, 1993; Eason et al., 1994).
The greatest degree of amino acid similarity among GPCRs is found in the 
TM regions. Sequence similarity varies between 20-90% with the greatest 
conservation of sequence observed between subtypes of receptor families (Probst et 
al., 1992). Particularly well conserved throughout the GPCR superfamily are Pro 
residues occurring in TM regions 4, 5, 6  and 7. These residues are thought to be 
important for formation of the ligand binding pocket in receptors such as the mACh 
receptors and also for expression of the p2AdR receptor at the cell surface (Strader,
1989). The sequence Asp-Arg-Tyr (DRY) occurring at the intracellular side of 
transmembrane region 3 is very highly conserved. The arginine residue is invariant, 
with the Asp and Tyr being only conservatively replaced in some receptors. For 
almost all GPCRs, this region along with the membrane proximal region of the 
second intracellular loop, is thought to be involved in receptor-G-protein coupling.
1.2.2 Receptor and G-protein interactions
Mutagenesis and biochemical experiments using a variety of GPCRs suggests 
that receptor activation by a ligand causes changes in the orientation of TM helices 3 
and 6 . These changes affect the conformation of the intracellular loops of the 
receptors and uncover previously masked G-protein binding sites (Farrens et al., 
1996, Bourne, 1997). Deletion and site-directed mutagenesis studies have 
established that receptor-G-protein interaction relies on the receptor’s third 
cytoplasmic loop, and in particular, the regions of the loop lying immediately 
adjacent to TM regions 5 and 6  (Savarese and Fraser, 1992).
Although much is known about the structural features of GPCRs involved in 
ligand recognition and G-protein binding, the mechanisms underlying ligand 
activation and subsequent G-protein coupling remains unclear. The DRY motif is a 
highly conserved triplet of amino acids located at the transmembrane region of helix 
three and the second intracellular loop (Probst et al., 1992). The Arg residue is the 
only fully conserved residue in the sequence. Mutations of this residue in the Ml 
muscarinic receptor and alpha IB adrenergic receptor (ocmAdR) have resulted in
receptors with impaired signal transduction properties and it is therefore thought to 
be a key residue required for interaction of receptor with G-protein (Zhu et a l, 1994; 
Jones et al., 1995;Schee et al., 1996). The importance of this sequence in the second 
intracellular loop has also been described for rhodopsin, the angiotensin II (Ang II) 
receptor and more recently the interleukin- 8  receptor (Konig et al., 1989; Ohyama et 
al., 1992; Damaj et al., 1996). Analysis of several gain-of-flinction mutant receptors 
that result in constitutive receptor activity have shown that multiple regions of the 
receptor including the extracellular, intracellular and TM domains may be involved 
in molecular mechanisms that keep the receptor in a constrained state in the absence 
of agonist (Leff, 1995; Lefkowitz, 1993; Lefkowitz et al., 1993). In the presence of 
agonist, conformational changes in the receptor lead to a disruption of complex 
intramolecular interactions that constrain the receptor in the inactive state. This 
causes rearrangement of the TM domains and exposure of the cytoplasmic regions to 
the G-protein whereby ligand binding triggers signal transduction via GPCRs (Ulloa- 
Aguirre et al., 1999). Taken together, these structural features determine the GPCRs 
ligand binding and G protein coupling characteristics.
1.2.3 Adenosine Receptors
Purines and pyrimidines mediate their effects by interactions with distinct 
cell-surface purine receptors (Ralevick and Bumstock, 1998). There are two main 
families of purine receptors: Pi, or adenosine receptors (ARs) and receptors that 
primarily recognise adenosine triphosphate, adenosine diphosphate (ADP), uridine 
triphosphate (UTP) and uridine diphosphate (UDF). ?i/ARs can be further divided 
into four subtypes, A%, A2A, A2B and A3 (Tucker and Linden, 1993) which all couple 
to G-proteins, while P2 receptors have been divided into P2X, ligand-gated ion 
channels (Benham and Tsien, 1987) and P2Y, GPCRs (Abbracchio and Bumstock, 
1994; Fredholm et al., 1994).
In common with other GPCRs, ARs consist of an extracellular N- and 
intracellular C-termini linked by 7 hydrophobic TM regions (Palmer and Stiles, 
1995a). The ARs also display several common stmctural features that are conserved 
throughout the GPCR superfamily, such as glycosylation and phosphorylation sites. 
All four subtypes have been cloned from rat and human sources (Fig. 1.5).
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Figure 1.5 Sequence alignment of rat adenosine receptors
Shown opposite is a sequence alignment of rat Ai, A ja, A jb and A3 adenosine 
receptors. Residues conserved in at least two of the four sequences are highlighted in 
yellow with the predicted ti'ansmembrane spanning domains indicated by a black line 
above the appropriate region. Conserved Cys residues possibly involved in receptor 
palmitoylation are indicated by (*).
This comparison was obtained using the MegaAlign programme within the Dnastar 
molecular biology analysis suite.
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R a t AjA R
R a t A 2 aAR
R a t A 2 bAR
R a t A 3 AR
______________ TM_1_______________
1 M P P Y I S A F Q A A ----------------- Y I G I E V L I A L V S V P G N V L V I W A V K
1 M G ------------------ S S V ----------------- Y I T V E L A I A V L A I L G N V L V C W A V W
1 M Q - - L E T Q D A L ----------------- Y V A L E L V I A A L A V A G N V L V C A A V G
1 M K A N N T T T S A L W L Q I T Y V T M E A A I G L C A V V G N M L V I W V V K
_______________ TM2________________
3 6  V N Q A L R D A T F C F I V S L A V A D V A V G A L V I P L A I L I N I G P Q T  R a t A ^ A R
3 0  I N S N L Q N V T N F F V V S L A A A D I A V G V L A I  P F A I T I S T G F C A  R a t A j ^ A R
3 4  A S  S  A L Q T  P T N  Y F L  V S  L A T  A D  V A  V G L  F A I  P F A  I  T I  S  L G  F C  T R a t  A^gAR
4 1  L N R T L R T T T F Y F I V S L A L A D I A V G V L V I P L A I A V S L E V Q M  R a t  A 3 AR
TM3
7 6  Y F H T C L M V A C P V L I L T Q S S I L A L L A I A V D R Y L R V K I P L R Y  
7 0  A C H G C L F F A C F V L V L T Q S S I F S L L A I A I D R Y I A I R I P L R Y  
7 4  D F H S C L F L A C F V L V L T Q S S I F S L L A V A V D R Y L A I R V P L R Y  
8 1  H F Y A C L F M S C V L L V F T H A S I M S L L A I A V D R Y L R V K L T V R Y
______________ TM4______________
1 1 6  K T V V T Q R R A A V A I A G C W I L S L V V G L T P M F G W N N L S V V E Q D
1 1 0  N G L V T G V R A K G I I A I C W V L S F A I G L T P M L G W N -----------------------N
1 1 4  K G L V T G T R A R G I I A V L W V L A F G I G L T P F L G W N S K D R A T S N  
1 2 1  R T V T T Q R R I W L F L G L C W L V S F L V G L T P M F G W N R K V T L E L -
TM5
1 5 6  W R A N G --------------------S V G E P V I K C E F E K V I S M E Y M V Y F N F F V W V
1 4 3  C S Q K - D G N S T K T C G E G R V T C L F E D V V P M N Y M V Y Y N F F A F V  
1 5 4  C T E P G D G I T N K S C - - C P V K C L F E N V V P M S Y M V Y F N F F G C V  
1 6 0   S Q N S S T L S C H F R F V V G L D Y M V F F S F I T W I
TM5
1 9 0  L P P L L L M V L I Y L E V F Y L I R K Q L N K K - - V S A S S - G D P Q K Y Y  
1 8 2  L L P L L L M L A I Y L R I F L A A R R Q L K Q M E S Q P L P G - E R T R S T L
1 9 2  L P P L L I M M V I Y I K I F M V A C K Q L Q H M E L M ---------------- E H S R T T L
1 8 9  L I P L V V M C I I Y L D I F Y I I R N K L S Q -------------N L T G F R E T R A F Y
TM6
R a t Aj  AR
R a t A 2 aAR
R a t A 2 bAR
R a t A 3 AR
2 2 7  G K E L K I A K S L A L I L F L F A L S W L P L H I L N C I T L F C P T - - C Q  
2 2 1  Q K E V H A A K S L A I I V G L F A L C W L P L H I I N C F T F F C S T - C R H  
2 2 7  Q R E I H A A K S L A M I V G I F A L C W L P V H A I N C I T L F H P A L A K D  
2 2 5  G R E F K T A K S L F L V L F L F A L C W L P L S I I N F V S Y F N V K I --------
TM7
R a t A iA R
R a t A2aAR
R a t A2bAR
R a t A 3 AR
R a t AjA R
R a t A2aAR
R a t AogAR
R a t A 3 AR
R a t A iA R
R a t A2aAR
R a t A2bAR
R a t A 3 AR
R a t AjA R
R a t A2aAR
R a t A2bAR
R a t A 3 AR
2 6 5  K P S I L I Y I A I F L T H G N S A M N P I V Y A F R I H K F R V T F L K I W N  R a t  A^AR
2 6 0  A P P W L M Y L A I I L S H S N S V V N P F I Y A Y R I R E F R Q T F R K I I R  R a t  Ag^AR
2 6 7  K P K W V M N V A I L L S H A N S V V N P I V Y A Y R N R D F R Y S F H R I I S  R a t  AjgAR
2  6 2  - P E I A M C L G I L L S H A N S M M N P I V Y A C K N K K V Q R N H F V I L R  R a t  A 3 AR
*  *
3 0 5  OH F R C Q P K  P --------------------------------------------------------------------------------------------------
3 0 0  T H V L  R R Q E  P F Q  A G  G S  S  AW A L  A A H  S T E G E Q V S L R L N  G H  P L G R a t  Az^AR 
3 0 7  R Y V L C Q T D -----------------------------------------------------------------------------------------------------
3 0 1  A C R L C Q T S D --------------------------------------------------------------------------------------------------
R a t Aj  AR
^a
R a t A 2 bAR
R a t A 3 AR
3 1 4
3 1 5  -  -  T K G  G S G Q  A G G Q  S T -  F S L S L
3 1 0  ----------------------------------------------------------------------
3 2 4  A E D
3 8 0  R Q E G Q E H P G L R G H L V Q A R V G A S S W S S E F A P S  
3 3 2
3 1 0   S L D S N L E Q T -----------------------------------------T E
R a t AjAR
R a t A 2 aAR
R a t A 2 bAR
R a t A 3 AR
R a t AjAR
R a t A 2 aAR
R a t A 2 bAR
R a t A 3 AR
As with most GPCRs, the TM regions of the ARs are highly conserved. TM 
regions 2, 3 and 5 show particularly long stretches of homology between the four 
subtypes (Palmer and Stiles, 1995a) and it is residues within these transmembrane 
regions that have been shown to be crucial for ligand binding and specificity (Olah et 
al., 1994, 1995). Early work by Klotz et al. (1988) implicated multiple His residues 
in the agonist and antagonist binding specificity of the AiAR. These residues have 
also been linked to A2A receptor ligand binding (Jacobson et al., 1992a). A;, A2A, and 
A2B contain only two His residues in the TM domains, one at position 256 in TM 
region 6  and the other at position 274 in TM region 7. Individual mutations of these 
residues in the bovine A%AR abolished both agonist and antagonist binding and 
replacement of His 256 with Leu resulted in a 4-fold decrease in affinity for 
antagonist, supporting a role of these residues in ligand binding (Olah et al., 1992).
Other features of GPCRs that are conserved in ARs are the presence of Cys 
residues in the extracellular loops. As stated previously, these residues contribute to 
the formation of disulfide bonds, which may confer conformational stability to 
GPCRs once inserted into the plasma membrane (PM). ARs also display consensus 
sites of N-linked glycosylation (N-X-Ser/Thr; Olah et al., 1990; Barrington et al., 
1990; Palmer et al., 1992). These sites are found primarily on the second 
extracellular loops of the ARs with the A3AR possessing an additional site within its 
N-terminal domain. As has been shown with other GPCRs, the exact role of ARs N- 
linked glycosylation remains unclear.
ARs initiate their effects through interaction of agonist-occupied receptors 
with G-proteins (Gilman, 1987). As with most other GPCRs, ARs contain a DRY 
motif in their second intracellular loop, which has been suggested to be a site of G- 
protein interaction (Fraser et al., 1988). Short amino acid sequences containing the 
motif BBXB or BBXXB, where B is a basic residue and X is any amino acid, can 
also be found in the intracellular regions of A2A, A2B and A3ARS. As with the DRY 
motif, these sites have been documented as being involved in receptor-G-protein 
coupling (Okamoto and Nishimoto, 1992). The presence of a B/X motif is not 
compulsory for G-protein binding as canine and bovine AiARs do not possess such 
sequences within their cytoplasmic tails. However, they do contain clusters of basic 
residues in the third cytoplasmic loop and regions of the C-terminal tail in close 
contact to the membrane. In contrast, the A2aAR contains two such B/X motifs in its
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intracellular region, one in the third cytoplasmic loop and the other proximal to TM 7 
in the C-terminal domain.
The C-terminal regions of ARs contain numerous sites of interest. Ai, A2B 
and A3ARS have conserved Cys residues in their C-terminal tails (Fig. 1.5). Previous 
studies on the P2AdR and rhodopsin have suggested this residue to be a site of 
receptor palmitoylation (O’Dowd et al., 1989; Ovchinnikov et al., 1988). When this 
residue is mutated, these receptors display phosphorylation at a basal level prior to 
agonist stimulation. A2aARs do not possess an analogous Cys residue, suggesting 
that these residues have an important, albeit not conserved role in receptor signalling 
(Wedegaertner et al., 1995). It has also been suggested that the C-terminal tail of 
many receptors play a regulatory role in receptor signalling (Parent et al., 1999). The 
presence of multiple Ser and Thr residues in the C-terminal domains of the A2A and 
A3ARS suggests this is a site of regulation via receptor phosphorylation. Palmer et 
al., (1994) and Ramkumar et al., (1991) have noted that the A2aARs undergo a rapid 
agonist-induced functional desensitisation that is associated with receptor 
phosphorylation (Palmer et al., 1997). The significance of these predicted 
palmitoylation and phosphorylation sites in A3AR activation will be discussed 
elsewhere. Receptors from each of the four distinct subtypes have been cloned from 
a variety of species and characterised by expression in various cell types.
1.2.4 Adenosine Receptor subtypes 
(a) AiAR
AiARs have been cloned from several species including rat (Mahan et al., 
1991; Reppert et al., 1991), cow (Olah et al., 1992; Tucker et al., 1992) and man 
(Libert et al., 1992; Townsend-Nicholson et al., 1992; Ren and Stiles, 1994). These 
each encode open reading frames (ORFs) of 326 aa with a corresponding protein size 
of -36,700 Daltons (Da). AiARs across the different species display -87% amino 
acid identity, with this value rising to 92% within the TM regions. mRNA analysis 
has shown the AiAR to be expressed in brain, testis (Mahan et al., 1991; Reppert et 
al., 1991), heart and kidney (Olah et al., 1992). AiARs have classically been 
associated with the inhibition of adenylyl cyclase (AC) and activation of 
phospholipase C (PLC) leading to a decrease in cyclic AMP (cAMP) levels and 
mobilisation of intracellular Ca^ '*’ via the inhibitory (Gi/Go) family of G-proteins (van 
Calker et al., 1979; Londos et al., 1980; Freissmuth et al., 1991; Munshi et al., 1991).
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(b) A2aAR
À2aARs have been cloned from numerous species including dog (Maenhaut 
et ah, 1990), rat (Fink et ah, 1992) man (Furlong et ah, 1992), rabbit, sheep and 
mouse. They show an overall sequence identity of 84% between rat and human and 
82% between rat and canine. These receptors are 410-412 aa in length (~ 45,000 Da) 
with approximately 120 of these aa’s constituting the carboxyl terminal tail (Olah et 
ah, 1997; Barrington et ah, 1990). A2aARs are most commonly known to signal 
through the Gs-linked family of G-proteins leading to the activation of AC (Daly et 
ah, 1983), but can also activate p21Ras and extracellular regulated kinase (ERK) in 
endothelial cells and protein kinase CÇ (PKCQ in PC12 cells (Huang et ah, 2001). 
A2aARs have a broad distribution including the immune system, platelets, vascular 
smooth muscle and endothelial cells. Within the brain, the highest levels of A2aARs 
are found in regions that are rich in dopamine including the striatum, nucleus 
accumbens and olfactory tubercle (Ongini and Fredholm, 1996).
(c) A2bAR
A2bARs have been cloned from human hippocampus (Pierce et ah, 1992), rat 
brain (Rivkees and Reppert, 1992; Stehle et ah, 1992) and mouse bone marrow- 
derived mast cells (Marquardt et ah, 1994). The C-terminal tail of the A2B receptor 
contains -80 aa fewer than that of the A2A receptor and is therefore similar to the Ai 
and A3 ARs in size (36-37 kDa). A2bARs have been reported to couple to different 
signalling pathways dependent upon species. These include activation of AC, 
coupling to PLC via the Gq/Gn family leading to an Inositol trisphosphate (IP3)- 
dependent increase in Ca^  ^ when expressed in human mast cells (Feokstitov and 
Biaggioni, 1995) and coupling to PLC in Xenopus oocytes (Yakel et ah, 1993). 
Recently, the A2 bAR has been shown to be involved in netrin-dependent growth of 
axons in the dorsal spinal cord via interaction with DCC protein (deleted in 
colorectal cancer; Corset et ah, 2000). This suggests a novel role for these receptors 
in the nervous system distinct from their activities in neurotransmission.
(d) A3AR
The A3AR was cloned by the use of polymerase chain reaction (PCR) with 
degenerate nucleotide primers directed towards the conserved third and sixth 
transmembrane regions of GPCRs (Zhou, 1992). A resulting 226 aa fragment was
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used to screen a rat brain copy DNA (cDNA) library and found to be closely related 
to A] and AaARs, with 58% and 57% homology respectively in putative TM 
domains (Zhou, 1992). This clone was identical to one obtained previously from a 
rat testis cDNA library which encoded a GPCR with greater than 40% sequence 
homology to canine Ai and A2aARs (Meyerhof et al., 1991). Homologues of rat 
A]AR have been cloned from sheep (Linden et al., 1993) and humans (Salvatore et 
al., 1993) and display a 72% overall amino acid identity to the rat receptor. A splice 
variant of the rat A3AR containing a 17 amino acid insertion in the second 
intracellular loop has also been cloned and characterised (Sajjadi et al., 1996). 
Experimental analysis of the receptor transfected into Chinese hamster ovary (CHO) 
cells indicated that it inhibited AC (Zhou et al., 1992; Abbracchio et al., 1995) 
through interaction with a pertussis toxin-sensitive (PTX) G-protein, Gi and to a 
lesser extent Gq/n (Palmer et al., 1995). Although widely distributed in humans, the 
physiological roles of the A3 AR are still under investigation. It has, however, been 
implicated in the release of histamine from mast cells (Ramkumar et al., 1993) and in 
the cardioprotective effect of adenosine following ischaemia reperfusion injury 
(Auchampach et al., 1997; Stambaugh et al., 1997). A3AR mRNA is found 
expressed in testis, lung, kidney, heart, brain, mast cells, eosinophils and spleen 
depending on the species examined (see Table 1.1). Highest levels ai'e found in the 
testis (Linden et al., 1993; Salvatore et al., 1993) lung (Salvatore et al., 1993) and 
spleen (Linden at al., 1993) for rat, human and sheep respectively.
1.3 G-Proteins
The term G-protein refers to a heterotrimeric plasma membrane-associated 
GTP binding protein which functions as an intermediary in transmembrane signalling 
pathways to transduce signals across the plasma membrane from activated receptors 
to effector enzymes or ion channels (Gilman, 1987). Evidence for the existence of 
G-proteins first came from Rodbell and Bimbaumer (1971) who described the 
stimulation of AC to be dependent upon the presence of guanosine triphosphate 
(GTP). It was not until 1981 (Stemweis et al) that the first G-protein was purified 
and initially described as ‘a GTP-binding regulatory component of AC’. This 45 
kDa protein is now better known as the stimulatory G-protein a-subunit Gsa 
(Gilman, 1987). Another G-protein was soon described as the inhibitory regulatory
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Table 1.1 Distribution of adenosine receptor mRNA expression
All ARs exhibit overlapping distribution thi'oughout the different species examined. 
The table opposite illustrates the expression of each AR subtype in cloned species.
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Table 1.1
Receptor Subtype Species Location
AiAR Rat
Bovine
Human
Cortex, cerebellum, thalamus 
hippocampus, spinal cord, fat, 
testis, heart, kidney
A2aAR Canine
Rat
Human
Striatum, nucleus accumbens, 
olfactory tubercule, cortex, 
heart, kidney, lung, blood 
vessels, immune tissues
A2bAR Rat
Human
Large intestine, brain, spinal 
cord, lung, aorta, airway smooth 
muscle, endothelium, mast cells
A3AR Rat
Sheep
Human
Testis, lung, kidney, heart, 
cardiac myocytes, brain, 
eosinophils, mast cells
component of AC and termed Gi (Bokoch et al., 1983). G-proteins consist of distinct 
heterotrimeric subunits, namely a, P and y of which there are known to be 2 0 -a, 6 -P 
and 12-y genes cloned to date (Hamm, 1998). These subunits participate in a 
complex activation-deactivation cycle in which the a-subunit dissociates and re­
associates with the py-subunit in a guanine nucleotide-dependent manner (Gilman, 
1987).
It is proposed that an equilibrium state exists between two forms of a 
receptor. The inactive form (R) can bind ligands (H) but cannot bind G-protein (G). 
The presence of ligand pushes the equilibrium toward the active form of ligand- 
receptor (H-R*) and the presence of G-protein pushes the equilibrium toward 
interaction of activated receptor (R*) with G-protein (R*-G). The active form of 
receptor has a greater affinity for ligand than the inactive form (R). In normal 
receptor systems, in the presence of G-protein but absence of ligand, there is a 
preponderance of the inactive form of the receptor (Baldwin, 1994). In an inactive 
form, guanosine diphosphate (GDP) is bound to the a  subunit of the G-protein. 
Receptor activation by ligand produces changes in the orientation of the TM helices 
of the GPCR which in turn affects the conformation of the intracellular loops 
interacting with the G-protein (Altenbach et al., 1996; Farrens et al., 1996). At this 
point, the GDP bound to the a-subunit is exchanged for GTP and the G« and Gpy 
subunits dissociate. Multiple receptors can converge on a single G-protein and in 
some cases, a single receptor can activate more than one G-protein, thereby 
modulating a plethora of intracellular signals (Bourne, 1997, Fig. 1.6).
1.3.1 Ga-subunits
Ga subunits contain an intrinsic GTPase activity that determines the lifetime 
of the active, dissociated state of the G-protein heterotrimer (Morris and Scarlata,
1997). The members of this family can be subdivided into four groups, each of 
which controls multiple effectors:
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Figure 1.6 Regulatory cycle of G-protein
activation/deactivation
The figure opposite depicts the mechanism by which ligand activates G-protein by 
interaction with receptor. Receptor mediates the exchange of GDP for GTP on the 
a-subunit leading to activation of the heterotrimer and dissociation of the a-GTP 
from Py. The dissociated subunits can activate the appropriate effector enzymes, a 
process that is turned off by the intrinsic GTPase activity of the a-subunit, allowing 
reassociation of a-GDP with py to initiate another cycle.
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Gs family Gs is defined functionally by its ability to stimulate AC and 
open Ca^  ^channels and contains two major isoforms of 45 and 52 kDa (Northup et 
al., 1980 and Stemweis et ah, 1981) resulting from four splice variants of the same 
gene. Members of this family are ubiquitously expressed and are sensitive to cholera 
toxin (CTX) which adenosine diphosphate-ribosylates (ADP) the a-subunit at Arg 
201, inactivating its GTPase activity causing persistent activation of Gsa (Bourne et 
ah, 1991).
Gi family Gi is divided into three subtypes: Gi-i, Gi_2 and Gi-3 which 
range in size from 40-41 kDa and mediate the inhibition of cAMP synthesis (Gilman, 
1987). It has been suggested that phosphorylation of the p2AdR is a crucial 
molecular switch to subsequently allow Gj-mediated activation of ERK (Daaka et ah,
1997). Similarly, Gi is involved in IGF-induced neuronal MAPK activation, required 
for neuronal development and reorganisation (Hallak et ah, 2000). This family also 
includes two ‘o’ subtypes, Goi and G0 2 , of 39-41 kDa (Hsu et ah, 1990). One 
possible function of the Go-subtypes includes stimulation of PLC (Moriarty et ah,
1990). The Gi family is sensitive to PTX that causes ADP-ribosylation of a Cys 
residue in the C-terminus of Gi/Go, causing inactivation of GTPase activity with GDP 
being bound. This increases the affinity of the a-subunit for Py and inactivates Gi/Go 
by preventing the interaction of the a-subunit with receptors (Katada et ah, 1984). 
This family also includes the PTX- and CTX-sensitive transducins Gti and Gt2 which 
couple to rhodopsin to activate retinal cGMP-phosphodiesterase (PDE, Stryer, 1986).
Gq family This family comprises of Gq, Gn, G14, G15 and G16 (Pang and 
Stemweis, 1990). It is a toxin-insensitive family and has been implicated in the 
PTX-insensitive activation of some of the 6 PLC subtypes (Park et ah, 1992). 
Suggestions of ‘cross-talk’ or co-stimulation of the Gq and Gi families can lead to 
augmentation of physiological responses such as muscle contraction (Selbie and Hill,
1998) by increasing PLC and PKC activity within cells.
Gi2 family The 44 kDa proteins G12 and G13 which make up this family 
are responsible for functions including the activation of INK (c-Jun N-terminal 
kinase) and reorganisation of the cytoskeleton (Prasad et ah, 1995; Buhl et ah, 1995).
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They have also been indicated in the regulation of small molecular weight G-proteins 
and Na'^-H^ exchange (Milligan and Rees, 1999). They are expressed ubiquitously, 
are toxin-insensitive and their primary structure varies significantly from the other G- 
proteins by greater than 50% (Simon et al., 1991).
1.3.2 Gpy-subunits
Less is known about the 35-36 kDa p-subunits and the 8-9 kDa y-subunits. 
Despite this fact, Gpy has been shown to directly bind and activate a number of 
effectors such as phospholipase Az (PLA2 ; Kim et al., 1989), PLC (Pang and 
Stemweis, 1990; Wilkie et al., 1991) and AC (Tang and Gilman, 1991 and Federman 
et al,, 1992). The 20-a, 6 -p and 12-y subunits theoretically provide 1440 aPy 
combinations. Altematively, while a , p and y can form any combination, it has been 
speculated that GPCRs recognise and interact exclusively with only one combination 
of a , p and y which helps to explain the specificity of GPCR signalling (Lefkowitz,
1992). As each a, p and y subunit interacts with distinct and specific effectors, the 
heterotrimeric nature of G-proteins increases the number of control mechanisms or 
effector molecules activated via ligand binding to GPCRs (Clapham and Neer, 1997).
Although the py-subunit is a heterodimer, functionally it is a monomer, as 
these two subunits cannot be dissociated except by dénaturation (Clapham and Neer, 
1997). The Gpy-subunit induces conformational changes on the Ga when they come 
together to form the heterotrimer, increasing G« affinity for GDP (Brandt and Ross, 
1985) and enhancing binding of Ga to its appropriate receptor (Higashijima et al., 
1987; Heithier, 1992 and Phillips, 1992). The C-terminal region of the Gy-subunit 
contains a CAAX motif that directs prénylation of the molecule (Resh, 1996). 
Prénylation involves attachment of either a 15-carbon famesyl or 20-carbon 
geranylgeranyl isoprenoid to a conserved Cys residue of proteins (Casey, 1994). Gpy 
subunits containing Gy in which the Cys has been mutated to Ser, results in the 
prevention of prénylation and expression of the mutated py-subunits in the cytosol 
rather than being membrane bound (Muntz et al., 1992 and Simonds et al., 1991). 
This suggests that one function of the prenyl group is to form a membrane 
attachment to anchor the heterodimer at the plasma membrane. It has also been 
suggested that Gp can become phosphorylated on a His residue by an enzyme that 
uses GTP as a substrate (Wieland et ah, 1993). This led to the hypothesis that the
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phosphate group of the GTP could be transferred from His to GDP, leading to an 
alternative pathway for G«-subunit activation (Kowluru et ah, 1996). This has since 
been shown not to occur in biological systems (Hohenegger et al., 1996).
1.4 GPCR Regulation
In order to respond to the rapid changes in agonist concentration, receptors 
must be inactivated and restored to the cell surface for further stimulation. Chronic 
exposure of GPCRs to their agonists triggers multiple cellular changes leading to 
receptor desensitisation (seconds), sequestration (minutes) and down-regulation 
(hours-days). The best characterised of these systems is the ^ 2AdR and the light 
activated rhodopsin which have been shown to follow the three steps outlined above.
1.4.1 Desensitisation
(a) Phosphorylation
Desensitisation has traditionally been defined as the process whereby a 
GPCR-initiated response reaches a plateau and then diminishes despite the sustained 
presence of agonist. The phenomenon of desensitisation can be subdivided 
depending on the nature of the causative stimulus. Homologous desensitisation is 
agonist specific and occurs only at agonist-stimulated receptors. Consequently, only 
the activated receptor itself becomes desensitised. In contrast, heterologous 
desensitisation is a process where activation of one type of receptor causes 
desensitisation of other receptor types also. Heterologous desensitisation involves 
phosphorylation of GPCRs by second messenger-activated kinases such as cAMP- 
dependent protein kinase and PKC. Phosphorylation by these kinases impairs the 
ability of receptors to stimulate their associated G-proteins (Benovic et al., 1985 and 
(Pitcher et al., 1992). Investigation into the homologous desensitisation of ^2AdR 
and rhodopsin, showed that agonist-stimulated |3 2AdR phosphorylation occurred 
even in the absence of cAMP-dependent protein kinase (Stadel et al., 1983 and 
Strasser et al., 1986). The enzyme responsible for this activity was purified from 
bovine brain (Benovic et al., 1987a) and termed P-adrenergic receptor kinase 
(pARK), later renamed as G-protein coupled receptor kinase-2 (GRK2). Rhodopsin
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kinase (GRKl) is the enzyme responsible for phosphorylating light-activated 
rhodopsin in rod outer segments (Shichi and Somers, 1978).
Six mammalian GRKs have been cloned to date: GRKl (rhodopsin kinase, 
Lorenz et al., 1991); GRK2 (P-adrenergic receptor kinase-1, Benovic et al., 1991a); 
GRK3 (P-adrenergic receptor kinase-2, Benovic et al., 1991); GRK4 (IT-11, 
Ambrose et al., 1992); GRK5 (Kunapuli and Benovic, 1993 and Premont et al.,
1994) and GRK6  (Benovic and Gomez, 1993). With the exceptions of GRKl 
(retina) and GRK4 (testis), GRKs are ubiquitously expressed (Freedman and 
Lefkowitz, 1996), suggesting a role for these kinases in a multitude of diverse 
signalling pathways.
(b) Structural features of GRKs
Structurally, GRKs contain a centrally located catalytic domain of 263-266 
amino acids flanked by large amino- and carboxyl-terminal regulatory domains (Fig. 
1.7). The amino-terminal domains are of common size, approximately 185 aa’s, and 
demonstrate a good degree of structural homology. The C-terminal domains, in 
contrast, are highly variable in length, ranging from 100-230 aa’s, and structure, 
which include many post-translational modifications (Krupnick and Benovic, 1998). 
GRKs do however exhibit several common characteristics in that they: 1) 
preferentially phosphorylate agonist-occupied receptors; 2 ) interact with their 
activated receptor substrates which potently activates these enzymes and 3) GRK- 
mediated GPCR phosphorylation requires the participation of regulatory mechanisms 
responsible for the localisation and receptor targeting of these enzymes (Pitcher et 
al., 1998). GRKs do not appear to bind to a clear consensus sequence in their 
substrates. However, they have been shown to bind preferentially to residues 
containing pairs of acidic (GRKl and 2, Fredericks et al., 1996) or basic (GRK5 and 
6 , Kunapuli et al., 1994) residues located N-terminally to the last phosphorylated 
residue in the GPCR sequence.
GRKs 2 and 3 contain a pleckstrin homology (PH) domain within their 
carboxyl terminal. Pleckstrin, the major protein kinase C substrate in platelets, 
contains two PH domains that are thought to be involved in protein-protein 
interactions. This region of sequence has been described in more than 70 proteins so 
far and has been proposed to function as a mediator of protein/protein and 
protein/membrane interactions. Several different ligands for PH domains have been
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Figure 1.7 Domain architecture of G-protein coupled
receptor kinases (GRKs)
The sequence of the 6  known mammalian GRKs is shown opposite. GRKs contain a 
central catalytic domain flanked by an approximate 180 aa N-terminal domain and a 
highly conserved region. The carboxyl-tenninal domains are variable in length and 
contain many post-translational modifications. Rhodopsin kinase (RK, GRKl) is 
fainesylated, PARK and pARK2 (GRKs 2 and 3) contain a Py binding domain, 
GRKs 4 and 6  are palmitoylated and GRK5 contains a basic phospholipid binding 
domain.
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identified including PKC, IP3 and the py-subunit of heterotrimeric G-proteins (Shaw, 
1996). Although GRK 2 was initially described to be a soluble, cytosolic enzyme 
that translocated to the membrane upon receptor activation (Daaka et al., 1997a), 
recent data have indicated that several pools of GRK2 exist inside cells: cytosolic, 
membrane bound and microsomal membrane bound (Murga, et ah, 1996; 1997). 
GRK2 activity is regulated upon interaction with several lipids and proteins present 
within the three cellular pools and translocation to the PM is facilitated by its 
interaction with free py-subunits released upon receptor activation (Premont et ah,
1995). It was shown that Gpy bound the C-terminal tail of these enzymes and so led 
to the redistribution of the GRKs to the membrane (Pitcher et ah, 1992 and Koch et 
ah, 1993). This association dramatically enhanced GRK2-mediated phosphorylation 
of activated GPCRs such as the paAdR and the m2 muscarinic AchR (Pitcher et ah, 
1992 and 1995). On the basis of this, it has been proposed that receptor stimulation 
leads to activation of a heterotrimeric G-protein and the subsequent dissociation of 
the a- and py-subunits. The membrane-localised Gpy interacts with GRK2 and 
targets this enzyme to interact with its membrane-bound receptor substrate (Daaka et 
ah, 1997). Recent studies have shown that GRKs can be regulated via interaction 
with many cellular components including actin (GRK5; Freeman et ah, 1998), 
caveolin (GRKl-6 ; Carmen et ah, 1999) and phospholipids (GRK 2,3,5; Carman et 
ah, 2000). However to date, GRK2 and 3 are the only Gpy-regulated GRKs to be 
identified (Pitcher et ah, 1998; Carman et ah, 2000).
1.4.2 Sequestration
(a) Arrestins
The interaction of GRK with activated receptor not only brings about receptor 
phosphorylation, but also serves to attract arrestin molecules to the plasma 
membrane. Arrestins are a class of protein that function in concert with GRKs to 
stop or ‘arrest’ intracellular signalling. Arrestins uncouple activated receptors from 
G-proteins leading to a functional desensitisation and promotion of clustering of 
activated receptors to clathrin-coated pits prior to sequestration away from the PM. 
There are currently four known mammalian arrestins: rod arrestin, (arrestin 1, 
Shinohara et ah, 1986), parrestin (arrestin2, Lohse et ah, 1990), parrestin2 (arrestin3, 
Gurevich et ah, 1993) and cone arrestin (arrestin4, Murakami et ah, 1993; Fig. 1.8).
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Figure 1.8 Domain architecture of arrestin proteins
The sequence of the four known mammalian arrestins is represented schematically. 
The solid lines are regions of invariant amino acid sequence and the divergence near 
the C-temiinus represents divergence in sequence between the visual (arrestin-1 and 
aiTestin-4) and non-visual (arrestin-2 and anestin-3) arrestins.
A activation recognition domain
P phosphorylation recognition domain
S secondary hydrophobic interaction domain
C clatlirin binding domain
+ basic amino tenninus
acidic C-terminus
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The prototypic arrestin is a 48 kDa protein, initially termed S-antigen, first 
identified as the causative agent of a degenerative eye disease. It was subsequently 
demonstrated that this protein quenched light-dependent signal transduction in rod 
photoreceptor cells and was named visual arrestin (Pfister et al., 1985). More 
recently, a second retinal-specific arrestin with -  50% homology to visual arrestin 
was cloned. This arrestin was found to be restricted to cone photoreceptors and was 
therefore termed cone arrestin (Murakami et al., 1993 and Craft et al., 1994). It was 
postulated that the rhodopsin signal was quenched by arrestin via direct competition 
between arrestin and transducin for binding of phosphorylated light-activated 
rhodopsin (Kuhn et al., 1984). This has since been confirmed by direct binding 
studies with purified arrestin, transducin preparations and rod outer segments 
(Krupnick et ah, 1997b). In 1987, Benovic and co-workers discovered a related 
protein that enhanced the inactivating effects of GRK2 on the PzAdR and was 
postulated to be an arrestin-like protein. The protein was cloned by Lohse et ah, 
(1990) by screening of a bovine brain library with a 1262bp cDNA probe comprising 
the entire coding sequence of visual arrestin. A positive clone was found to encode 
a 418aa protein with high homology to visual arrestin, originally termed ‘p-arrestin’ 
since it blunted PAdR signalling and it was subsequently named arrestin2. A second 
non-visual arrestin (arrestinS) was cloned from bovine brain (Steme-Marr et ah,
1993), human thyroid (Rapoport et ah, 1992) and rat brain (Attramadal et ah, 1992) 
using comparable screening strategies. Overall, the arrestins are 45% identical and 
show 70% similarity between residues 16 and 349 of the visual arrestins. Arrestins2 
and 3 are ubiquitously expressed, and as such, have been suggested to regulate a 
wide variety of GPCRs.
(b) Requirement for arrestin in sequestration
A role for arrestins in homologous desensitisation has been shown for many 
receptors including PiAdR (Pippig et ah, 1993), piAdR (Freedman et ah, 1995), 
aieAdR (Diviani et ah, 1996) and odorant receptors (Dawson et ah, 1993). Co­
expression of these receptors with arrestin2 or arrestin3 showed that arrestin 
enhanced the rate of receptor desensitisation following agonist stimulation, 
suggesting that arrestin could discriminate between agonist-activated and non­
agonist activated states of GPCRs. From this observation, the concept has arisen that
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arrestins contain distinct domains that would interact specifically with GPCRs in 
their activated state. Analysis of several truncation mutants of visual and non-visual 
arrestins provided evidence that this region, called the ‘activation-recognition 
region’, was located within the N-terminal half of the arrestin molecule (Gurevich 
and Benovic, 1992; Gurevich et al., 1993 and 1995). In addition, direct binding 
studies using various receptor-GST (glutathione-S-transferase) fusion constructs 
demonstrated that the third cytoplasmic loop of the m2 and m3 muscarinic Ach and 
otzAdR specifically bound to non-visual arrestins (Wu et al., 1997). Arrestins could 
discriminate between activated and non-activated receptors suggesting that they 
contained a recognition sequence specific to the area of the GPCR that is 
phosphorylated upon agonist exposure (Palczewski et ah, 1991). This 
‘phosphorylation-recognition region’ was determined once again by utilising 
truncated arrestin molecules. Mutants of visual arrestin and arrestin2 and 3 were 
shown to retain the ability to bind phosphorylated rhodopsin (Gurevich and Benovic,
1992) and the m2 mAChR (Gurevich et ah, 1993, 1995).
(c) Arrestins as scaffolding proteins
Many GPCRs have been shown to activate the ERK/MAPK cascade via 
termination of membrane receptor signalling by sequestration (Luttrell et ah, 1997; 
Della Rocca et ah, 1999) or by stimulation of tyrosine kinase signalling cascades 
(van Biesen et ah, 1996b; Gutkind, 1998). GPCR-mediated activation of ERK 
requires tyrosine phosphorylation and assembly of a membrane-associated Ras 
activation complex. Stimulation of receptors coupled to the Gi and Gq classes of G- 
protein a-subunit induces rapid tyrosine phosphorylation of the She and Gabl 
adapter or ‘scaffold’ proteins followed by Grb2-dependent recruitment of the Ras 
guanine nucleotide exchange factor mSOS, leading to ERK activation (Luttrell et ah, 
1999a). Arrestin has been shown to redistribute to the plasma membrane with 
activated Src (c-Src), a kinase which mediates tyrosine phosphorylation of She and 
Gabl, in cells expressing |3 2 Ad receptors following agonist stimulation (Luttrell et 
ah, 1999). In the absence of arrestin, c-Src was no longer able to associate with the 
p2AdR. This suggested a role for arrestins as a scaffold, able to complex other small 
molecules for initiation of distinct signalling events. In support of this, expression of 
dominant-negative mutants of arrestin and dynamin, which block receptor
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endocytosis, have been shown to block the activation of MAPK (Lin et al., 1998; 
Ahn et al., 1999) via receptors including the pzAd, thrombin and 5- 
hydroxytryptamine lA  receptor (5-HTia, Luttrell et ah, 1997; Della Rocca et ah, 
1999). However, this is not universal to clathrin-sequestered receptors as the k  
opioid receptor can still activate the MAPK cascade without being internalised (Li et 
ah, 1999).
(d) Clathrin-coated vesicles
Numerous studies have demonstrated that agonist activation of GPCRs leads 
to translocation of these receptors from the cell surface to distinct intracellular 
vesicles. One mechanism by which GPCRs internalise is via clathrin-coated pits 
(Von Zastrow and Kobilka, 1992). Clathrin is a triskelion made up of three 190 kDa 
heavy chains, each with an associated light chain radiating from a central hub 
(Pearse, 1976, Fig. 1.9). Each leg is ~ 475 Â in length and has a uniform thickness 
of ~20Â. The coat is made up of triskelions which come together to form a lattice of 
pentagons and hexagons that curve round each other to enclose a bilayer vesicle 
(Kanaseki and Kadota, 1969, Fig. 1.9). CCVs are found in all nucleated cells from 
yeast to humans and are a means of transporting proteins and lipids from the plasma 
membrane to internal compartments (endosomes). They are also responsible for the 
transport of newly synthesised proteins from the trans-Golgi network (TGN) to the 
endosomes. Having shown that GRKs and arrestins were involved in receptor 
desensitisation, Krupnick et al. (1997b) suggested that non-visual arrestins contained 
a clathrin-binding domain that targeted desensitised GPCRs for sequestration. Using 
chimeric proteins containing the N-terminal region of visual arrestin and the 
carboxyl-terminal region of arrestin2 , and vice versa, it was shown that the non­
visual arrestins were able to interact with clathrin through their C-terminal domains. 
The site of interaction was further localised to between residues 367 and 385 of 
arrestin3. Analysis of the C-terminal domains of the four mammalian arrestins 
showed that arrestin2 and 3 had greater than 80% homology in this region. In 
contrast, visual arrestins lacked a significant portion of this region and showed less 
than 30% homology in the remaining residues (Krupnick et al., 1997b). These data 
put forward a putative clathrin-binding domain present in the non-visual arrestins 
(Fig. 1.10).
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Figure 1.9 Components of clathrin triskelions and 3D
structure of a clathrin coat
(A) The "height" of clatln-iii is 200 A, and the distance between the terminal 
domains ranges between 300 and 400 A. Each leg of the triskelion is 475 A in 
length, and are of relatively unifoiTn thickness ( 2 0  A). A strongly curved 
region near the middle of the leg imparts a regular swirl to the trimer, and the 
somewhat straighter segments of the leg to either side of this curve are known 
as the distal and proximal domains, respectively.
(B) Representation of a clathrin barrel lattice. The N-terminal domains, which 
face inward toward the enclosed membrane, are in close contact with the 
adaptors (not shown). Each edge of a pentagon or a hexagon is made of two 
proximal segments belonging to two adjacent triskelions and two distal 
segments from two other, nonadjacent triskelions.
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Figure 1.10 Alignment of bovine arrestins clathrin binding
domain
Bovine aiTestin-3 was aligned with the clathrin binding domains (residues 346-391) 
of bovine visual arrestin, cone aiTestin and arrestin-2. Shaded areas denote the 
residues involved in clathrin binding.
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(e) Cytosolic ‘helper’ proteins
A second major constituent of CCVs is the adapter protein (AP) eomplex. 
AP complexes form two subtypes, API and AP2, which play multiple roles in 
controlling coated-vesicle formation (Pearse and Robinson, 1990). They are 
selectively targeted to either the TGN (API) or the plasma membrane (AP2) and 
direct the formation of clathrin-coated vesicles by acting as a connector between the 
activated receptor and the clathrin triskelions (Pearse and Bretscher, 1981).
The binding of clathrin is the first step in the initiation of a complex pathway 
that brings about receptor sequestration. In vitro data has shown that the assembly of 
clathrin coat proteins is insufficient in itself to drive receptor sequestration. 
Additional cytosolic proteins as well as ATP and GTP hydrolysis are required 
(Schmid and Damke, 1995). The final membrane fusion event leading to vesicle 
budding requires both ATP and GTP hydrolysis. ATPases involved in the budding 
stage have yet to be identified, however, the small GTPase dynamin has been shown 
to have a role (Van der Bliek et al., 1993; Herskovitz et al., 1993 and Damke et al., 
1994). Dynamin is a 100 kDa protein originally purified from bovine brain and 
characterised as a microtubule (MT)-stimulated GTPase with MT-bundling activity 
(Shpetner and Vallee, 1989). The effect of dynamin on endocytosis was first 
observed in Drosophila. Temperature sensitive Drosophila shibire mutants were 
seen to undergo paralysis after shift to the restricted temperature (Koenig and Ikeda,
1989) and accumulated a high number of clathrin-coated and uncoated pits. The role 
of dynamin was confirmed in mammalian cells by the expression of GTPase 
deficient dynamin mutants which lead to inhibition of endocytosis (Van der Bliek et 
al., 1993 and Herkovits et al., 1993). Mammalian dynamin occurs in 3 different 
isoforms: dynamin-1, expressed exclusively in neurones and 70% identical to shibire 
dynamin; dynamin-2, ubiquitously expressed and dynamin-3, expressed in the testis 
(Van Deurs et al., 1989 and Vallee and Okamoto, 1995). As well as its N-terminal 
GTPase domain, dynamin contains a cluster of proline-rich sequences at its C- 
terminus which have the potential to interact with various Src homology (SH) 3 
domains (Gout et al., 1993 and Okamoto et al., 1997). SH3 domains are found 
commonly in signal transduction and cytoskeletal proteins and mediate protein- 
protein interactions by binding to pro line-rich sequences. Amphiphysin is a highly 
acidic, hydrophilic protein which can be found in soluble and particulate fi-actions of 
brain homogenates (David et al., 1996). There are two isoforms of amphiphysin,
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Amphl and Amph2 which share 49% amino acid sequence identity (Owen et ah, 
1998) and contain SH3 domains in their C-terminal regions (Lichte et al., 1992). 
Recent work suggested that amphiphysins are major physiological binding partners 
for dynamin in clathrin-mediated endocytosis (Wigge and McMahon, 1998).
By the use of numerous GTPase defective dynamin mutants (Van der Bliek et 
al., 1993 and Herskovits et al., 1993) and the introduction of SH3 domains into live 
cells (Wigge et al., 1997), a specific role for dynamin in endocytosis has been 
demonstrated (Damke et al., 1996). In this model, dynamin is GDP-bound (inactive) 
and targeted to the clathrin-coated pit by interaction with: 1) AP2 complexes (Wang 
et a l, 1995) and 2) the SH3-domain containing protein amphiphysin (David et a l, 
1996) via a Pro-Arg-rich C-terminal domain. Amphiphysin binds the clathrin 
adapter AP2 via a region distinct from its SH3 domain resulting in an efficient 
recruitment of dynamin to the CCVs. GTP/GDP exchange triggers the re­
distribution of dynamin from the clathrin lattice allowing it to self-assemble into 
helical rings at the neck of the coated pit. Intrinsic GTPase activity of dynamin 
results in a conformational change that closes the collar of the pit and pinches the 
CCV away from the membrane. The GDP-bound form of dynamin would then be 
disassembled and recycled (Damke, 1996).
1.4.3 Down-regulation
Prolonged agonist exposure over a period of hours results in receptor down- 
regulation, being defined as an overall decrease in receptor number (Gagnon et al, 
1998). Using the PiAdR as a model, it has been suggested that sequestered receptors 
traffick from early endosomes to lysosomes where they undergo degradation. Many 
GPCRs including the thrombin (Hein et a l, 1994), thyrotropin (Petrou et a l, 1997) 
and cholecystokinin (Tarasova et a l, 1997) receptors have been shown to be sorted 
to lysosomes in an agonist-dependent manner.
After receptors and their ligands have been sequestered via CCVs, the 
vesicles are uncoated and the internalised molecules are delivered to ‘early’ or 
‘sorting’ endosomes (Braell et a l, 1984; Rothman and Schmid, 1986; Al-Awqati, 
1986; Tycko and Maxfield, 1982). Due to the acidic pH in the early endosomes, the 
receptors and ligands are dissociated and the receptors are recycled back to the 
membrane for another round of agonist activation (Davis et a l, 1987; DiPaolo and 
Maxfield, 1984; Yamashiro and Maxfield, 1987). The remaining molecules are
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destined for degradation via late endosomes or lysosomes (Fig. 1.11). Not all 
receptor-ligand partnerships follow this pathway. Receptors such as Tfn remain 
associated with their ligand and traffic via the same route as low-density lipoprotein 
(LDL) receptors (Dautry-Varsat et al., 1983) i.e. they recycle from early endosomes, 
and although most receptors recycle back to the PM, some can be degraded after 
internalisation (Felder et al., 1990; Herbst et al., 1994). A variety of experimental 
techniques including biochemical purification and morphological analysis by 
microscopy, have been used to characterise endocytic organelles.
(a) Lysosomal degradation
Lysosomes are membrane-bound cytoplasmic organelles that serve as a 
major degradative compartment in eukaryotic cells (de Deuve, 1963; Komfeld and 
Mellman, 1989 and Hunziker and Geuze, 1996). Both endogenous and exogenous 
molecules can be delivered to lysosomes where they are degraded by acid-dependent 
hydrolases contained within the lysosomal lumen (de Duve, 1963). Lysosomes are 
morphologically heterogeneous and often resemble organelles of the endocytic and 
secretory pathways (Komfeld and Mellman, 1989). They can however be 
distinguished by their appearance under the electron microscope. Lysosomes appear 
as an electron-dense organelle and are therefore known as ‘dense bodies’, enclosed 
by a single membrane. They can also be seen to show a clear region just below the 
membrane ( ‘halo’). This halo is rich in carbohydrates and is thought to protect the 
lysosomal membrane protein from degradation from its own acidic hydrolases.
(b) Ubiquitination
Another pathway of down-regulation involves the ubiquitin system. In this 
pathway, proteins are targeted for degradation by ligation to ubiquitin, a highly 
conserved 76 aa residue protein. The ligation of ubiquitin to the internalised proteins 
happens in three stages: 1) the C-tenninal Gly residue of ubiquitin is activated in an 
ATP-requiring step by an activating enzyme E l; 2) activated ubiquitin is then 
transferred to a ubiquitin-carrier protein, E2, on an active Cys residue; 3) ubiquitin is 
linked by an amide isopeptide linkage to an amino group of the substrate protein’s 
lysine (Lys) residues by a ubiquitin-protein ligase, E3. The ubiquitin pathway of 
degradation has been implicated in the immune response (Cox et al., 1995 and Dick
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Figure 1.11 Diagrammatic view of receptor transport 
pathways
Upon ligand binding, receptors undergo sequestration via many pathways of which 
clathrin is the best studied. The clathrin vesicles are uncoated and receptors are 
delivered to acidic sorting endosomes where receptor and ligand are dissociated in 
preparation for recycling back to the membrane or down-regulation. A schematic 
representation of receptor transport pathways is shown opposite.
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et al., 1994), programmed cell death (Schwartz et al., 1990) as well as receptor 
down-regulation (Mori et al., 1995).
1.4.4 Tools of the Trade
In order to study the pathways of sequestration and down-regulation, 
numerous mutants and fluorescently labelled proteins involved in the pathways have 
been utilised (Chapter 4). One of the most common fluorescent tags used is that of 
green fluorescent protein (GFP).
GFP from the jellyfish Aequorea victoria, was first discovered in 1969 by 
Shimomura and Johnson and has since been utilised by many as a marker to visualise 
numerous cellular functions. Shimomura and Johnson noted that the purified protein 
“ gave solutions a slightly greenish look in sunlight, and exhibited a very bright 
greenish fluorescence in the ultraviolet” (UV). The same group soon published the 
emission spectrum of GFP that peaked at 508nm when excited at 470nm. Morise et 
al, in 1974, purified and crystallised GFP and in 1978, Prendergast and Mann 
obtained the first estimate for the monomer molecular weight.
GFP is a single chain polypeptide of 238 amino acids with a calculated 
molecular weight of approximately 27kDa. Although GFP was crystallised in 1974, 
Ormd et al and Yang et al independently solved the first structure in 1996. GFP is an 
11-stranded p-barrel threaded by an a-helix running up the axis of the cylinder (Fig. 
1.12). The chromophore of GFP is covalently bound and is formed by modification 
of a Ser-Tyr-Gly sequence at aa’s 65-67 in the native protein. It is attached to the a- 
helix and buried almost perfectly in the centre of the cylinder. Due to this structure, 
the chromophore is stable when exposed to a variety of harsh treatments including 
heat, extreme pH and chemical dénaturants (Bokman and Ward, 1981) and the 
fluorescence survives glutaraldehyde and formaldehyde fixatives (Chalfie et al.,
1994). The GFP most commonly used to date is an enhanced form which contains 
mutations of Ser to Thr at position 65 and phenylalanine (Phe) to Leu at position 64 
giving a improved fluorescence over WT GFP. It is also encoded by a gene with 
human optimised codons (Cormack et al., 1996;1996 and Yang et al.,1996).
35
Figure 1.12 Three-dimensional structure of green fluorescent
protein (GFP)
GFP consists of a single polypeptide chain forming an 11 p-stranded hollow cylinder 
tlirough which is tlneaded an a-helix bearing the chromophore, shown in ball-and- 
stick representation opposite. Mutations in the chromophore are responsible for 
producing spectrum-shifted mutants that show enhanced or altered emission 
wavelengths.
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This enhanced form of GFP (EGFP) absorbs blue light at 488nm and emits green 
light at 509nm (Tsien, 1998).
GFP has many cell biological applications in which it is used as a tag or 
indicator. The most successful use of GFP has been as a genetic fusion partner to 
proteins of interest to monitor their cellular localisation and fate. One of the most 
well-known fusion strategies is that of GFP fusion with the C-terminal of GPCRs. 
Expression of these GPCR-GFP fusions in various cell types and systems has 
allowed the visualisation of receptor trafficking in response to agonist stimulation. 
These receptors include the PzAdR (Barak et al., 1997a), cholecystokinin A receptor 
(Tarasova et al., 1997), TRHR (Drmota et al., 1998 and 1999), aiA and (XisAdR 
(Hirasawa et al., 1997), vasopressin VzR (Schulein et al., 1998), ETA and B receptors 
(Abe et al., 2000) and the Ai and AgARs (unpublished data).
Mutations in GFP cDNA have resulted in the production of many 
‘fluorescently shifted’ proteins (Table 1.2). These range from the UV through the 
visible spectrum of light and have dramatically increased the applications of 
fluorescent proteins. One way to exploit these biochemically enhanced GFPs is to 
use fluorescence resonance energy transfer or FRET. FRET occurs when two 
fluorophores are in molecular proximity (<1 0 0 Â apart) and the emission spectrum of 
one fluorophore, the donor, overlaps the excitation spectrum of the second 
fluorophore, the acceptor (Tsien et al., 1993). The light emitted can be used to detect 
the interaction of the two labelled proteins. In principal the use of FRET offers 
advantages and disadvantages over other current methods for detecting protein- 
protein interactions (Tsien, 1998). The biggest disadvantage is the high level of 
background obtained as the donor emission has a tail that extends into the acceptor’s 
emission band and the acceptor excitation has a tail that extends into the donor’s 
excitation band. For this reason, FRET is best used at later stages of analysis when 
the two host proteins have been biochemically and molecularly well characterised 
and only the dynamics of their interaction is to be determined.
The process of sequestration has been subject to many disruptions. A subtle 
way of interfering in this system is by the use of mutant proteins. As previously 
stated, GRKs, arrestin, amphiphysin and dynamin are important in the initiation and 
‘pinching-off’ of CCVs. Numerous truncations and mutations have been made of 
these proteins and all have unique effects on receptor sequestration (Chapter 4).
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Table 1.2 Table of GFP chromophore mutations
The table opposite illustrates some of the ‘fluorescently shifted’ GFP moleeules 
obtained by mutation of the centrally located chromophore (Ser-Tyr-Gly). These 
GFPs range from the UV through the visible spectrum of light.
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Table 1.2
Amino Acid Change Excitation / Emission Effects
S65G 513/527nm Red-shifted FP
S65T 488/51 Inm
Shifted emission 
maximum a few nm, 
increased fluorescence 
yield
Y6 6 H 382/448nm Blue FP, extremely dim
Y6 6 F N/A Non-fluorescent
V6 8 L 513/527nm Red-shifted FP
S72A 513/527nm Red-shifted FP
S205 N/A Hydrogen bonds with 
E222
E222G 485/506nm
Single excitation peak, 
hydrogen bonds shown to 
be important in UV vs 
blue excitation 
photoisomers
1.5 Adenosine receptors and their ligands
Adenosine acting on its cell-surface receptors can elicit numerous responses 
within varying organ systems. ARs can be activated via endogenous adenosine when 
local levels rise due to stress in situations such as cardiac hypoxia (Fenton and 
Dobson, 1987) and ischaemia (Hagberg et al., 1987), or by externally administered 
adenosine and its analogues. The regulation of AR activation has therefore been 
recognised as having possible therapeutic functions.
1.5.1 AR Agonists
Agonists can be defined as compounds that act on receptors to elicit a 
response. Modifications of the and C2 positions of the adenine ring and the 5’- 
position of the ribose moiety produce analogues of adenosine which are more stable 
than adenosine itself, and have been used extensively to characterise the ARs 
(Ralevic and Bumstock, 1998). Agonists such as NECA (N- 
ethylcarboxamidoadenosine, Williams, 1989), APNEA (N-[2-(4- 
aminophenyl)ethyl]adenosine, Fozard and Carruthers, 1993) and ^^^1-AB-MECA 
(’^ ^I-aminobenzyl)-5’-N-methylcarboxamidoadenosine, Olah et al., 1994) do not 
show selectivity between AR subtypes (Fig. 1.13).
(a) AiAR Agonists
Certain N^-substituted adenosine derivatives including N^- 
cyclopentyladenosine (CPA) and N^-cyclohexyladenosine (CHA) and (R)N^- 
phenylisopropyladenosine ((R)-PIA) are selective agonists of AiARs (Jacobson et 
al., 1992a). Substitutions at both the N  ^ and C2 positions has produced a 2-chloro- 
CPA (CCPA) which has been found to be 1500-fold more potent at the A]AR than 
the A2AR following ligand binding studies using rat brain (Lohse et al., 1988; 
Jacobson et al., 1992b; Fig. 1.13).
(b) A2aAR Agonists
Generally, A2aARs do not bind to N^-substituted analogues but show a 
preference for derivatives that have been modified at the second position of the 
adenine ring. Bulky substitutions at this position have been shown to selectively 
enhance binding to A 2aARs, leading to several A2A-selective agonists being
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produced (Jacobson et al., 1992b; Siddiqi et al., 1995). The C2-substituted derivative 
of NECA, CGS 21680, has been shown to be 140-fold more selective for A%A than 
AiARs (Hutchison et al., 1990) but has very low affinity for A2bARs. This allows 
CGS 21680 to be used as a screen to discriminate between A2A and A2 B receptor 
subtypes (Jarvis et al., 1989; Lupica et al., 1990). Although NECA itself is almost 
equipotent at Ai and A2 receptors, it can be used in characterisation of A2A ARs 
providing that the Ai-selective ligands used do not show equivalent effects. It should 
be noted however, that most of the agonist studies have been carried out in species 
other than human, with the human A2A ARs showing a much lower binding affinity 
for CGS 21680 and other AR agonists.
(c) A2bAR Agonists
Selective agonists for the A2bAR have, as yet, failed to be found. In order to 
determine the presence of A2bARs, accumulation of AC in membranes is used as 
long as a lack of activity/ binding of Ai, A2A and Ag-selective agonists is confirmed 
(Ralevic and Bumstock, 1998). As with A2A“Selective agonists, A2bARs show 
preference for derivatives with substitution at the C2 position of the adenine ring. So 
far, NECA is the most potent adenosine analogue, even though it shows only low 
micromolar affinity for the receptor (Brackett and Daly, 1994). In a recent study 
netrin-1 , a laminin-related secreted protein critical for controlling axon elongation, 
has been shown to bind to A2bARs and induce cAMP accumulation. This could 
suggest a second physiological ligand and possible selective agonist for these 
receptors (Corset et al., 2000).
(d) A3AR Agonists
As observed with AiARs, the main class of Ag-selective adenosine analogues 
contains a substitution at the position of the adenine ring (Fig. 1.13). IB-MECA, 
(N6-(3-iodobenzyl)-5’-(N-methylcarbamoyl)adenosine), is 50-fold more selective for 
rat brain A3 ARs than A] or A2A (Gallo-Rodriguez et al., 1994) and the iodinated 
radioligand ^^^I-AB-MECA has been shown to bind AgARs with nanomaolar affinity. 
Selectivity of these ligands can be enhanced by substitution at the C2 position of 
these compounds, forming for example, 2-chloro-IB-MECA (2C1-B-MECA) which 
has a 2500- and 1400-fold greater selectivity for A3 ARs over A% and A2aARs 
respectively (Kim et al., 1994).
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Figure 1.13 Chemical structure of non-selective adenosine
receptor agonists
Shown opposite are representations of the chemical structures of the adenosine 
analogues N-ethyIcarboxamidoadenosine (NECA), R-A^-(phenylisopropyl)adenosine 
((R)-PIA) and (^^^I-4-aminobenzyl-5’-N~methylcarboxamidoadenosine) [^^^I]AB- 
MECA. These compounds are non-selective agonists for the adenosine receptors.
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1.5.2 AR Antagonists
Xanthines and their derivatives, including natural derivatives such as 
caffeine, are non-selective, although not universal, AR antagonists. Antagonists can 
be defined as ligands that inhibit the action of agonists, binding to the R and R* 
states of a receptor with equal affinity.
(a) AiAR Antagonists
Substitutions into position 8  of the xanthine ring have yielded potent and 
selective AiAR antagonists for example DPCPX ( 1,3-dipropyl-8 - 
cyclopentylxanthine) and XAC (xanthine amine conger). Of these compounds, 
DPCPX has the greatest affinity for the rat AiARs (Bruns et al., 1987; Lohse et al., 
1987) with a lower affinity for human Ai receptors (Libert et ah, 1992; Klotz et ah, 
1998). Some non-xanthine antagonists have also been described which show 
reasonable affinity and selectivity for AiARs.
(b) A2aAR Antagonists
Several AzaAR antagonists have been described and synthesised. CSC (8-(3- 
chlorostyryl)caffeine) is a potent AzA-selective antagonist often used in radioligand 
binding assays. It is 520-fold more selective at the A2aAR than the Ai and has been 
shown to reverse the effects of agonist on AC (Jacobson et ah, 1993). The non­
xanthine antagonist of the A2aAR, ZM 241385 ((4-(2-[7-amino-2-(2-
furyl)[l,2,4]triazolo[2,3-a][l,3,5]triazin-5-yl amino]ethyl)phenol)), displays 1000- 
and 91-fold selectivity for the A2aAR versus the A% and A2 B receptors respectively, 
and has absolutely no effect at A3 ARs (Poucher et ah, 1995). This has been used to 
generate a high-affinity selective antagonist radioligand 241385 (Palmer et
ah, 1995c).
(c) A2bAR Antagonists
As with A2 bAR agonists, there are very few compounds, either xanthines or 
non-xanthines, which can be classed as A2B-selective antagonists. One compound, 
enprofylline (propyl-xanthine) used as an anti-inflammatory in asthma, has been 
shown to be inactive at Ai, A2A and A3 ARs and may therefore be a starting point to 
develop a selective A2B antagonist (Feoktistov and Biagionni, 1996). Recently, the 
first potent and selective antagonists of A2bARs have been described. These
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compounds, MRS 1754 in particular, are anilide derivatives of 8 -phenylxanthine. The 
availability of AisAR antagonists increases the opportunity to explore this receptor 
in asthma and holds promise for the treatment of inflammatory and ischaemic 
diseases (Kim et al., 2000; Linden, 2001).
(d) A3AR Antagonists
Selectivity of A3AR antagonists has been found to be very much dependent 
upon the species being investigated. Xanthine derivatives display a higher affinity 
for human and sheep A3 ARs compared to rat, rabbit and gerbil (Zhou et al., 1992; 
Linden et al., 1993; Salvatore et al., 1993; Ji et al., 1994), varying from nanomolar to 
micromolar, respectively. Five chemical classes and three flavanoid classes of A3- 
selective antagonists have also been described (Jacobson et ah, 1996). The chemical 
class includes the compound L-268605 (3-(4-methoxyphenyl)-5-amino-7-oxo- 
thiazolo [3,2] pyrimidine) which is potently selective for A3 ARs and has no 
appreciable effect on human Ai or A2A receptors (Jacobson et ah, 1996). The 
flavanoid class of antagonists again, shows species selectivity. This class includes 
MRS 1523 (9-chlor-2-(2-furyl)5-phenylacetylamino [1,2,4] triazolo [1,5-c] 
quinazoline) which is selective for rat A3 versus human (Jacobson et ah, 1997; Fig. 
1.14).
1.6 Therapeutic roles of adenosine and the A3AR
Despite the recent identification of the A3AR (Zhou et ah, 1992), several 
studies have implicated this receptor in mediating effects of adenosine which may 
have therapeutic potential. Since the first physiological effects of adenosine were 
documented (Drury andSzent-Gyorgi, 1927), investigators have demonstrated that 
this small molecule, acting through its A3 receptor, is involved in cardioprotection 
(Fenton and Dobson, 1983; Stambaugh et ah, 1997) and neuroprotection (von Lubitz 
et ah, 1994) from ischaemia-induced damage, bronchoconstriction (Linden et ah, 
1993; Salvatore et ah, 1993; Sajjadi and Firestein, 1993), induction of hypotension 
(Fozard and Carruthers, 1993) and mast cell and eosinophil degranulation (Kohno et 
ah, 1996). These data gives strong weight to the therapeutic advantages of 
manipulation of adenosine regulation in disease states such as cardiac disease, stroke 
and asthma.
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Figure 1.14 Chemical structure of an A3AR antagonist
Shown opposite is a schematic representation of the chemical structure of an A3AR- 
selective antagonist, MRS 1523. This is the first relatively potent and selective A3AR 
antagonist for non-primate species, notably rat. In radioligand binding studies, MRS 
1523 displayed a K, value of 130nM (Li et al., 1998).
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1.6.1 Cardioprotection
Upon binding to A3 ARs, adenosine leads to interaction of the receptors with 
the Gi family of G-proteins (Palmer et ah, 1995b). This inhibits AC, and activates 
PLC to elevate IP3 concentration and mobilise intracellular Ca^ "^  (Abbracchio et al.,
1995).
The phenomenon of ischaemic preconditioning was first reported by Murray 
et al. in 1986, who discovered that brief ischaemic periods that were too brief to 
cause necrosis themselves, greatly reduced the amount of infarction from a 
subsequent, sustained occlusion. Pre-conditioning, a brief period of reduced blood 
flow leading to a decrease of oxygen to the tissues, can thus protect the heart from a 
subsequent prolonged ischaemic episode (Tracey et al., 1997). This loss of blood 
flow to the myocardium causes breakdown of ATP, resulting in an increase in levels 
of adenosine in the interstitial fluid. The involvement of adenosine and the ARs in 
this process was not discovered until 1991 when Lui et al. administered AR 
antagonists to preconditioned hearts and found that the protective effect was blocked. 
The adenosine released binds AiARs and A3ARS present on cardiac myocytes and 
limits the damage sustained by the myocardium during the ischaemic episode (Lui et 
al., 1994; Auchampach et al., 1997). As infarcted tissue is no longer able to contract, 
the global functioning of the heart can become progressively impaired, ultimately 
leading to heart failure. Since the discovery of preconditioning, it has been 
suggested that manipulation of the signalling pathway used in this phenomenon can 
be manipulated to develop an effective strategy to block infarction.
One possible way of increasing the adenosine concentration in the heart is to 
administer precursors or inhibitors of adenosine metabolism, providing the highest 
concentration of adenosine at the target sites i.e. the cardiac cells (Smolensk! et al., 
1998). An alternative approach increases the concentration of endogenous adenosine 
by inhibiting its transport across the cell membrane (Van Belle, 1993). This protects 
adenosine released from the cell during ischaemia from degradation by uptake and 
metabolism into the vascular endothelium, prolonging the presence of adenosine in 
the interstitial space. Several benefits of this approach in recovering cardiac function 
following ischaemia have already been documented (Masuda et al., Van Belle et al.,
1993). Adenosine concentration has been increased in the ischaemic heart by the 
administration of the ADA inhibitor EHNA (erythro-9(2-hydroxy-3-nonyl)adenine). 
This prevents the degradation of endogenously formed adenosine, providing
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significant improvement of myocardial infarction following ischaemia (Bolling et ah,
1990).
Coronary vasodilation has long been recognised as a physiological effect of 
adenosine (Berne, 1980). The heart, under normal conditions, extracts most of the 
oxygen from the coronary blood. Unlike skeletal muscle, cardiac muscle must 
maintain a balance between energy supply and utilisation. This involves cross-talk 
between cardiac cells and the coronary blood vessels. As oxygen pressure rises, the 
rate of formation of potentially harmful oxidants increases and may result in myocyte 
damage (Winegrad et ah, 1999). Cardiac myocytes in the intact organism are 
exposed to oxygen levels in the range of 6  to 7%. With increasing oxygen 
concentrations, cardiac myocytes produce angiotensin I (Ang I), which is converted 
into Ang II by angiotensin converting enzyme (ACE) in the blood vessel, and thus 
increases vascular tone (Bmtseart et ah, 1988). Below normal physiological oxygen 
levels, adenosine is released from the myocytes and acts directly on the vascular 
smooth muscle cells to counteract the rise in tension. This effect is normally 
produced by a-adrenergic receptor (aAdR)stimulation, suggesting that adenosine 
acts by either altering the a-adrenergic receptor directly or some factor downstream 
from it (Winegrad et ah, 1999).
1.6.2 Neuroprotection
Although presence of the A3AR in brain is 10-30 times lower then Ai (cortex) 
or AiARs (striatum; Jacobson et ah, 1995), it can elicit a wide range of neuronal and 
astrocytic responses that, dependent upon the pattern of activation, can be 
exceedingly lethal or highly protective. The pathophysiology of brain ischaemia can 
be summarised by a complex cascade of biochemical and electrophysiological 
processes. A decrease in cerebral blood flow leads to energy failure and disrupted 
ion homeostasis due to an enhanced efflux of cellular and influx of Ca^  ^and Na"^ . 
This leads to membrane depolarisation and cytotoxic oedema. Release of excitatory 
neurotransmitters triggers further membrane depolarisation and the additional 
accumulation of cytosolic Ca^ "^  by cellular influx (Simon et ah, 1984). This Ca^  ^
accumulation plays a key role in circulation of irreversible neuronal damage leading 
to free radical generation, activation of proteolytic enzymes and activation of 
apoptotic genes (Siesjo et ah, 1989).
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Adenosine levels in the brain are elevated during seizures, producing two 
distinct effects. Short-term activation of the A3 receptors appears to increase the 
amount of damage seen after cerebral ischaemia whereas a prolonged exposure to the 
agonist has a neuroprotective effect. It is thought that adenosine can dampen the 
inflammatory response and induce dilation of cerebral vessels (Ongini et al., 1997, 
von Lubitz, 1997) resulting in increased blood flow to the brain. Adenosine receptor 
activation initiates numerous cellular responses, decreasing neuronal activity and 
increasing nutrient supply. These responses include; 1) presynaptic attenuation of 
neurotransmitter release (Dolphin and Archer, 1983); 2) postsynaptic inhibition of 
sustained membrane depolarisation (Schubert et al., 1985) and 3) hyperpolarisation 
of astrocyte membranes to improve uptake of extracellular K'*' and glutamate (Drejer 
et al., 1985). It has been shown that an increase in extracellular adenosine levels can 
lead to the stimulation of A2AR present in the brain vasculature causing: 1) smooth 
muscle relaxation leading to vasodilation and an increase in blood flow and nutrient 
supply (Collis, 1989) and 2) inhibition of the inflammatory response which would 
otherwise lead to capillary blockage (Grisham et al., 1989; Cronstein et al., 1986).
Adenosine itself has a very short biological half-life, somewhere in the range 
of 3-6 seconds (Rudolphi et al., 1992), probably penetrating the blood-brain barrier 
poorly. Therefore, in order to attenuate the effects of the endogenous adenosine 
released during cerebral ischaemia, compounds that would interfere with its 
inactivation and/or increase adenosine release or inhibit AR transport would be of 
great therapeutic potential. Administration of inhibitors of the enzymes ADA and 
adenosine kinase would increase the chance of endogenously formed adenosine to 
interact with its receptors at the exterior surface of the cell membrane. The actions 
of these inhibitors would be more or less specific, restricted to areas where adenosine 
levels are increased, thereby limiting the risks of problematic side effects. Few 
studies on the effects of these compounds have been published and those that have 
display conflicting results. Despite these data, there is a large body of evidence to 
suggest that adenosine does have a neuroprotective effect in ischaemic brain.
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1.6.3 Mast cell and eosinophil activation
Allergic inflammation involves a complex interaction of many different 
inflammatory cells that release a spectrum of chemical mediators. Allergic reactions 
consist of an early phase response that primarily involves the degranulation of mast 
cells. Mast cells are found in most organs in the body including heart, brain, lungs 
and kidneys. Degranulation is accompanied by a release of histamine and 
leukotrienes leading to the migration of inflammatory cells from the circulation, and 
it has been shown that adenosine under stress conditions can induce degranulation 
without the aid of antigens (Linden, 1994). In the bronchi, degranulation causes the 
release of mediators that bring about constriction of the bronchiolar smooth muscle 
(Jin et al., 1997), while reperfusion after ischaemia in the heart leads to neutrophil 
accumulation and inflammatory tissue damage (Zimmerman and Granger, 1992). 
Both systems suggest the possible involvement of adenosine in the pathophysiology 
of asthma and inflammatory disease.
The indication that AgARs were involved in mast cell degranulation was first 
proposed by Ramkumar et ah, (1993) when they identified A3 ARs on the surface of 
RBL-2H3 cells, a tumour cell line derived from rat mast cells. Further studies using 
hamster cheek pouch arterioles and A3AR-selective agonists and antagonist 
correlated these initial findings, although the presence of other AR subtypes could 
not be completely ruled out (Doyle et al., 1994).
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1.7 Project Aims
In order to manipulate the A3AR in disease states, we must first understand 
how it is regulated in response to agonist exposure. The aims of this project were 
therefore three-fold: (1) to determine if there is a link between A3AR 
phosphorylation and internalisation; (2 ) to identify the specific residues involved in 
the phosphorylation and desensitisation of A3AR function and (3) to determine the 
cellular distribution of A3AR.S following agonist binding. Molecular biological 
techniques were used to create GFP-tagged forms of WT and mutant rat A3ARS that 
allowed further investigation of these receptors by confocal microscopy. Coupled 
with previous data and computational analysis, these procedures individually and 
collectively led to characterisation of the rat A3 AR.
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Chapter 2 
Materials and Methods
2.1 Materials
All reagents used were of the highest grade commercially available and obtained by 
the following suppliers:
Alexis Corporation, San Diego, CA, USA 
DTT
Amersham 
Iodine-125
BDH Chemicals Ltd., Poole, UK
Aery 1 amide, coverslips
Calbiochem-Novabiochem (UK) Ltd., Nottingham, UK
Forskolin, PM A
Costar, Cambridge, MA, USA
75cm^ tissue culture flasks, 60mm and 100mm tissue culture dishes, 6,12 and 24 well 
tissue culture plates, cryovials
Cruachem, Glasgow, UK
Oligonucleotides
Fisher Scientific, Loughborough, Leicestershire, UK
HEPES, sodium dodecyl sulphate, EDTA, DMSO, ethidium bromide solution, 
glacial acetic acid, methanol, ethanol, concentrated HCl, sodium fluoride, sodium 
phosphate
GIB CO BRL Life Technologies, Paisley, UK
Phenol:chlorofonn, LipofectAMINE, new bom calf serum, OptiMEM, phosphate 
free DMEM
Melford, Chelsworth, Ipswich, Suffolk, UK
Kanamycin
5 0
Merck, Darmstadt, Germany
Bactotryptone, agar
Molecular Probes
Transferrin-Alexa'^'^594 conjugate, Alexa’^ ^594 Goat-anti-mouse IgG conjugate, 
Alexa™594 Goat-anti-rabbit IgG conjugate, LysoTracker® Red DND-99, 
Concanavalin A Alex a Fluor™594 conjugate
New England Biolabs Inc,, Beverley
Protein molecular weight marker, restriction enzymes
NENLife Science Products Inc., Boston
ECL reagents, ^^P-orthophosphate, X-ray film
Pierce, Rockford, IL 61105, USA
EZ-Link™ Biotin-LC-hydrazide, HRP-streptavidin
Promega, Southampton, UK
T4 DNA ligase, SV mini-prep kit, G-418 sulphate, restriction enzymes
Qiagen, Crawley, West Sussex 
Gel purification kit, plasmid maxi kit
Research Biochemicals International, Natick, MA, USA 
(R)-PIA, NECA
Roche Molecular Biochemicals/Boehringer-Mannheim, Mannheim, Germany
Tris, DNA molecular weight marker, restriction enzymes, anti-HA mouse 
monoclonal IgG (clone 12CA5), adenosine deaminase
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA
P-arrestin2 (N-16) goat polyclonal IgG, dynamin I/II (N-19) goat polclonal IgG, 
CPLA2 (N-216) rabbit polyclonal IgG, GFP (FL) rabbit polyclonal IgG
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK
Triton X-100, soybean, benzamidine, pepstatin A, bovine serum albumin, protein A 
sepharose, sodium periodate, bisacrylamide, HRP anti-mouse IgG, HRP goat anti­
rabbit IgG, HRP rabbit anti-goat IgG, HRP-streptavidin, thimerosal, bromophenol 
blue, bichinchonic acid, sodium azide, CHAPS, DEAE-Dextran, FITC-Dextran, 
agarose, deoxycholic acid, polyethylenimine, ampicillin, adenosine deaminase, 
paraformaldehyde, TEMED, PMSF, chlorpromazine, 8-bromo-cGMP, Ham’s F-12, 
DMEM, PBS (sterile), foetal bovine serum, trypsin, penicillin/streptomycin, L- 
glutamine
Stratagene
Pfu Turbo DNA polymerase
Tocris/Semat Technical (UK) Ltd., St. Albans, Herts., UK
A23187
Whatman International Ltd., Maidstone, UK
GF/C glass fibre filters
IB-MECA and the As-selective antagonist MRS 1523 were the generous gifts of Dr 
Ken Jacobson, National Institutes of Health, Bethesda, MD.
A mutant human A%AR cDNA in which the Cys 309 was changed to Ala was a gift 
from Dr Mark Olah, University of Cincinnati College of Medicine, Cincinnati, OH.
^^^I-AB-MECA was synthesised and purified by high performance liquid 
chromatography as described previously (Olah et al. 1994).
9E10 monoclonal antibody specific to myc-epitope, was prepared in-house at Duke 
University, Durham, NC by Dr Tim Palmer.
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2.2 Cell Culture and Transfections
2.2.1 Cell Maintenance
CHO cells were maintained in Ham’s F-12 medium and Human embryonic 
kidney 293 (HEK293) and COS-P cells maintained in DMEM, supplemented with 
10%(v/v) FBS, penicillin (lOOunits/ml), streptomycin (lOOpg/ml) and 1% L- 
glutamine in a 37°C humidified atmosphere containing 5% CO2 . Cells stably 
expressing adenosine receptors were maintained in the appropriate medium 
supplemented with G-418. Cells were routinely passaged 1:8. When confluent, cell 
monolayers were washed with PBS without CaCl2 and MgCl2 , 1ml of trypsin added 
and the flasks returned to the incubator to allow cells to detach. 7mls of medium 
were then added to the flasks and the cells pipetted gently to allow resuspension. 
Cells were either passaged into flasks to maintain the cell line or seeded into dishes 
for experimental analysis.
2.2.2 Transient Transfections using LipofectAMINE
On the day prior to transfection, 75cm^ flasks of CHO or HEK293 cells were 
passaged 1:8 into 6 well plates and cells left overnight to plate down. For each well 
to be transfected, 2p,g DNA and 4pl of LipofectAMINE reagent were mixed with 
0.24ml OptiMEM and incubated at room temperature for 15 - 45 minutes in the dark. 
During the incubation, cell monolayers were washed with OptiMEM and the medium 
replaced with 0.76ml / well OptiMEM. The DNA-LipofectAMINE mix was added 
dropwise to the cells and the plates returned to the incubator for 3 hours. Following 
incubation, the DNA-OptiMEM was removed and replaced with fresh medium minus 
G-418. Cells were analysed 24 - 48 hours post- transfection.
2.2.3 Transient Transfections using DEAE-Dextran
On day 1, a confluent 75cm^ flask of COS-P cells was passaged 1:4 into 
100mm dishes and left to plate down overnight. On reaching 70-80% confluency, 
the cells were transfected. For each plate to be transfected, 4.75ml PBS-CM, 
(136mM NaCl, 2.7mM KCl, 8mM disodium hydrogenphosphate, 1.47mM potassium 
dihydrogenorthophosphate (pH 7.2 -  7.5), supplemented with ImM MgCE, O.lmM 
CaCE), 2.5-25pg of maxiprep purified DNA and 0.25ml of DEAE-Dextran
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(lOmg/ml solution made up in PBS-CM) were added to a sterile centrifuge tube and 
vortexed briefly before and after the addition of the dextran. Equal volumes of 
solution were added to the cell monolayers and incubated for 35-45 mins at 37°C in 
the incubator. 4.5mls of the transfection mix was removed, replaced with lOmls of 
medium supplemented with chloroquine (100|uM) and the dishes returned to the 
incubator for a further 2.5-3 hours. The medium/chloroquine mix was removed and 
replaced with 2mls/dish of medium supplemented with 10% (v/v) dimethyl sulfoxide 
(DMSO) for 2-3 minutes at room temperature. Medium/DMSG was aspirated off, 
cells washed twice with PBS-CM and replaced with lOmls of regular medium. Fresh 
media was added to the cells 24 hours post-transfection and cells harvested for 
analysis between 48 and 72 hours post-transfection
2.2.4 Stable Transfection of CHO cells
Cell lines stably expressing AR’s were generated using a modified calcium 
phosphate precipitation / glycerol shock procedure (Olah et al. 1992). Confluent 
CHO cells in 75cm^ flasks were split 1:5 into 100mm dishes and the medium 
changed the following morning. The transfection mixture of 1.5pg DNA, IM CaCE 
(125pi) and water to a final volume of 375pl was prepared, to which 0.5mls of 2 x 
HEPES buffered saline stock (HBSS, 280mM NaCl, 50mM HEPES, 1.5mM 
Na2HP0 4  pH 7.13) was added and gently bubbled through. Once the mix appeared 
milky, it was left at room temperature for 40 minutes, after which, it was added 
dropwise onto the cell monolayer and returned to the incubator for 4-5 hours. 
Following incubation, the media was apirated off, the cells washed once with PBS, 
2mls of 15% (v/v) glycerol added and the cells allowed to incubate at 37°C for 2 
minutes. On removal of the glycerol, the cells were washed three times with PBS, 
lOmls medium (minus G-418) replaced and the cells incubated overnight. Medium 
was changed the following day.
48 hours after transfection, the monolayer was washed with PBS, cells split 
1:8 as normal and titrated into 100mm dishes in volumes ranging from 0.25 -  4mls 
of cell suspension. Ham’s F-12 medium supplemented with G-418 was added to a 
final volume of 10 mis. Medium was changed every 2 days until single colonies 
could be observed. Colonies were picked and expanded. Those colonies containing 
GFP-tagged clones were screened using fluorescence microscopy.
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2.3 Molecular Biology
2.3.1 Preparation of antibiotic agar plates
LB agar (1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
with 1.5% (w/v) agar) was prepared, autoclaved and allowed to cool before the 
addition of the appropraite antibiotic (ampicillin 50pg/ml, kanamycin 30pg/ml). The 
liquid LB agar was poured into 90mm diameter Petri dishes and allowed to solidify 
and sweat overnight at room temperature. Plates were then stored at 4°C until 
required.
2.3.2 Preparation of competent XLl Blue E.coli
An overnight culture of XLl Blue E.coli was grown in 3ml of LB broth 
containing tetracycline (50pg/ml). The next day, the culture was used to inoculate 
250ml of LB broth, which was grown with aeration until the cells reached log phase, 
following which they were transferred into 2 x 250ml centrifuge tubes on ice and left 
for Ihour.
Log phase was determined when the optical density (ODeoo) reached 
approximately 0.35-0.375. Cells were spun at 6K at 4°C for 20 minutes, the 
supernatant decanted and the cells resuspended and washed in % starting volume of 
ice-cold O.IM (w/v) MgCE. Following a second 20 minute spin, the cells were 
resuspended in % starting volume of ice-cold O.IM (w/v) CaCE and placed on ice for 
20 minutes. Cells were spun again for 20 minutes, the supernatant discarded and 
cells resuspended in 15ml of ice-cold 15% (v/v) glycerol with O.IM (w/v) CaCE- 
250pl of cells were aliquoted into sterile microfuge tubes on dry iee/methanol to 
obtain rapid freezing, and stored at -80°C until required.
2.3.3 Transformation of competent XLl Blue E.coli with plasmid DNA
30-50ng of DNA was incubated with 50pl of competent XLl-blue cells on 
ice for 10 minutes. The cells were then placed for 5 minutes in a 37°C shaking 
waterbath before the addition of 0.5mls LB broth. The mix was then returned to the 
waterbath and incubated for 45 minutes. 200pl from each transformation was spread 
onto agar plates containing the appropriate antibiotic. Plates were incubated 
overnight at 37°C and transformed colonies selected the next day.
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2.3.4 Preparaton of plasmid DNA
Transformed colonies were picked from agar plates and grown overnight in 
5-10 mis of LB broth containing the appropriate antibiotic (Amp 50pg/ml, Kan 
30pg/ml). Plasmid DNA was prepared using the Promega™ Wizard Plus SV 
miniprep purification system as per the manufacturers instructions. For larger 
quantities of DNA, the initial overnight culture was transferred to 500mls of LB 
broth containing antibiotic and again grown overnight. DNA purification was by the 
Qiagen plasmid maxi kit system. The concentration of DNA obtained was 
determined by measuring the absorbance at 260nm (A26 0) of a 1:50 dilution in sterile 
H2O, assuming that 1 absorbance unit was equivalent to 50p,g/ml of double stranded 
DNA.
2.3.5 Digestion of plasmid DNA
1-2 pg of plasmid DNA was digested in a volume of lOpl using the buffer 
conditions recommended by the manufacturer with 2-4 units of the appropriate 
restriction enzyme. Digested DNA was analysed by agarose gel electrophoresis in 
which samples were prepared by the addition of a 1:3 dilution of loading buffer. 
Electrophoresis took place on a 1% (w/v) gel containing 2.5mg/ml ethidium bromide 
at 75 volts for 20-30 minutes in 1 x TAE buffer (40mM Tris-acetate, ImM EDTA, 
glacial acetic acid). Purification of DNA from agarose gels was by Quiagen 
QlAquick gel purification kit, as per the manufacturers instructions.
2.3.6 Ligation of DNA fragments
Ligation of vector DNA was carried out overnight at 4°C in a reaction volume 
of lOpl containing 1 x ligation buffer (30mM Tris-HCl, pH 7.8, lOmM MgC12, 
lOmM DDT, ImM ATP), vector and insert DNAs and T4 DNA ligase. Reactions 
were performed with the ratio of vector:insert of 1:4. Ligated DNA was transformed 
as described in Section 2.3.3.
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2.3.7 Construction of Adenosine Receptor-GFP fusion constructs
Modification of the pEGFP-Nl vector
A region of the enhanced green fluorescent protein vector, pEGFP-Nl 
(Clontech), multiple cloning site was modified by polymerase chain reaction (PCR) 
to convert the initiating methionine of GFP to alanine. A typical PCR contained 
lOOng template DNA, lOOpM dNTP’s, 50pmol sense / anti sense primers, 0.002 units 
Pfu turbo, 10% (v/v) amplification buffer and 5% (v/v) DMSO in a final volume of 
lOOpl. The reaction was initiated by a dénaturation cycle of 95®C for 5 mins, 
followed by 25-30 annealing and extension cycles of 95°C (Imin), 55°C (Imin) and 
72°C (l.Smins). A final cycle of 95°C (Imin), 55°C (Imin) and 72°C (lOmins) was 
used before reactions were placed at 4°C until required.
Oligonucleotide primers, 5 ’ - ATT ACCGGTCGCC ACCGC AGTGAGC AAG- 
3’(sense) and 5’-CAAATGTGGTATGGCTGATTAT-3’ (antisense) were used. The 
bases defining the methionine (Met) to Ala mutation are shown in bold. The sense 
primer also included an Agel restriction site (underlined). The antisense primer was 
constructed to read through a unique Notl site in the pEGFP-Nl cDNA. The Agel / 
Notl digested PCR product was subcloned into similarly digested pEGFP-Nl to give 
a pEGFP vector with the desired Met to Ala mutation (termed pEGFPAlal). 
Restriction sites were confirmed by overnight digestion of the constructs with one 
enzyme followed by phenohchloroform extraction of the DNA and digestion with the 
second enzyme of interest. Completed digests were run out on 1% agarose gels at 
75v in Ix Tris-Acetate-EDTA buffer. The Met to Ala mutation was confirmed by 
the use of dideoxynucleotide sequencing.
Generation of Rat AiAR-GFP cDNA Expression Constructs
These constructs were generated by PCR using previously described pCMV5 
/ HA epitope tagged WT, Cys (302, 305) Ala and Thr (307, 318, 319) ^  Ala 
mutant AgAR cDNAs as templates (Palmer and Stiles, 2000). In each case, the 
following primers were used:
5 ’-TGATTAAGCTTCCACC/fTGAAAGCCAACAATACCACGAC-3 ’ (sense) and 
5’-TGATTCCCGGGCAGCGTAGTCTGGGACGTC-3’ (antisense). The sense 
primer was designed to remove the N-terminal HA epitope tag sequence and add a 
Hindlll site (bold) upstream of a consensus Kozak sequence (underlined) and the 
A3AR initiating methionine (italics). The antisense primer was designed to remove
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the A3AR stop codon and add a Smal site (underlined). This was to allow in-frame 
ligation of the A3AR coding region with that of GFP following subcloning of Hindlll 
/ Smal digested PCR products into similarly digested pEGFPAlal. PCR was carried 
out as previously described.
An A 1-A3AR chimeric receptor was also generated with a GFP tag. The 
template employed was an HA epitope tagged AiCT3AR previously described by 
Palmer et al. (1996). The primers:
5’-ATTTGGAATTCCCACCATGCCGCCCTCCATCTCAGC-3’ (sense) and 5’- 
ATTTCGGTACCGCAGCTAGTCTGGGAC-3 ' (antisense) removed the HA tag as 
before and inserted an EcoRI site at the N-terminus. A Kpnl site was inserted at the 
C-terminal tail. Restriction sites are underlined. pEGFPAlal and AiCT3AR were 
digested with EcoRI and Kpnl and ligated to give the chimeric receptor expressing 
GFP. The presence of all indicated mutations in each construct was verified by the 
use of dideoxynucleotide sequencing.
2.4 Experimental Techniques
2.4.1 SDS-PAGE Electrophoresis
Samples were separated by SDS-PAGE using a 10% acrylamide resolving gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M Tris (pH 8 .8 ), 0.1% (w/v) 
SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) 
TEMED) and 3% acrylamide stacking gel (3% (v/v) acrylamide, 0,1% (v/v) 
bisacrylamide, O.IM Tris (pH 6 .8 ), 0.1% (w/v) SDS, 0.01% (w/v) ammonium 
persulphate and 0.001% (v/v) TEMED). Electrophoresis of the samples was carried 
out alongside prestained SDS molecular weight markers (6.5 -  175 kDa) in a running 
buffer (27.4mM Tris, 0.19M glycine, 0.1% (w/v) SDS) at 150 Volts until the dye 
front reached the end of the gel. At this point electrophoresis was stopped and the 
proteins transferred to nitrocellulose at 400 mA for 45 minutes in transfer buffer 
(24.7mM Tris 0.19M glycine, 20% (v/v) methanol).
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2.4.2 Cell surface labelling with biotin-LC-hydrazide / receptor internalisation
assay
Confluent CHO cells expressing adenosine receptors were passaged 1 : 8  from 
75cm^ flasks into 6 -well dishes and cultured overnight in regular medium. The next 
day, the cells were washed and 0.75ml of Ham’s F-12 medium applied. Time 
courses of receptor internalisation were initiated by the addition of lp,M (R)-PIA to 
the cells for the desired time period. Reversal of internalisation was brought about 
by the removal of agonist, washing once with pre-warmed medium and addition of 
the antagonist MRS 1523 for the time required. Experiments were terminated by 
placing the cells on ice. All subsequent steps were carried out at 4®C unless 
otherwise stated.
Cell monolayers were washed three times with ice cold PBS-CM and sodium 
periodate in PBS-CM added at a concentration of lOmM for 30 minutes. After 
removal of the sodium periodate, the monolayers were washed twice with PBS-CM 
and three times with O.IM sodium acetate-CM (O.IM sodium acetate (pH 5.5) 
supplemented with ImM MgCli, O.lmM CaClz). O.lmM biotin -  LC -  hydrazide in 
sodium acetate-CM was added to the cells for a further 30 minutes. Termination of 
the labelling was brought about by removal of the biotin with subsequent washing of 
the monolayers three times in PBS. Cells were solubilised by the addition of 0.5ml / 
well immunoprécipitation buffer (RIPA buffer [49.92mM HEPES (pH 7.5), 
149.76mM NaCl, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxycholate and 0.1% 
(w/v) SDS] supplemented with O.IM NaF, 5mM EDTA (pH 8 ), O.OIM NaP0 4 , 
O.lmM PMSF, O.Olmg/ml soybean, lOmg/ml benzamidine, 0.7jug/ml pepstatin A) 
and incubation at 4°C for 1 hour on a rotating wheel. Insoluble material was pelleted 
by centrifugation for 15 minutes at 14,000g and the supernatant removed to fresh 
microfrige tubes.
BSA standards ranging from 0-2mg/ml were used to obtain a best-fit straight 
line of A4 9 2  in a bichinchonic acid (BCA) based assay using the graph package 
“Prism”. Protein concentrations of lOpl samples of each unknown extract were 
calculated by comparison to the BSA standards. Specific proteins were 
immunoprecipitated by incubating the extracts with lOpl protein-A Sepharose beads 
with 0.4% (w/v) IgG free BSA in the presence of Ipg 12CA5 overnight.
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Immune complexes, isolated by centrifugation, were washed twice (1 ml/wash) 
with immunoprécipitation buffer supplemented with 0.2M ammonium sulphate, once 
with immunoprécipitation buffer alone, and eluted from the protein A-Sepharose by 
a 1 hour incubation at 37®C with SOpl electrophoresis sample buffer (50mM Tris pH 
6 .8 , 10% (v/v) glyerol, 12% SDS, few grains bromophenol blue).
20|l i 1 of each sample were separated by SDS-PAGE and transferred to nitrocellulose
(2.4.1), Membranes were washed twice briefly in PBS and non -  specific protein 
binding sites blocked by a 60 minute incubation in Blotto (5% (w/v) skimmed milk 
powder, 0.2% (v/v) Triton X-100, 0.001% (w/v) thimerosal in PBS) at room 
temperature.
Cell surface biotin-labelled receptors were identified by incubation of the 
membrane with horseradish peroxidase (HRP)-conjugated streptavidin for 60 
minutes at room temperature and visualisation detected by an enhanced 
chemiluminescent procedure (ECL).
2.4.3 Preparation of cell extracts for immunoblotting
Confluent monolayers in 6 -well dishes were washed three times with PBS 
and solubilised by adding 0.25 ml/well of immunoprécipitation buffer and scraping
(2.4.2). Following transfer to microfuge tubes, solubilisation was achieved by a 
Ihour incubation on a rotating wheel at 4*^ C. Insoluble material was pelleted and the 
supernatant removed to a fresh tube. Protein concentrations were calculated as 
described (2.4.2), an equivalent volume of loading buffer added and the samples run 
directly on SDS-PAGE.
2.4.4 Immunoblotting
Samples separated by SDS-PAGE were transferred to nitrocellulose and non­
specific binding sites blocked with Blotto. Membranes were then incubated with the 
appropriate dilution of primary antibody in fresh blocking buffer for 1 hour, washed 
three times with Blotto and HRP-conjugated secondary antibody added in fresh, high 
detergent blotto (Blotto supplemented with 1.02% Triton X-100 and 0.1% SDS). 
Primary antibodies giving weak signals were incubated in low detergent blotto 
(Blotto supplemented with 0.02% Triton X-100 and 0.1% SDS).
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2.4.5 Receptor phosphorylation
Confluent receptor-expressing CHO cells in 6 -well dishes were washed twice 
with phosphate-ffee DMEM and returned to the incubator for 90 minutes with 
medium supplemented with 0.2pCi / ml of carrier free ^^P-phosphate to label the 
intracellular ATP pool. After incubation with the indicated drug for the appropriate 
time period, reactions were terminated by placing the cells on ice. The monolayers 
were washed three times with ice-cold PBS and solubilised as previously described 
for the receptor internalisation assay. Receptors were then subject to 
immunoprécipitation with 12CA5 (2.4.2) and equal amounts of protein separated by 
SDS-PAGE. On completion of electrophoresis, the gel was removed, dried down 
and analysed by autoradiography.
2.4.6 Saturation radioligand binding assays with ^^^I-AB-MECA in isolated
membranes
A confluent 75cm^ flask containing receptor expressing CHO cells was placed 
on ice and washed three times with ice-cold PBS. The cells were scraped from the 
bottom of the flask into 4mls of PBS and transferred to a pre-chilled, 13ml centrifuge 
tube on ice. Cells were pelleted by a 4K 10 minute spin at 4°C, the supernatant 
removed and the cell pellet resuspended in 1ml of lysis buffer (lOmM Tris, 5mM 
EDTA [pH 7.5]). Disruption of cells on ice was by twenty up and down strokes in a 
glass-on-glass Dounce homogeniser. The homogenate was removed to a micro fuge 
tube and membranes pelleted by centrifugation at 14,000g for 15 minutes.
On removal of the supernatant, the pellet was resuspended in 4mls of 
radioligand binding buffer (50mM Tris, lOmM MgClz, ImM EDTA [pH 8.26]) and 
transferred to the homogeniser. Ipl of stock ADA was then added to give a final 
concentration of 0.47units/ml, and the cells disrupted by Dounce homogenisation as 
before. 150pl of the membranes were added immediately to duplicate assay tubes 
containing iodinated radioligand, ranging from 0.25-8.OnM, and incubated at 37°C 
for 30 - 45 minutes in a shaking water bath. Non-specific binding was defined in 
parallel by the inclusion of (R)-PIA to a final concentration of lOpM. A GF/B filter 
was pre-soaked in distilled water containing 0.03% (v/v) polyethyleneimine in 
preparation of harvesting using a Brandel cell harvester. The binding samples were 
washed through the filter three times with wash buffer (binding buffer supplemented
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with 0.01% (w/v) CHAPS), filter discs removed to scintillation vials and the 
radioactivity counted.
To obtain the specific binding achieved by the radioligand on the receptors, 
non-specific counts were subtracted from the total counts and the resulting values 
plotted against [^^^I-AB-MECA] nM. To determine the total number of receptors 
expressed (Bmax) and the equilibrium dissociation constant (Kd), the data was fitted to 
a nonlinear regression equation using the graph package ‘Prism’. A bichinchonic 
acid (BCA) protein assay, as described in 2.4.2, was used to determine the pg of 
protein added per tube. Combining the calculated B^ax, final assay volume in litres 
and pg protein added per tube, the receptor level was expressed in pmol/mg. An 
example of this calculation can be found in Appendix 1.
2.4.7 Competition Radioligand Binding with ^^^I-AB-MECA in isolated 
membranes
Duplicate tubes were set up containing, 50pl water, (R)-PIA (50pM) or MRS 
1523 (ranging from lO'^ -^lO'^^M) to which was added 50pl of 0.5nM ^^^I-AB-MECA. 
In all competition bindings, non-specific binding was determined as counts per 
minute (cpm) after addition of lOpM (R)-PIA (final concentration).
Cells were prepared as for the saturation binding assay and 150pl added per 
reaction tube. Specific binding was calculated by subtraction of non-specific binding 
from total binding and the data plotted as cpm v log [MRS 1523] M using a 
nonlinear regression fit (‘Prism’) to obtain the concentration at which 50% of 
specific binding was inhibited (IC50). The equilibrium dissociation constant for 
binding of the competing unlabelled drug (Ki) was then determined using the Cheng- 
Prusoff equation (Cheng and Prusoff, 1973) and expressed as a p,M concentration 
(Appendix 2).
2.4.8 Confocal Laser Scanning Microscopy
HEK 293 or CHO cells were split, transfected appropriately and analysed 24- 
48 hours post-transfection.
Live cells were used to visualise the internalisation and recycling of the receptor. 
Cells were grown on glass coverslips, mounted on the imaging chamber and 
maintained at 37®C in Krebs-Ringer-HEPES-BSA (KRHB) buffer (120mM NaCl,
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5mM KCl, 1.2mM MgS0 4 , 1.2mM CaCh, 20mM HEPES, 1.2mM Na2HP0 4 , lOmM 
glucose, 0.1% BSA). All agonists and antagonists were applied in KRHB buffer. 
For other studies, fixed cells were used. The cells on the coverslips were washed 
with PBS and fixed for 20 minutes at room temperature using 4% (w/v) 
paraformaldehyde in 5% (w/v) sucrose / PBS (pH 7.2). Cells were washed again 
with PBS and permeabilised for 3 minutes with 0.4% (v/v) Triton X-100 in PBS. 
Antibody dilutions were prepared in 0.1% (v/v) new bom calf serum (NBCS) / 0.2% 
(w/v) gelatin / PBS. With the exception of the Alexa-labelled Concanavalin A 
antibody (1 :1 0 0 ,0 0 0 ), primary and secondary antibodies were used at 1 : 2 0 0  and 
1:400 dilutions respectively. lOOjil of antibody dilution for each coverslip was 
placed onto nescofilm, the coverslips placed with the cells facing downwards and 
incubated at room temperature for 1 hour. Cells were then washed twice with 
PBS/NBCS/gelatin and placed onto nescofilm with secondary antibody for a further 
Ihour. Coverslips were then washed twice with PBS/NBCS/gelatin and once with 
PBS prior to mounting on microscope slides with 40% (v/v) glycerol in PBS.
Cells were observed using a Zeiss Axiovert 100 laser scanning confocal 
microscope (Zeiss, Oberkochen, Germany) using a Zeiss Plan-Apo 63 x 1.4 NA oil 
immersion objective, pinhole of 20 and electronic zoom between 1 and 4. GFP was 
excited using a 488 nm argon / krypton laser and detected with 515-540 nm band 
pass filter. The Alexa-modified antibodies were excited at 543nm and detected with 
a long pass band filter 590nm. The images were manipulated with Zeiss LSM or 
MetaMorph software (Universal Imaging Corporation, West Chester, PA).
2.4.9 Statistical Analysis
All statistical analysis was carried out using the student t-test as described in 
the GraphPad softwear, ‘Prism 3.0’.
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Chapter 3
Kinetics of Inhibitory Adenosine Receptor Internalisation
3.1 Introduction
The A3AR is the most recently cloned of the adenosine receptors, a family of 
GPCRs comprising of Ai, A2A, A2B and A3 (Zhou 1992). The A; and A3ARS have 
been shown to be important in cardioprotection (Auchampach & Bolli, 1999), mast 
cell and eosinophil activation (Kohno et ah, 1996) and neuroprotection (Abbracchio 
et al., 1997). Due to the critical role of adenosine in these processes, it is crucial that 
we understand both the signalling pathways that are activated by these receptors and 
how signalling is regulated at the molecular level. This information may allow us to 
propose strategies with which to modify AR signalling in disease states.
ARs couple to the inhibitory (Gi) family of G proteins. Upon agonist binding, 
Gi inhibits AC (Gilman; 1987) leading to a decrease in intracellular cAMP levels, 
activates the MAPK signalling cascade, and elevates intracellular IP3 concentration 
via activation of PLC-P (Ramkumar et al., 1993). Rapid termination of GPCR 
signalling is typically regulated via receptor phosphorylation by either second 
messenger-activated and/or GRKs (Haussdorf, 1990). The A3AR as been shown to 
have 3 principal phosphorylation sites in its C-terminal tail at Thr 307, 318 and 319 
which are targets for the GRK-family (Palmer et al; 1995, 1996 and 2000). Work 
principally performed on the ^ 2AdR has resulted in a model where agonist stimulated 
phosphorylation of GPCRs by GRKs leads to the binding of arrestin proteins 
(Krupnick and Benovic, 1998; Pitcher et al.; 1998) resulting in: 1) uncoupling of 
activated receptors from G-proteins leading to a functional desensitisation of G- 
protein-linked signalling; 2) clustering of activated receptors to CCVs - it is thought 
that receptors proceed from the CCVs to endosomes where they may either be 
dephosphorylated and recycled back to the plasma membrane for another round of 
agonist activation, or targeted to lysosomes where they are degraded and down- 
regulated; and 3) recruitment and activation of src family tyrosine kinases leading to 
activation of the ERK signalling cascade (Luttrell et al., 1997,1999a,b)
Desensitisation, the process whereby a GPCR-initiated response reaches a 
plateau and then diminishes despite the continual presence of agonist, can 
simultaneously initiate alternate signalling pathways after receptor clustering and 
internalisation (Lefkowitz; 1998). However, not all GPCRs follow this paradigm. 
For example, activation of the ERK pathway by the AiAR precedes the onset of 
receptor internalisation. (Dickenson et al.; 1998). We must therefore understand the 
unique roles played by receptor phosphorylation and/or internalisation in controlling
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AsAR-activated intracellular signalling cascades.
In the case of the A3AR, although it has been shown to be rapidly 
phosphorylated in response to agonist exposure (Palmer et al,, 1995c), it is not 
known if the receptor is internalised. By employing a panel of wild type and mutant 
A3 and AiARs, the sensitivity of these receptors to agonist stimulated 
phosphorylation and internalisation was examined.
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3.2 Results
The role of AsAR-activated signalling cascades on receptor internalisation 
was investigated by treating AgAR-expressing CHO cells with an AR agonist and 
activators of various second messenger regulated kinases. As described in the 
Methods, the presence of a HA - epitope tag at the N and C-termini of the A3AR 
facilitated identification of cell surface A3AR glycoproteins. This was utilised as an 
assay for detecting reductions in cell-surface A3 ARs. Following treatment as shown 
in the Figure Legend, cell surface glycoproteins were labelled with biotin and the 
cells solubilised with immunoprécipitation buffer (see Methods, section 2.4.2). As 
biotin hydrazide does not cross the cell membrane, only receptors present at the cell 
surface are labelled. Receptor proteins were immunoprecipitated with the HA- 
specific antibody 12CA5, fractionated by SDS-PAGE and transferred to a 
nitrocellulose membrane. The cell surface biotin-labelled receptors were identified 
by incubation of the membrane with horseradish peroxidase-conjugated (HRP) 
streptavidin and enhanced chemiluminescence (ECL). Figure 3.1 shows the results 
of this assay.
The AR agonist NECA induced a 56 ± 18% (p<0.05) loss of receptor from 
the cell surface. Several activators of second messenger-regulated kinases such as 
the phorbol ester phorbol-1 2 -myristate-l 3-acetate (a direct stimulator of 
conventional and novel PKC enzymes), the calcium ionophore A23187, and 8 - 
bromo-cyclic guanosine monophosphate (cGMP), which activates cGMP-dependent 
protein kinases, could not mimic the action of NECA. However, elevation of 
intracellular cAMP levels by forskolin resulted in a smaller reduction in cell-surface 
receptor levels than NECA and induced a reduced mobility of the A3AR protein on 
SDS-PAGE. Phosphorylation is known to reduce the electrophoretic mobility of a 
variety of GPCRs (Ali et ah, 1993) but an increase in phosphorylation was 
undetectable in response to forskolin treatment, consistent with previous 
observations (Palmer et ah, 1995c, Fig. 3.2). The elevation of cAMP levels is 
unlikely to be responsible for the effects of agonist on A3AR internalisation for three 
reasons. Firstly, studies on the A3AR have shown it to be linked to Gi, leading to a 
decrease in cAMP levels (Linden et ah, 1993; Palmer et ah, 1995b). Secondly, 
unlike the effect of forskolin treatment, exposure to agonist does not alter the 
mobility of the A3AR protein on SDS-PAGE. Thirdly, agonist treatment induces a 
much greater level of internalisation of cell-surface A3ARS than that observed after
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forskolin treatment. Taken together these data suggest that agonist and forskolin are 
causing loss of receptor via distinct mechanisms.
To further characterise the effect of agonist on loss of cell surface receptors, 
the relationship between agonist concentration and the extent of receptor 
internalisation was assessed (Fig. 3.3). The response appeared to be biphasic, with 
low nanomolar concentrations of (R)-PIA (5-50nM) consistently producing a small, 
albeit statistically insignificant (p>0.05, N/S) increase in the levels of cell-surface 
AgARs, with higher concentrations giving an effective concentration 50% (EC50) 
value for loss of cell surface AgARs of approximately 0.2pM.
To determine if A3AR internalisation was agonist-specific, the effect of pre­
incubating transfected cells with MRS 1523, a selective A3AR antagonist, was 
assessed (Li et ah, 1998). CHO cells stably transfected with the WT A3AR were pre­
incubated for 30 minutes with increasing concentrations of MRS 1523 (2.5nM- 
2,5pM). Cells were then washed and stimulated with IpM (R)-PIA, an agonist 
concentration sufficient to produce maximal receptor internalisation (Fig. 3.3). MRS 
1523 alone had no observed effect on cell surface receptor levels, but after agonist 
stimulation, it was found to inhibit (R)-PIA-induced internalisation in a 
concentration-dependent manner. Quantitation of the blots revealed that half- 
maximal internalisation occurred between 2.5 and 25nM MRS 1523 (Fig. 3.4). 
Having shown concentration-dependent antagonism of agonist-mediated receptor 
internalisation by MRS 1523, the effect of this A3AR-selective antagonist on 
receptor phosphorylation was assessed. A3AR-expressing CHO cells were pre­
labelled with ^^P-orthophosphate and incubated with the indicated concentrations of 
MRS 1523 for 30 minutes prior to treatment with (R)-PIA at a final concentration of 
IpM for 10 minutes (Fig. 3.5). As was seen with internalisation, increasing MRS 
1523 concentration led to inhibition of receptor phosphorylation with an IC50 value 
between 0.5 and 5pM. These data demonstrate that both phosphorylation and 
internalisation of the A3AR are agonist-mediated processes that can be blocked by 
the A3AR-selective antagonist MRS 1523. Competition binding studies carried out 
in membranes isolated from the same transfected cells using MRS 1523 versus 
AB-MECA produced a Ki value of 130 ± 0.3nM coiTesponding to a previously 
reported Ki value of 130nM for this antagonist at the rat A3AR (Li et al., 1998) (Fig. 
3.6).
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To further characterise any relationship between A3AR phosphorylation and 
internalisation, we compared the time-courses for (R)-PIA-mediated phosphorylation 
and internalisation of WT A3 ARs. CHO cells expressing the WT A3AR were 
labelled with ^^P-orthophosphate and stimulated with lOpM (R)-PIA at the time 
points indicated (Fig. 3.7). Following immunoprécipitation with 12CA5 and SDS- 
PAGE, phosphorylated A3ARS were visualised by autoradiography. The for 
phosphorylation was determined to be approximately 1 minute (Fig. 3.7, n = 3). Cell 
surface labelling experiments demonstrated that over a 60 minute time-course, the 
number of cell surface receptors decreased by 78 ± 6 % (p<0.05), with a tvj of 
approximately 10 minutes (Fig. 3.8). Together, these data show internalisation of the 
A3AR is temporally preceded by receptor phosphorylation (ty^  = 1 & 10 minutes for 
phosphorylation and internalisation respectively). This suggests that the A3AR may 
require phosphorylation to enable it to undergo internalisation.
In contrast to the A3AR, the AiAR has no defined phosphorylation sites in its 
C-terminal tail (Fig. 3.9). Despite coupling to the same inhibitory G protein, it is 
hypothesised that the AiAR may show differences in its ability to undergo agonist- 
mediated phosphorylation and internalisation. Time-courses of phosphorylation and 
internalisation of HA-tagged A^ARs expressed in CHO cells were carried out as 
previously described. Treatment with 5qM (R)-PIA induced no visible 
phosphorylation of AiARs compared to WT AgARs after 10 minutes (Fig. 3.10). 
Agonist stimulation of Ai AR-expressing CHO cells with 1 jiiM (R)-PIA induced a 55 
± 4% (p<0.05) reduction of AiAR from the cell membrane with a t.^  of 90 minutes 
(Fig. 3.11). This contrasts dramatically with ty^  of internalisation of 10 minutes 
displayed by the A3AR.
Experimental work on other receptors has shown the C-terminal domain to be 
important in controlling receptor regulation (Cyr et al.; 1993, Koshimizu et al.; 1995, 
Shibasaki et al.; 1999 and Trejo et al.; 1999). In contrast to the AiAR, the A3AR is a 
good substrate for agonist-mediated phosphorylation by GRKs on Thr residues 
present in its C-terminal tail (Palmer et al.; 1996). To ascertain if the rapid 
internalisation of the A3AR was initiated by phosphorylation of the receptor by 
GRKs, an A3AR in which the GRK phosphorylation sites at Thr 307, 318 and 319 
were mutated to non-phosphorylatable Ala residues was constructed and termed (T- 
A)A3AR. This mutant receptor was subjected to treatment with (R)-PIA as before. In
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contrast to WT A3AR, after 10 minutes of 5pM (R)-PIA stimulation, no 
phosphorylation of the (T-A)A3AR was detectable (Fig. 3.12) and only following a 
60 minute treatment was a small reduction in cell surface receptor observed (8 . 2  ± 
9.5%, p>0.05 N/S, Fig. 3.13). These data suggest that disruption of the GRK 
phosphorylation sites lead to a dramatic impairment in the ability of the A3AR to 
undergo agonist-mediated internalisation. In addition, it supports the hypothesis that 
phosphorylation is required for rapid A3 AR internalisation.
By employing a second mutant A3 receptor, the (C-A)A3AR, in which the 
predicted palmitoylation sites at Cys 302 and 305 were mutated to non- 
palmitoylatable Ala, the effect of loss of palmitoylation on receptor phopshorylation 
and internalisation was investigated. On comparison to WT A3AR, the Cys to Ala 
mutant was found to display substantial basal phosphorylation (Fig. 3.14). However 
following agonist stimulation, the overall phosphorylation level reached was 
equivalent to WT A3AR. Following agonist stimulation, (C-A)A3AR internalised at 
a faster rate than WT with a ty, of approximately 3-4 minutes (Fig. 3.15). As this 
mutation increased the rate of receptor internalisation, potential effects on receptor 
recycling following agonist removal were examined. CHO cells transfected with 
WT A3 or (C-A) A3 ARs were stimulated with IpM (R)-PIA for 30 minutes, a time 
sufficient to allow maximal internalisation of both receptors. Following agonist 
removal, monolayers were washed and MRS 1523 added to a final concentration of 
5pM for a further 30 minutes. Cell surface receptors were then labelled with biotin 
hydrazide and immunoprecipitated as described previously. These experiments 
revealed that the (C-A)A3AR recycled back to the membrane at a greater rate (Fig. 
3.16, ty, = 6  mins) than WT and a visibly, statistically significantly higher percentage 
was recovered (94 ± 5% compared with 49 ± 11% for WT, p<0.05). Having shown 
the C-terminal tail to be important in regulating A3AR phosphorylation and 
internalisation, these data suggest that this region of the A3AR controls the 
internalisation kinetics of this receptor.
With the main differences between the Ai and A3ARS being their ability to 
undergo phosphorylation and subsequent internalisation upon agonist stimulation, the 
possibility that the A3AR could confer regulatory kinetics to the Ai AR by exchange 
of the C-terminal tails was investigated using a chimeric receptor termed AiCT3AR. 
Constructed by Palmer et al.(1996), this receptor comprises the main body of the
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human AiAR (aa’s 1 - 310), up to and including its predicted palmitoylation site 
(Cys 309), fused to the 14 C-terminal amino acids of the rat AgAR (Fig. 3.17) 
containing the GRK phosphorylation sites at Thr 307, 318 and 319. This chimera 
had been shown to be pharmacologically similar to the AiAR with respect to its 
ability to bind AiAR-selective ligands (Palmer et ah, 1996). Time-course 
experiments revealed that AiCTSAR phosphorylation occurred with a t.^  of 
approximately 1 minute (Fig. 3.18). Analysis of loss of receptor from the cell 
surface revealed that the chimeric receptor internalised in a time-frame that both 
followed that of receptor phosphorylation, and was similar to that of WT A3AR (t/j = 
15 minutes. Fig. 3.19). It can therefore be suggested that the rapid agonist induced 
internalisation of the A3AR, is regulated entirely by phosphorylation in its C-terminal 
region by GRKs.
A substantial body of biochemical and functional data revealed that Ai and 
AgARs were subject to distinct regulation. We were interested in visualising the 
dynamics of this in real time in single cells. The use of chimeric proteins containing 
modified forms of the GFP from Aequorea victoria has provided the means to 
visualise the expression, distribution and trafficking of proteins in response to 
stimulation in intact cells in real-time (Barak et ah; 1997, Kallal et ah; 1998, Drmota 
et ah; 1998 and Groarke et ah; 1999). Visualisation of a panel of ARs was by the 
fusion of an enhanced form of GFP at the C-terminus of each receptor (see Methods, 
section 2.3.7 & Figs. 3.20, 3.21). The enhanced form of GFP, approximately 27kDa 
in size, has a mutation at Ser65 (S65T). This single mutation causes a shift in the 
excitation spectrum of the protein leading to an enhanced fluorescence compared to 
WT GFP (Barak et ah, 1997). One issue in any approach of this nature must be to 
demonstrate that the chimeric receptor-GFP maintains the pharmacological and 
signal transduction properties of the native receptor. To investigate this, CHO cells 
were transfected with WT Ag or A3AR-GFP, labelled with biotin and 
immunoprecipitated using 12CA5, which binds the HA-epitope tag present on both 
receptors. Both WT and GFP-tagged receptors were detected by biotin labelling, 
suggesting that the receptor-GFP construct could be processed correctly and targeted 
to the membrane (Fig. 3.22). To determine if the addition of GFP altered agonist 
binding to the receptors, COS cells were transiently transfected with either WT or 
A3AR-GFP receptors and membranes prepared for ^^^I-AB-MECA radioligand 
binding assays (see Methods, section 2.4.6). Saturation isotherm analysis of ^^^I-AB-
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MECA binding produced a Kd of 2.175 ± 0.31 nM and 2.03 ± O.lSnM (p>0.05, N/S) 
and Bmax of 1.2 ± 0.3pmol/mg and 1.4 ± 0.2pmol/mg (p>0.05, N/S) for the WT and 
GFP-tagged ARs respectively (Fig. 3.23), indicating that the presence of the GFP tag 
had no effect on agonist binding affinity. These values for transfected AgARs 
correlate with binding data obtained from RBL-2H3 cells that express the A3AR 
endogenously (Kd = 3.61 ± 0.3nM; Olah et al., 1994). To determine if agonist- 
mediated GRK phosphorylation of the receptors was affected by the presence of the 
GFP tag at the C-terminus of the ARs, CHO cells were transfected without or with 
WT A3 or A3AR-GFP and labelled with ^^P-orthophosphate prior to agonist 
stimulation as previously described. Following a 5 minute agonist exposure, 
phosphorylation was detected for both the WT A3 and A3AR-GFP (Fig. 3.24). This 
suggested that accessibility of the phosphorylation sites in the C-terminal tail to GRK 
was not being blocked by the presence of GFP. Finally, although the AgAR-GFP 
construct had been shown to bind ligand and become phosphorylated after agonist 
exposure, to use these GFP-tagged receptors for visualisation of receptor trafficking, 
we had to ensure that the A3AR-GFP construct did in fact undergo internalisation 
following agonist stimulation. A time course of agonist-mediated internalisation was 
carried out for A3AR-GFP as previously described. As Fig. 3.25 shows, agonist 
stimulated loss of cell surface receptors was detectable despite the addition of the 
GFP tag.
Having constructed GFP-tagged receptors demonstrating pharmacological 
and signal transduction properties similar to the WT receptor, the next step was to 
gain a visual perspective on the biochemical data obtained. GFP-tagged receptors 
were transiently transfected into CHO cells and seeded onto coverslips prior to 
visualisation of receptor distribution by confocal laser scanning microscopy (see 
Methods, section 2.4.8). AR-GFP constructs were subjected to treatment with IqM 
(R)-PIA and images collected between 0 - 3 0  minutes following agonist addition.
In the basal state, the expressed receptors had a predominantly plasma 
membrane localisation with only low levels of receptor visible intracellularly. 
Following agonist stimulation, WT A3 AR-GFP was seen initially to cluster into 
distinct punctate spots on the cell surface. Over a 30 minute time period, cells 
underwent structural changes and ruffling of the cell membrane became apparent. 
This was associated with the formation of small extensions of the cell, which could 
be identified as lamellipodia. Receptors internalised to cluster in a peri-nuclear
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location by approximately 15 minutes (Fig. 3.26). Images obtained for the (C- 
A)A3AR-GFP displayed the enhanced internalisation rate (t/, = 4 minutes) observed 
in immunoprécipitation assays (Fig. 3.27) although changes in cell structure were not 
as apparent. In contrast, the phosphorylation-deficient (T-A) A3 AR-GFP receptor 
remained at the cell membrane over the 30 minute time-course (Fig.3.28), providing 
further visual evidence for the requirement of phosphorylation to induce A3AR 
internalisation. While the (T-A) A3 AR-GFP transfected cells displayed the cellular 
protrusions observed with the WT A3AR-GFP stimulation, this appeared to be a 
transient phenomenon, with the cells returning to basal morphology approximately 
20-30 minutes after agonist treatment.
As with the WT A3 AR-GFP, the WT Ai AR-GFP clustered at the cell 
membrane, but over a 30 minute time period, no significant internalisation was 
evident (Fig. 3.29). Structural changes were minor, could not be defined, and were 
seen to be transient as for (T-A) A3 AR-GFP. This was in dramatic contrast to the 
chimeric AiCT3AR-GFP which again showed receptor clustering, but was followed 
by rapid internalisation (ty^  =15 min, Fig. 3.30). The membranes of the cells became 
ruffled and extensions were observed as seen for the WT A3ARS, which were 
sustained for at least 30 minutes. Internalised AiCT3AR-GFP appeared not to 
cluster so much to a peri-nuclear location as that observed for WT A3AR-GFP, but 
was seen to distribute in small punctate spots throughout the cytoplasm.
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Figure 3.1 Effect of short-term agonist exposure and
activators of second messenger regulated kinases 
on cell-surface A3AR levels
CHO cells stably expressing an HA-tagged WT A3AR were subjected to a 30 minute 
exposure at 37°C to either vehicle, AR agonist (NECA), phorbol-12-myristate-l3- 
acetate (PMA), calcium ionophore A23187, forskolin or 8 -bromo-cGMP at the 
concentrations shown. The cell surface glycoproteins were then labelled with biotin 
hydrazide followed by receptor immunoprécipitation with 12CA5. 
Immunoprecipitates were separated by SDS-PAGE and biotin-labelled cell-surface 
receptors visualised by transfer to nitrocellulose and blotting with straptavidin- 
conjugated HRP as described in the Methods. Typical data is shown from one of 
tluee experiments.
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Figure 3.2 Effect of forskolin treatment on A3AR
phosphorylation
^^P-labelled CHO cells expressing the WT A3AR were incubated with or without 
lOpM NECA for 5 minutes or with foskolin for 1 or 2 hours at 37°C, Reactions were 
terminated and receptors immunoprecipitated with 12CA5 as previously described. 
Immunoprecipitated proteins were fractionated by SDS-PAGE, the gel dried and 
visualised by autoradiography. Typical data is shown from one of three experiments.
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Figure 3,3 Effect of increasing agonist concentration on
A 3 A R  receptor internalisation
WT A3AR expressing CHO cells were incubated with (R)-PIA at the concentrations 
indicated for 30 minutes at 37°C. Cell surface glycoproteins were then labelled with 
biotin before receptor immunoprécipitation with 12CA5 and visualisation as 
described in the Methods (section 2,4.2). Blots were quantified by densitometric 
scanning and values represent mean ± S.E. for thiee experiments. The level of cell 
surface receptor in the absence of agonist is set at 1 0 0 %.
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Figure 3.4 Effect of increasing antagonist concentration on
rat A3AR internalisation
CHO ceils stably expressing HA-tagged A3 ARs were subjected to pre-treatment with 
increasing concenti ations of the Ag-selective antagonist MRS 1523 for 30 minutes at 
37°C. Vehicle or (R)-PIA to a final concentration of IpM was then added for a 
fiirther 30 minutes. Placing the cells on ice terminated the reaction. The loss of cell- 
surface receptors was detected by labelling the cell-surface glycoproteins with biotin 
prior to receptor immunoprécipitation with 12CA5. Immunoprecipitates were
resolved by SDS-PAGE and cell-surface AgARs visualised by enhanced 
chemiluminescence as described in the Methods.
Blots obtained from three experiments were quantitated by densitometric scanning. 
The levels of cell-surface receptors in untreated cells were set at 100% and those 
treated only with agonist at 0%. The levels of cell-surface receptors in the agonist 
treated samples were normalised with respect to these limits. The figures opposite 
are a representative example of three experiments that produced similar results.
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Figure 3.5 Effect of increasing concentrations of the A3-
selective antagonist MRS 1523 on agonist- 
stimulated A3AR phosphorylation
^^P-labelled CHO cells stably expressing the A3AR were incubated for 30 minutes 
with increasing concentrations of MRS 1523 at 37°C as described in the Methods. 
Vehicle or (R)-PIA (final concentration of IpM) was then added for 10 minutes. 
Reactions were terminated and receptors immunoprecipitated with 12CA5 as 
previously described. Immunoprecipitated proteins were fractionated by SDS- 
PAGE, the gel dried and visualised by autoradiography (top). The graph shown 
opposite was calculated fi'om three autoradiographs and plotted as mean ± S.E. 
Receptor stimulation with agonist alone was set at 100%.
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Figure 3.6 MRS 1523 competition curves versus I-AB-
MECA binding in CHO cells stably expressing 
HA-tagged A 3 A R
Competition binding studies were earned out between ‘^ ^I-AB-MECA (0.5nM) and 
increasing concentrations of the -selective antagonist MRS 1523 in
membranes isolated from cells expressing HA-tagged WT A^ARs. Data was plotted 
as ‘^ ^I-AB-MECA (cpm) v log [MRS 1523] M using a non-linear regression curve- 
fitting programme. Result shown is a representative example from one of three 
experiments.
Average Kj values of 0.13 ± 0.03pM were calculated from 3 experiments.
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Figure 3.7 Time course of phosphorylation of WT A3AR
pre-treated CHO cells expressing the WT A3AR were incubated with lOpM (R)- 
PIA for the indicated times at 37°C. The reaction was then terminated and receptors 
immunoprecipitated with 12CA5 as described in the Methods. Proteins were 
separated by SDS-PAGE, the gel dried and phosphorylated A^ARs visualised by 
autoradiography. Quantitative analysis is from data pooled from three such 
experiments.
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Figure 3.8 Time course of agonist-mediated internalisation of
WT A AR
A3 expressing CHO cells were incubated with IpM (R)-PIA for the indicated times at 
37°C. Cell surface glycoproteins were then labelled with biotin hydrazide before 
receptor immunoprécipitation with 12CA5 and visualisation as described in the 
Methods. Blots were quantified by densitometric scanning and the values shown 
represent mean ± S.E. for three experiments. The levels of cell-surface receptors 
observed in the absence of agonist were set at 1 0 0 %.
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Figure 3.9 Alignment of AjAR and A3AR C-terminal
domains
The primary sequences of the C-terminal domains of the human AjAR and rat A3AR 
are shown. Phosphorylation sites at Thr 307, 318 and 319 of the A3AR are shown in 
blue.
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Figure 3.10 Comparison of agonist-mediated phosphorylation
of WT A3 and A^ARs
^^P-labelled CHO cells expressing the WT AiAR and WT A3ARS were incubated for 
10 minutes with or without 5p.M (R)-PIA at 37°C. The reaction was terminated and 
receptors immunoprecipitated with 12CA5 as described in the Methods. Proteins 
were separated by SDS-PAGE. Panel (A) shows a Western blot of the 
immunoprecipitated samples, demonstrating equal loading of each receptor construct. 
This process was cairied out for all subsequent experiments. Phosphorylated AgARs 
were visualised by autoradiography (B) following drying of the gel. This is a 
representative of multiple experiments giving the same results.
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Figure 3.11 Time course of agonist-mediated internalisation of
WT AiAR
Aj expressing CHO cells were incubated with 5pM (R)-PIA over a 20 hour period, as 
shown opposite, at 37°C. Cell surface glycoproteins were then labelled with biotin 
before receptor immunoprécipitation with 12CA5 and visualisation as described in 
the Methods. Blots were quantified by densitometric scanning and the values shown 
represent mean ± S.E. for three experiments. The levels of cell-surface receptors 
observed in the absence of agonist were set at 1 0 0 %.
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Figure 3.12 Comparison of agonist-mediated phosphorylation
of WT and (T-A)A3ARs
^^P-labelled CHO cells expressing the mutant (T-A)A3AR were incubated for 10 
minutes with or without 5pM (R)-PIA at 2>TC. The reaction was then terminated and 
receptors immunoprecipitated with 12CA5 as described in the Methods. Proteins 
were separated by SDS-PAGE, the gel dried and phosphorylated AjARs visualised 
by autoradiography. This is a representative example of three experiments showing 
the same results.
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Figure 3.13 Comparison of the effects of agonist treatment on 
cell surface levels of WT and (T-A)AgARs
CHO cells stably expressing the WT A3AR (top) or the phosphorylation deficient 
mutant (T-A)A3AR (bottom) were incubated with 5pM (R)-PIA for the indicated 
times at 3>TC. Cell surface glycoproteins were labelled with biotin before 
immunoprécipitation of receptors with 12CA5. Visualisation was as described in the 
Methods. This is a representative example of one of three experiments showing 
essentially identical results.
The graph shown represents quantitation of the results obtained from the blots and 
shows a statistically significant difference {p < 0.05) in the internalisation of the two 
receptors at 60 minutes.
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Figure 3.14 Comparison of agonist-mediated phosphorylation
ofWT and (C-A)A3AR
pre-treated CHO cells expressing the mutant (C-A)A3AR were incubated for 10 
minutes with or without 5pM (R)-PIA for the 10 minutes at 37°C. The reaction was 
then terminated and receptors immunoprecipitated with 12CA5 as described in the 
Methods. Proteins were separated by SDS-PAGE, the gel dried and phosphorylated 
AjARs visualised by autoradiography. This is a representative of three experiments 
giving the same results.
86
200
95
68 —
My (xlO-3)
43 ------
A3AR
29 —
18 —
+ ± 5 pM R-PIA, 10 Mins
Figure 3.15 Time course of agonist-mediated internalisation of
the mutant (C-A)AgAR
(C-A)A3AR expressing CHO cells were incubated with IpM (R)-PIA over a 20 
minute period at 37°C. Cell-surface glycoproteins were then labelled with biotin 
hydrazide before receptor immunoprécipitation with 12CA5 and visualisation as 
described in the Methods. Blots were quantified by densitometric scanning and the 
values shown represent mean + S.E. for three experiments. The levels of cell-surface 
receptors obseiwed in the absence of agonist were set at 1 0 0 %.
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Figure 3.16 Effect of MRS 1523 on (R)-PIA-induced 
internalisation and recycling of WT A3 and (C-
A)A3A R s
CHO cells transiently transfected with WT A3AR or (C-A)A3AR cDNAs were 
incubated with l|uM (R)~PIA for 30 minutes at 37°C. Membranes were then washed 
once with hesh medium and incubated with MRS 1523 to a final concentration of 
5p.M for the indicated times. Cell surface glycoproteins were labelled with biotin 
hydrazide before receptor immunoprécipitation with 12CA5 and visualisation as 
described in the Methods. Blots were quantified by densitometric scanning and the 
values shown represent mean ± S.E. for three experiments. The levels of cell-surface 
receptors observed in the absence of agonist were set at 1 0 0 %.
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Figure 3.17 2D snake diagram of AiCT3AR
Schematic representation of the chimeric A1-A3AR constructed by Palmer et 
al ,( 1996). The C-terminal tail of the A3AR was exchanged with that of the non- 
phosphorylatable A|AR. The main body of the A,AR was left intact up to and 
including its predicted palmitoylation site at Cys 309. HA-epitope tags were present 
at both the N and C-termini.
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Figure 3.18 Time course of agonist-stimulated
phosphorylation of the chimeric A^CTSAR
^^P-labelled CHO cells stably expressing A^CTSAR were treated ± IpM  (R)-PIA at 
37°C for the indicated times before termination of the reaction and receptor 
immunoprécipitation with 12CA5 as described in the Methods. Proteins were 
separated by SDS-PAGE and gels visualised by autoradiography. Quantitative 
analysis is from data pooled from three such experiments.
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Figure 3.19 Time course of agonist-mediated internalisation of
the AiCT3AR
CHO cells expressing the A,CT3AR were incubated with IjuM (R)-PIA for the 
indicated times at 37°C. Cell-surface glycoproteins were labelled with biotin and 
immunoprécipitation carried out using 12CA5 prior to visualisation as previously 
described. Blots were quantified by densitometric scanning. Values represent mean 
± S.E. for tliree experiments, with the levels of cell-surface receptor in the absence of 
agonist set at 1 0 0 %.
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Figure 3.20 Schematic representation of GFP-tagged A^ARs
The C-terminal HA-tag present on the A3AR was removed by PCR and the mutated 
receptor ligated into the multiple cloning site of pEGFP-Nl at Hindlll / Smal. The 
N-terminal HA-tag was left intact. The ATG start codon of GFP was mutated to Ala 
so that the ATG start codon of the A3AR was the only consensus initiator of 
translation for the whole construct. The Thr and Cys residues mutated to give the (T- 
A) and (C-A) mutant A3 receptors are also shown.
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Figure 3.21 Schematic representation of GFP-tagged
WT AjAR AND A]CT3AR
The C-teiTninal HA-tag present on the AjAR was again removed by PCR and the 
mutated receptor ligated into the multiple cloning site of pEGFP-Nl at Hindlll / 
Kpnl. The N-terminal HA-tag was left intact. The ATG start codon of GFP was 
mutated to Ala so that the ATG start codon of the AjAR was the only consensus 
initiator of translation for the whole construct. The C-terminal tail insertion, present 
in the A,CT3AR, is also shown.
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Figure 3.22 Cell-surface labelling of A3AR and A3AR-GFP
CHO cells expressing either WT or GFP-tagged AjARs were labelled with biotin and 
cell surface receptors iinmunoprecipitated with 12CA5 as previously described. 
Immunoprecipitates were resolved by SDS-PAGE and biotin-labelled cell-surface 
receptors visualised by transfer to nitrocellulose and blotting with straptavidin- 
conjugated HRP as described in the Methods (section 2.4.2). This is a representative 
example of one of three experiments giving the same results.
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Figure 3.23 Saturation analysis of I-AB-MECA binding to 
WT and GFP-tagged rat A3ARS
Membranes prepared from COS cells transiently transfected with WT (blue) and 
GFP-tagged (red) foims of the rat A3 AR were used in saturation binding studies with 
'^^1-AB-MECA. Membrane preparation and radioligand binding procedures are as 
described in the Methods (Section 2.4.6).
To obtain the specific binding achieved by the radioligand on the receptors, non­
specific counts were subtracted from the total counts and the resulting values plotted 
against [^^^I-AB-MECA] nM. To determine the total number of agonist binding sites 
(Bmax) and the equilibrium dissociation constant (Kd), the data was fitted by 
nonlinear regression analysis (Graphpad Prism). Average Kd and B^ax values of 
three experiments are shown in Table 3.1.
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Table 3.1 Table of ligand affinities and expression levels 
of WT A3AR and A3AR-GFP
Receptor Kd (nM) Bmax (pmol/mg) Signifîcance
W TA 3AR 2.175 ±0.31 1.2 ±0.3 p>0.05
A 3AR-GFP 2.03 + 0.18 1.4 ±0.2 p>0.05
Figure 3.24 Agonist-stimulated phosphorylation of WTA3
and AgGFP-tagged receptors
^^ P“labelled CHO cells stably expressing WT A3AR and A3AR-GFP were treated 
with or without IpM (R)-PIA at 2>TC for 5 minutes before termination of the 
reaction and receptor immunoprécipitation with 12CA5 as described in the Methods. 
Proteins were separated by SDS-PAGE and gels visualised by autoradiography. 
Shown opposite is a representative example of three experiments showing essentially 
identical results.
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Figure 3.25 Time course of agonist-mediated internalisation
of A3AR-GFP
A3AR-GFP expressing CHO cells were incubated with IpM (R)-PIA over a 60 
minute period at 37°C. Cell-surface glycoproteins were then labelled with biotin 
hydrazide before receptor immunoprécipitation with 12CA5 and visualisation as 
described in the Methods. Shown opposite is a representative example of three 
experiments showing essentially identical results.
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Figure 3.26 Real time visualisation of WT A3AR-GFP
Internalisation
CHO cells transiently transfected with WT A3AR-GFP cDNA were examined in live 
cell confocal microscopy experiments. Cells were maintained in KRHB buffer and 
treated with IpM (R)-PIA over a 30 minute period. Images were recorded at 1 
minute inteivals. Shown opposite is a representative example of multiple 
experiments that gave essentially identical results.
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Figure 3.27 Real time visualisation of (C-A)A3AR-GFP
internalisation
CHO cells transiently transfected with (C-A)A3AR-GFP cDNA were examined in 
live cell confocal microscopy experiments. Cells were sustained in KRHB buffer 
and treated with IpM (R)-PIA over a 30 minute period. Images were recorded at 1 
minute intervals. Shown opposite is a representative example of three experiments 
showing essentially identical results.
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Figure 3.28 Real time visualisation of (T - A) AR-GFP
internalisation
CHO cells transiently transfected with (T - A) AR-GFP cDNA were examined in 
live cell confocal microscopy experiments. Cells were sustained in KRHB buffer 
and treated with IpM (R)-PIA over a 30 minute period. Images were recorded at 1 
minute inteivals. Shown opposite is a representative example of three experiments 
showing essentially identical results.
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Figure 3.29 Real time visualisation of WT AjAR-GFP
internalisation
CHO cells ti'ansiently transfected with WT A|AR-GFP cDNA were examined in live 
cell confocal microscopy experiments. Cells were sustained in KRHB buffer and 
treated with IpM (R)-PIA over a 30 minute period. Images were recorded at 1 
minute intervals. Shown opposite is a representative example of three experiments 
showing essentially identical results.
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Figure 3.30 Real time visualisation of AjCT3AR-GFP
internalisation
CHO cells transiently transfected with AjCTSAR-GFP cDNA were examined in live 
cell confocal microscopy experiments. Cells were sustained in KRHB buffer and 
treated with IpM (R)-PIA over a 30 minute period. Images were recorded at 1 
minute intervals. Shown opposite is a representative example of three experiments 
showing essentially identical results.
1 0 2

3.3 Discussion
Each AR subtype has unique ligand-binding properties and distinct patterns 
of tissue expression. The purpose of this work was to examine the inhibitory A3AR 
and to characterise its regulation. As stated previously, AsARs have been shown to 
be important in mediating the effect of adenosine in cardioprotection (Tracey et al., 
1996, 1998; Liang et a l, 1998 (a), (b); Dougherty et a l, 1998 and Thourani et a l,
1999), neuroprotection (von Lubitz et al, 1994,1999 and Dunwiddie et a l, 1997) and 
mast cell and eosinophil activation (Ramkumar et a l, 1993; Shepherd et al, 1996; 
Ezeamuzie et a l, 1999 and Salvatore et a l, 2000). If the regulation of these 
receptors could be characterised, it would represent a significant step towards 
deriving ways to manipulate AR signalling for treatment of cardiac disease, stroke 
and asthma.
The internalisation and regulatory properties of the p2AdR were used as 
starting points for our initial experiments. Agonist occupancy of the PzAdR leads to 
phosphorylation of the receptor protein by GRKs 2 & 5 and cAMP-dependent 
protein kinase (PKA) (Haussdorf et a l, 1990, Pitcher et a l, 1998). It was shown by 
Palmer et al. (1995c, 1996) that the A3AR is phosphorylated by GRKs, a process 
occurring within seconds of agonist exposure (Ferguson et a l, 2000; Fig. 3.7). 
Sibley and co-workers (1987) demonstrated that GRK phosphorylates only agonist- 
occupied or activated GPCRs. This initiates the binding of additional cytosolic 
factors such as arrestins (Lohse et a l, 1992). Arrestins are a class of soluble proteins 
that function in partnership with GRKs to stop or ‘arrest’ intracellular signalling by 
disrupting receptor-G-protein interaction, and targeting cytosolic proteins required 
for CCV formation to the membrane, initiating receptor sequestration. From work 
on the paAdR it was proposed that receptor phosphorylation and subsequent binding 
of arrestin impairs interaction with the G-protein (Bouvier et a l, 1988; Hausdorff et 
a l, 1990). To determine if agonist activation was required in order for A3AR 
internalisation to occur, receptors were stimulated with agonist and several activators 
of second messenger regulated kinases (Fig. 3.1). The data obtained supported the 
theory that agonist activation was required to produce a decrease in the number of 
cell-surface receptors. However, a loss could also be detected following treatment 
with forskolin. Forskolin binds directly to AC leading to an increase in cAMP 
levels, which is opposite to the effect shown by the A3AR. Also, forskolin affected
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receptors were shown to have an impaired mobility on SDS-PAGE not accountable 
to receptor phosphorylation (Palmer et ah, 1995c, Fig 3.2) and induced a lower level 
of receptor internalisation. Therefore it could be concluded that the action of agonist 
and forskolin are via separate, distinct pathways with agonist treatment being 
predominant. The requirement of agonist binding and not just the presence of a 
ligand were supported by the treatment of AsARs with an A3 specific antagonist 
MRS 1523. This antagonist inhibited both the loss of cell surface receptors and 
agonist-stimulated phosphorylation in a concentration-dependent manner (Figs. 3.4 
and 3.5).
A more detailed investigation of agonist stimulation on A3AR internalisation 
revealed a biphasic response to increasing agonist concentration. It appeared that 
low-level agonist stimulation (nM) led to a noticeable albeit not significant (p>0.05), 
increase in the number of cell-surface receptors detected. It is possible that at low 
nM concentrations, signalling pathways regulating membrane trafficking are 
initiated, mobilising intracellular pools of receptor to the PM and producing the 
observed increase in receptor number at the cell surface. Increasing agonist 
concentration leads to an increase in receptor occupancy, thereby initiating receptor 
internalisation and causing the subsequent reduction in cell-surface receptor number 
(Fig. 3.3). In support of this theory, internal pools of receptor can be observed in the 
confocal images at the zero time points (Figs. 3.26-3.30).
Work by Palmer and Stiles (2000) localised the GRK phosphorylation sites of 
the A3AR to 3 specific threonine residues (Thr 307, 318 & 319) in the C-terminal 
tail. The Ai AR lacks equivalent residues and has been shown not to be a substrate for 
phosphorylation by GRKs (Palmer et al., 1996; Gao et al., 1999; Figs. 3.7 & 3.13). 
Time courses of agonist-mediated A3 and AiAR internalisation showed dramatic 
differences in the rates at which the receptors were removed from the cell surface (ti/j 
= 10 minutes and 90 minutes respectively; Figs 3.8 & 3.11). Further studies into the 
role of phosphorylation acting as a regulator of rapid inhibitory AR internalisation 
employed the use of a mutated receptor, (T-A)A3AR. Mutating Thr residues 307, 
318 and 319 to Ala produced a receptor that was deficient in agonist-mediated 
phosphorylation and showed no significant internalisation over the time course 
investigated compared to WT (Palmer and Stiles, 2000; Figs. 3.12 & 3.13). Either 
loss of native phosphorylation sites (A%AR) or mutation of GRK phosphorylation 
sites in A3AR produce receptors that fail to internalise after 60 minutes agonist
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exposure. This suggests that phosphorylation is important in the process of agonist- 
mediated internalisation.
So why have two distinctly regulated inhibitory receptors activated by the 
same endogenous ligand that both amplify the same signalling pathway? Stimulation 
of a wide variety of GPCRs leads to activation of many tyrosine kinases and proteins 
activating the MAPK signalling pathway, affecting the mitogenic response (van 
Biesen et al., 1996; Gutkind, 1998). It has been suggested that activation of the 
MAPK pathway requires endocytosis of these receptors (Luttrell et al., 1997; Daaka 
et al., 1998). However, agonist activation of AiARs in DDTlMF-2 cells has been 
shown to produce a rapid (5 minute) clustering of the receptors on the cell surface 
(Ciruela et al. 1997), with a considerable delay between receptor aggregation and 
internalisation (t<^  = 5hrs). As maximal MAPK activation was seen within 5 minutes 
of agonist exposure (Dickenson et al. 1998), this demonstrated that internalisation 
was not required to activate downstream signalling pathways. Lefkowitz (1998) 
suggested that agonist-occupied receptors may organise the assembly of multi­
protein signalling complexes at the PM including some or all of the components in 
the MAPK pathway, hence the appearance of receptor clustering (Lefkowitz, 1998). 
Further activation of the pathway in certain cases may require receptor internalisation 
which is in contrast to established paradigms for classical second messenger- 
activated signalling pathways such as those involving AC and PLC, pathways which 
do not require endocytosis and are unaffected by inhibition of CCV formation 
(Daaka et al., 1998). This could be of great significance in explaining why even 
though the Ai and AgARs couple to Gj, both display distinct patterns of sequestration 
in response to agonist stimulation, potentially controlling subtype-specific activation 
of various downstream signalling cascades.
A second important regulatory region of the AgAR C-terminal tail is the area 
encompassing the putative sites of palmitoylation at Cys 302 and 305. The role of 
palmitoylation in internalisation was first demonstrated for the Tfh receptor (Alvarez 
et al., 1990). Palmitoylation sites are typically found close to hydrophobic stretches 
of amino acids and the attached palmitate, a 16 carbon saturated fatty acid, may 
either be embedded in the lipid bilayer, or influence protein-protein interactions 
(Mumby et al., 1997). Palmitoylation sites are found in almost all GPCRs, as well as 
G-protein a-subunits and AC (Milligan et al., 1995). All of the AR subtypes, except 
the AzA, have one or more consensus sites for palmitoylation (Linden et al., 1994).
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One important aspect of palmitoylation, also found in the AiAR (Cao et ah,
2 0 0 0 ) is that in the presence of agonist, turnover of palmitate can be rapidly 
accelerated (Wedegaertner et ah, 1995; Loisel et al, 1996). Data have shown that 
p2AdR receptor has a palmitoylation site at Cys 341 that regulates the accessibility of 
a PKA phosphorylation site at Ser 345 & 346 (O’Dowd et al., 1989; Moffet et al., 
1993). Mutation of this Cys to Gly (C '^^ ^G) prevents palmitoylation and causes a 
reduction in the receptors ability to stimulate AC, associated with an increase in the 
basal phosphorylation state of the receptor. Cys residues located at similar positions 
to this Cys 341 have been found in most GPCRs. The occurrence of palmitoylation 
on these residues has been shown for the a 2Aadrenergic (Kennedy et al., 1993), 
dopamine D% (Ng et al., 1994), 5-HTia / 5-HTib (Butkeirat et al., 1995; Ng et al., 
1993) and luteinising hormone (LH) receptors (Kawate et al., 1994). The predicted 
palmitoylation sites in the AgAR are located 2 aa’s N-terminally from the first site of 
phosphorylation at Thr 307. These Cys residues at positions 302 and 305 may serve 
to anchor the C-terminal tail to the membrane forming a fourth intracellular loop. 
Mutation of these residues to non-palmitoylatable Ala (C^^ ’^ ^°^A) in the A3AR was 
used to examine effects on receptor phosphorylation and internalisation. Prior to 
agonist stimulation of the (C-A)A3AR, basal phosphorylation was observed (Palmer 
and Stiles, 2000; Fig. 3.14). However, equivalent phosphorylation levels were 
observed in the WT A3AR and (C-A)A3AR mutant after a 10 minute agonist 
treatment suggesting that a loss of predicted palmitoylation sites does not prevent 
agonist-mediated receptor phosphorylation. A time course of agonist-stimulated 
receptor internalisation revealed an increased internalisation rate (ti^  = 4-5 minutes; 
Fig. 3.15) for the (C-A)AsAR compared to WT. A possible explanation is that 
mutation of the Cys residues could result in the loss of palmitate anchorage of the C- 
terminal tail to the membrane. The tail may then move more freely in the cytoplasm 
allowing the phosphorylation sites at Thr 307, 318 and 319 to become more 
accessible to GRKs allowing basal phosphorylation. As the (C-A)AsAR mutant does 
not require depalmitoylation and is basally phosphorylated, the time required to bring 
about full agonist-mediated phosphorylation is reduced and the receptor undergoes 
an increased rate of internalisation. These data strongly suggest that Cys residues 
302 and 305 play an important role in A3AR phosphorylation and internalisation by 
controlling the accessibility of activated GRKs to the C-terminal regulatory domain. 
However, work by Eason et al. (1994) has shown that palmitoylated cysteine
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residues do not have a universal role as deletion of the Cys in the «iaAR had no 
effect on desensitisation. This could be associated with the fact that the 
phosphorylation sites of the Œ2aAR are present in the third intracellular loop and not 
in the C-terminal tail. Therefore, any disruption to the C-terminal domain proximal 
to these phosphorylation sites will exert no effect on receptor activation and 
subsequent desensitisation. Nevertheless, in the case of the A3AR, it appears that the 
absence of the predicted palmitoylated Cys residues may allow exposure of the C- 
terminal tail, influencing its interaction with various regulatory proteins. Previous 
studies on the P2AdR suggested that before resensitisation and recycling to the 
plasma membrane could take place, the sequestered receptors must be 
dephosphorylated (Yu et al., 1993; Pitcher et al., 1995). The (C-A)A3AR appears to 
contradict this model as it showed a basal level of phosphorylation with its 
internalisation and recycling upon agonist removal increased compared to WT 
A3AR, suggesting that in the case of this AR, complete dephosphorylation is not a 
requirement to bring about receptor resensitisation.
Having shown that the mechanism of termination of A3AR signalling is by 
phosphorylation on Thr residues present in its C-terminal tail by GRKs, the 
possibility that this regulation could be transferred to the non-phosphorylated AiAR 
was investigated. In recent years, the use of chimeric receptors has become a 
predominant tool with which to study the role of the C-terminal region of GPCRs. 
Whistler et al. (1999), constructed a chimeric receptor comprising the body of the 
p opioid receptor fused to the tail of the ô opioid receptor. Analysis showed that this 
mutation enhanced the endocytosis of the preceptor and uncoupling from G- 
proteins, but had no effect on the receptors function compared to WT (Afify et al. 
1998). Similarly, exchange of the ET a and ET b receptor tails (Abe et al.; 2000) 
resulted in re-localisation of the receptors. The ETa receptor C-terminal tail contains 
a sequence that anchors the receptor to the plasma membrane. Mutation of the tail to 
that of the ETb receptor promoted sorting of the chimera to lysosomes resulting in 
proteolytic degradation. The reciprocal is true for the E T b-ET a tail chimera. In the 
same way, using a chimeric receptor constructed by Palmer et al. (1996), A3AR 
internalisation kinetics were conferred onto a predominantly AiAR. Comprising of 
the main body of the AiAR fused to the C-terminal region of the A3AR, AiCT3 (Fig. 
3.17) was shown to be pharmacologically similar to the AiAR (Palmer et al., 1996).
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However, unlike the AiAR, the chimera was phosphorylated and internalised similar 
to the A3AR (ti/2 = 1 & 15 minutes respectively, Figs. 3.18 & 3.19). Thus the GRK 
phosphorylated C-terminal domain of the A3AR is able to confer the property of 
rapid agonist-induced internalisation on a predominantly AiAR-containing chimeric 
AR.
GFP, discovered by Shimomura and Johnson (1969), has been used 
extensively to enable visualisation of GPCRs and other proteins within individual 
cells (Tsien, 1998). It has been targeted successfully to almost every major cell 
organelle including the plasma membrane (Barak et al., 1997a), nucleus (Chatterjee 
and Stochaj, 1996), endoplasmic reticulum (ER), Golgi apparatus (Presley et ah, 
1997) and mitochondria (Yano et ah, 1997). GFP has commonly and most 
successfully been applied as a fusion to the protein of interest. The gene encoding 
GFP is fused in-frame with the gene encoding the protein under investigation and the 
resulting chimera expressed in the system of interest. Ideally, the activity and 
localisation of the protein would be unaffected by the GFP tag. With the C-terminal 
tail of GPCRs being shown to be important in receptor regulation, it could be 
expected that the addition of a 27kDa molecule to the end of this tail would disrupt 
regulation. It had been shown previously that the addition of a GFP tag had no 
adverse effects on the pharmacological or signal transduction properties of receptors 
such as cholecystokinin A (Tarasova et al., 1997), p2AdR (Barak et al., 1997a; Kallal 
et al., 1998; McLean et al., 1999) and the thyrotropin releasing hormone (TRH) 
receptor (Drmota et al., 1998). As discussed in this chapter, immunoblotting, 
phosphorylation and radioligand binding studies investigated any consequence of 
GFP-tagging the WT and mutant ARs. Biotin labelling experiments confirmed the 
presence of GFP-tagged receptors at the cell surface compared to WT A3ARS 
verifying that the GFP tag was not interfering with receptor assembly or targeting to 
the membrane (Fig. 3.22). Radioligand binding using ^^^I-AB-MECA demonstrated 
the ability of the GFP-tagged receptor to bind agonist (Fig. 3.23) resulting in receptor 
phosphorylation (Fig. 3.24) and subsequent internalisation (Fig, 3.25) as was seen for 
WT A3AR. These data suggested that the AR-GFP construct could be used in live 
cell systems to visualise receptor trafficking following agonist stimulation, as it 
appeared to be functionally indistinguishable from WT receptors.
In unstimulated cells, A3 AR-GFP was found predominantly at the cell surface 
with a small amount of receptor present intracellularly. Upon agonist stimulation,
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WT A3 , chimeric AiCT3 and mutant (C-A)A3ARs all containing phosphorylatable 
residues in the C-terminal tail, were seen to redistribute to intracellular pools (Figs. 
3.26, 3.27 & 3.30). Membrane localised fluorescence of the WT Ai and mutant (T- 
A)A3ARs were not seen to alter over the time-courses investigated (Fig. 3.28 & 
3.29). A noticeable consequence of agonist stimulation was the structural changes in 
cell shape over time. Dependent upon receptor type, these changes were either 
sustained to the end of the experiment (WT A3 & AiCT3AR-GFP) or transient, with 
small shape changes being observed within the first 1 0  minutes and the cells 
returning to the unstimulated morphology within the time-course investigated (WT 
Ai & (T-A) A3 AR-GFP). The actin cytoskeleton is a dynamic structure responding to 
multiple extracellular stimuli contributing to cell-cell and cell-substrate interactions 
by providing a structural framework and modulating signal transduction cascades 
(Yin & Stull, 1999). Low molecular weight G-proteins of the Rho subfamily (Rho 
GTPases comprising of Rho, Rac and Cdc42) are responsible for the organisation of 
the actin cytoskeleton (Tapon and Hall, 1997; Van Aelst and D ’Souza-Schorey, 
1997). Functioning of Rho has also been implicated in regulation of endocytosis, 
exocytosis and glucose transport (Sah et al., 2000). The phenomenon of endocytosis 
can be broken down into distinct steps, from membrane invagination, to removal of 
the new endocytic compartment from the plasma membrane to the cytosol 
(Qualmann et al., 2000), with each step possibly involving the actin cytoskeleton. It 
is possible that alterations in membrane lipids may trigger the recruitment of 
components required to initiate vesicle budding e.g. clathrin and dynamin, to the 
plasma membrane where they are organised or anchored by cytoskeletal components 
in preparation for internalisation (Lamaze et al., 1996). Actin may also be required 
to drive the detached endocytic vesicles through the cytoplasm to their final 
destination (Frischknecht et al., 1999; Merrifîeld et al., 1999 and Rozelle et al., 
2000).
As agonist stimulation of A3AR expressing cells results in changes in cell 
shape, further studies are required to determine any involvement of the actin 
cytoskeleton and small G-proteins in this process. It would also be of interest to 
determine which internalisation pathway is used by the A3AR upon its stimulation 
and the down-stream signalling pathways it activates.
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Chapter 4
Characterisation of A 3 A R  Internalisation via an 
Endosomal Pathway
4.1 Introduction
Having shown the A3AR to be phosphorylated by GRK and internalised in 
response to agonist, it was of importance to determine which endocytic pathway the 
receptor used. Receptor endocytosis has been best characterised for receptors such 
as low-density lipoprotein (LDL) and Tfn, receptors that cycle continuously between 
the cell surface and endosomes via the CCV pathway (Koenig and Edwardson, 
1997). In contrast to this ‘conveyor belt’ mode of operation, GPCRs reside 
predominantly at the plasma membrane and are endocytosed in response to agonist 
stimulation. The most well defined model for GPCR sequestration has been 
documented for receptors such as the P2AdR and Mi muscarinic receptor, where 
upon agonist stimulation, the receptor becomes phosphorylated and leads to the 
attraction of aiTestin molecules to the cell surface. Arrestins have a two-fold role in 
that they uncouple the receptor from the G-protein leading to an inhibition of signal 
and target phosphorylated receptors for endocytosis via CCVs. The binding of 
arrestin also serves to activate clathrin associated protein components such as 
amphiphysin and dynamin that are involved in the pinching off of the vesicles from 
the plasma membrane.
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4.2 Results
To determine if  the internalisation pathway utilised by the A3AR involved 
CCVs, we examined the interaction of GFP-tagged VSV-TRHR and A3AR with 
Alexa-labelled Tfii (red). TRHR has been shown to internalise via a clathrin- 
mediated pathway therefore this receptor was used as a control for comparison of 
subsequent data. HEK293 cells were plated onto coverslips and transiently 
transfected with either VSV-TRH-GFP or WT A3 AR-GFP as described in the 
Methods. Prior to agonist stimulation, cells were treated with Alexa-tagged Tfh 
(5units/ml) for 30 minutes. Cell monolayers were then washed once to remove any 
unbound Alexa-Tfh and internalisation initiated by the addition of lOpM TRH or 
IpM (R)-PIA over a 30 minute time-course. Cells were then fixed and visualised by 
confocal microscopy as described in the Methods. With no agonist treatment, 
images obtained for the control VSV-TRH-GFP revealed this receptor to be present 
predominately at the cell surface (green) with the Alexa-Tfh (red) visible in distinct 
punctate spots throughout the cell (Fig. 4.1). Agonist stimulation caused 
internalisation of VSV-TRH-GFP resulting in overlapping of the internal vesicles 
with Alexa-Tfh producing a distinct yellow staining (Fig. 4.1, merge 30 minutes). 
Similar distributions were observed for WT A3AR-GFP and Alexa-Tfh before (Fig. 
4.2, 0 minutes) and after (Fig, 4.2, 15minutes) agonist stimulation. This overlapping 
or co-localisation (yellow) of the GFP-tagged receptors with Alexa-Tfii suggested 
that A3AR-GFP is internalising via an endosomal pathway similar to that used by 
TRHR and TfhR. Co-expression of the inhibitory AiAR-GFP with Tfh failed to 
promote colocalisation following agonist stimulation (Fig. 4.3)
Having previously shown the C-terminal tail to be important in the regulation 
of receptor internalisation, one hypothesis is that alterations to this regulatory region 
could lead to a variation or complete deviation in the internalisation pathway being 
used. To determine this, the mutants (C-A) A3 AR-GFP and AiCT3 AR-GFP were 
transiently transfected into HEK 293 cells and treated with Alexa-Tfh prior to 
agonist stimulation as previously described. The confocal images obtained revealed 
that both (C-A)A3AR-GFP (Fig. 4.4) and AiCT3AR-GFP (Fig. 4.5) co-localised 
(yellow) with the Alexa-Tfii (red) an interaction which persisted for the duration of 
the time-course investigated. In both receptors, even though the C-terminal domain 
has been altered in some way, the receptor continues to internalise similar to WT
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As AR-GFP. These data show that mutation of the regulatory region of the A3AR 
does not inhibit agonist-mediated internalisation via an endosomal pathway.
Having determined that A3AR internalisation follows an endosomal pathway 
possibly involving CCVs, a more detailed study of the mechanisms of this pathway 
was explored. Internalisation mediated via CCVs has been described in great detail 
for receptors such as the ^ 2Ad and TRH. Fig 4.6 shows a schematic representation 
of this. Upon agonist stimulation, GPCRs interact with their G-proteins to initiate 
signalling through a  and Py subunits. This signalling is primarily ‘turned off’ by 
phosphorylation on Ser / Thr residues by GRKs. A chain of events is then initiated, 
beginning with the activation of arrestin molecules which uncouple the receptor from 
the G-protein and lead to the mobilisation of clathrin and other cytosolic factors 
involved in receptor internalisation. The C-terminal tail of non-visual arrestins 
interacts with clathrin through its N-terminal region leading to translocation of 
clathrin to the membrane. Clathrin triskelions interact to form a pit at the plasma 
membrane into which the receptor internalises. Clathrin simultaneously interacts 
with amphiphysin, recruiting dynamin to the collar of the clathrin vesicles through its 
SH3 domain. Dynamin, a GTPase, then hydrolyses GTP to GDP causing the clathrin 
to be displaced from the complex and the vesicle is pinched off from the membrane. 
Internalised receptor can then either be targeted for degradation or dephosphorylated 
and returned to the membrane for another round of agonist activation.
The role of arrestins in these events has been characterised for a number of 
receptors. Four isoforms of arrestin have been detailed; visual arrestin (arrestin 1), p- 
arrestinl (arrestin2 ), P-arrestin2 (arrestin3) and cone arrestin (arrestin4). Arrestins 1 
and 4 are localised in the eye and are involved in the regulation of rhodopsin 
following light activation. Arrestins 2 and 3 are expressed ubiquitously therefore 
their role in clathrin-mediated endocytosis has been studied extensively. To establish 
if AR internalisation was mediated by arrestin activation, GFP-tagged forms of 
arrestin2 and arrestin3 (Groarke et al. 1999) were transiently co-expressed in HEK 
293 cells on coverslips with VSV-TRHR or HA-tagged WT or mutant A3ARS, Cells 
were agonist treated over a 30 minute time course, fixed and permeabilised as 
described in the Methods, TRHR and A3ARS were visualised by treatment with anti- 
VSV or 12CA5 antibody respectively followed by secondary antibody incubation 
with Alexa-tagged anti-mouse antibody (red).
1 1 2
Confocal analysis of VSV-TRHR with air2-GFP or arr3-GFP showed VSV- 
TRHR (red) to be present predominately on the cell membrane with the arrestin 
(green) diffusely in the cytoplasm (Figs. 4.7 and 4.8). No co-localisation of receptor 
was observed with either arrestin isoform prior to agonist treatment (Figs. 4.7 and 
4.8, 0 minutes). Upon agonist exposure (lOpM TRH) the VSV-TRHR was seen to 
internalise to distinct spots within the cytoplasm. Over the time course, yellow spots 
were observed within cells expressing both the receptor (red) and either form of 
arrestin (green), indicating co-localisation of the two proteins (Figs. 4.7 and 4.8, 30 
minutes). This co-localisation persisted over the 30 minute time course investigated, 
providing data consistent with previous studies showing interactions of TRHR with 
both arrestin2 and arrestin3.
HEK 293 cells co-transfected with WT HA-A3AR and arr2-GFP revealed 
expression of WT A3AR at the membrane with arr2-GFP located in the cytoplasm 
(Fig. 4.9, 0 minutes). IpM  (R)-PIA exposure induced receptor internalisation but no 
co-localisation (yellow) of HA-tagged receptor (red) with arr2-GFP (green) was 
apparent over the 30 minute time course investigated (Fig. 4.9, 30 minutes). Co­
expression of WT HA-A3AR with arr3-GFP showed receptor and arrestin expression 
as seen previously (Fig. 4.10) at 0 minutes. However, a transient co-localisation of 
HA-A3AR and arr3-GFP was observed between 10 and 15 minutes following agonist 
treatment (Fig. 4.10, 10 minutes). This was not however, a consistent interaction as 
confocal images obtained at a later date were not seen to exhibit this phenomenon 
(Fig. 4.11), although arr3-GFP was seen to cluster into distinct spots within the 
cytoplasm.
The effect of mutating the A3AR8 predicted palmitoylation sites on the 
interaction with arrestin was investigated using the HA-(C-A)A3AR mutant. 
HA-(C-A)A3AR co-expressed with arr2-GFP was observed on the membrane with 
arr2-GFP located in the cytoplasm (Fig. 4.12, 0 minutes). IpM (R)-PIA stimulation 
led to a rapid internalisation of the mutant AR but no co-localisation (yellow) was 
observed between the HA-(C-A)A3AR (red) and arr2-GFP (green) over the time 
course investigated (Fig. 4.12, 4 minutes). HEK293 cells co-transfected with (C- 
A)A3AR and arr3-GFP were seen to express receptor and arrestin as described 
previously (Fig. 4.13, 0 minutes). Agonist stimulation promoted rapid receptor 
internalisation and, as seen with WT A3 and arr3-GFP, a transient co-localisation
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(yellow) of (C"A)A3AR and arr3-GFP was observed between 4 and 6  minutes. 
Again this was not seen to be a consistent interaction as later confocal experiments 
failed to produce similar results (Fig. 4.14).
With little evidence of arr2-GFP interacting with either WT A3AR or 
(C-A)A3AR it was decided to turn our attentions to arr3-GFP which appeared to be 
having some, if only a transient interaction with the ARs investigated so far. Having 
shown that exchange of the AiAR C-terminal tail for that of the A3AR (A]CT3AR) 
promoted receptor internalisation via an endosomal pathway (Figs. 4.3 and 4.5), we 
investigated the possible role of arr3 in the internalisation of this mutant. HEK 293 
cells were transiently transfected with A]CT3AR and arr3-GFP as previously 
described and subjected to confocal microscopy. As was observed with the other 
receptors, A;CT3AR was expressed on the membrane, arr3-GFP expressed in the 
cytoplasm and no co-localisation was detected at 0  minutes prior to agonist treatment 
(Fig. 4.15). Agonist stimulation promoted receptor internalisation but no co­
localisation (yellow) of the two proteins, receptor and arrestin, was detected over the 
time course investigated (Fig. 4.15, 15 minutes). However, the images obtained did 
show the arr3-GFP clustering into spots within the cytoplasm but staying distinct 
from those vesicles occupied by the internalised receptor (Fig. 4.15).
With the data obtained thus far being inconclusive as to the requirement of 
arrestin and clathrin vesicles in AR endocytosis, we decided to investigate the effects 
of mutating various co-factors involved at different stages of clathrin-mediated 
endocytosis. It has been shown for a number of receptor types that their 
internalisation via clathrin can be inhibited or enhanced by over-expression of 
dominant-negative or truncated versions of proteins required for clathrin-mediated 
endocytosis. In this study, using three modified proteins, their effects on AR 
endocytosis were investigated (Fig. 4.16). The A3AR is known to be phosphorylated 
by GRKs on its C-terminal tail following agonist stimulation, leading to receptor 
internalisation. To try to inhibit this phosphorylation, a truncated mutant of GRK2 
was transfected into CHO cells stably expressing HA-tagged WT A3AR. The 
mutant, pARK-CT (GRK2[BK-CT]), comprising the C-terminal tail of GRK2 
interacts with free Py subunits released following agonist binding to receptor, 
resulting in a decrease in receptor phosphorylation. To establish the concentration of 
GRK2[BK-CT] required to produce an effect in our system, WT bovine GRK2 and 
GRK2[BK-CT] were transiently transfected into plain CHO cells at increasing
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concentrations and solubilised cell extracts transferred to nitrocellulose as described 
in the Methods. Nitrocellulose membranes were probed with the GRK2-specific 
monoclonal antibody 3A 10 and then with HRP conjugated anti-mouse secondary 
antibody. WT GRK2 displayed an increase in band intensity with increasing 
concentration of transfected protein (Fig. 4.17a). However the mutant GRK2[BK- 
CT] appeared to reach a peak of intensity at 0.5|iig and then diminish (Fig. 4.17b).
To assess the effect of this GRK2 mutant on agonist-mediated A3AR 
phosphorylation, a concentration response to GRK2[BK-CT] was carried out. CHO 
cells expressing WT A3AR were transiently transfected with increasing 
concentrations of GRK2[BK-CT] ranging from 0 to 0.5pg, labelled with ^^P- 
orthophosphate and stimulated with or without lOpM (R)-PIA for 30 minutes. 
Receptors were immunoprecipitated with 12CA5 as previously described and 
fractionation of the proteins carried out using SDS-PAGE. Phosphorylated A3ARS 
were visualised by autoradiography. Resulting data showed a decrease in the level of 
receptor phosphorylation in the presence of increasing GRK2[BK-CT] concentration 
(Fig. 4.18). The effect of O.SjLig of GRK2[BK-CT] was found to be significantly 
different from the effect produced with cells expressing vector alone (p<0.05). To 
visualise this, CHO cells stably expressing A3AR-GFP were transfected with 
0.5|Lig/|Lil GRK2[BK-CT] and stimulated with IpM (R)-PIA over a 30 minute time 
period. Cells were fixed and solubilised as described in the Methods. The presence 
of GRK2[BK-CT] was detected with 3A10 primary antibody followed by Alexa- 
tagged anti-mouse secondary antibody (red). From the phosphorylation data 
obtained previously, it was hoped that internalisation of the A3AR-GFP construct 
would be inhibited in the presence of the mutant GRK2 molecule. Fig. 4.19 shows 
that in the presence of 0.5pg/pl GRK2[BK-CT] (red), a concentration sufficient to 
inhibit receptor phosphorylation, A3AR-GFP (green) underwent internalisation in a 
manner similar to that seen in cells not expressing the mutant GRK2.
Further characterisation of the internalisation pathway utilised by the A3AR 
employed a mutated form of arrestin. Consisting of the last 99 aa’s of the arrestin2 
molecule, arr2[319-418] has been shown to inhibit the clathrin-mediated endocytosis 
of many receptor types. As only the C-terminal region of arr2 is expressed, the 
airestin mutant interacts only with clathrin via its N-terminal domain and not with 
the receptor (Fig. 4.16), therefore inhibiting the interaction of clathrin with
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stimulated receptor and disrupting clathrin-mediated endocytosis. CHO cells were 
transiently transfected with increasing concentrations of arr2[319-418] (0-2)jig/well) 
and solubilised cell extracts transferred to nitrocellulose as described in the Methods. 
Nitrocellulose membranes were probed with the arrestin-specific monoclonal 
antibody P-arrestinl and then with HRP conjugated anti-mouse secondary antibody. 
From the blots obtained, (Fig. 4.20), a concentration of 0.5|Lig was used in subsequent 
experiments.
To investigate the effect of this mutant in the A3AR system, CHO cells stably 
expressing A3AR-GFP were tranfected with 0.5|ug/well of arr2[319-418] which was 
detected by incubation with anti-arrestin primary antibody followed by Alexa-tagged 
anti mouse secondary antibody (red). Confocal microscopy revealed that prior to 
agonist treatment (Fig. 4.21, 0 minutes) A3AR-GFP was expressed at the membrane 
(green) and the truncated arrestin molecule (red) was located in the cytoplasm as 
seen for WT arrestin expression (Fig. 4.7). arr2[319-418] was not seen to inhibit 
agonist-mediated internalisation over the time course investigated (Fig. 4.21). This 
effect was also observed with VSV-TRHR-GFP (Fig. 4.22) and (C-A)A3AR-GFP 
(Fig. 4.23).
In the case of clathrin-mediated endocytosis, if vesicles cannot be released 
from the membrane the receptor is unable to internalise and be targeted for recycling 
or down-regulation. Separation of clathrin vesicles from the membrane can be 
inhibited by expression of a dynamin mutant, Dyn[K44E], known to be defective in 
GTP hydrolysis. CHO cells transiently transfected with myc-epitope tagged 
Dyn[K44E] at increasing concentrations were subjected to immunoblotting analysis 
as described in the Methods. From the blots obtained (Fig. 4.24), a concentration of 
0.5jLig/well was transfected into CHO cells expressing A3 AR-GFP and visualised 
confocally by staining the permeabilised cells with anti-myc 9E10 primary antibody 
and Alexa-tagged anti mouse secondary antibody (red). Confocal imaging revealed 
A3 AR-GFP localisation to the membrane and myc-Dyn/Dyn [K44E] in the cytoplasm 
prior to agonist treatment (Fig. 4.25 and 4.26, 0 minutes). Agonist stimulation over 
30 minutes promoted receptor internalisation that was not seen to be inhibited by the 
presence of the mutant myc-Dyn[K44E] (Fig. 4.25 and 4.26). These data collected 
so far suggested either that the concentrations of mutants being used were
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insufficient to inhibit clathrin-mediated endocytosis in the A3AR system or that the 
A3AR was internalising via a clathrin-independent pathway.
One other procedure known to disrupt clathrin is the treatment of cells with a 
sucrose solution. Sucrose has been shown to inhibit the formation of CCVs by 
disrupting the interaction of the clathrin triskelions therefore inhibiting clathrin- 
mediated endocytosis. To investigate the effects of this, plain HEK 293 cells 
labelled with Alexa-tagged Tfn were subject to treatment in the absence or presence 
of 0.4M sucrose. In the absence of sucrose, Alexa-Tfh was seen to internalise and 
recycle normally (Fig. 4.27a). However, when cells were treated with Alexa-Tfh and 
sucrose simultaneously for 30 minutes (Fig. 4.27b), the Alexa-Tfh was seen to 
cluster at the membrane with very little staining observed internally, suggesting that 
sucrose was inhibiting the clathrin-mediated pathway of internalisation for the TfhR. 
The effect of sucrose on A3AR-GFP internalisation in stably transfected CHO cells 
was investigated in the same way. In the absence or presence of sucrose (Fig. 4.28a 
and 4.28b) prior to agonist treatment, A3AR-GFP was expressed predominately at the 
membrane. Upon agonist stimulation, A3AR-GFP was seen to internalise as had 
been observed previously (Fig. 4.28c) over a 30 minute time period. In the presence 
of 0.4M sucrose, agonist-mediated internalisation of A3AJR-GFP was inhibited and 
A3 AR-GFP remained at the membrane (Fig. 4.28d). These data suggest that 
internalisation of A3 AR-GFP is via a clathrin-mediated pathway which can be 
inhibited by disrupting the formation of clathrin vesicles. It must be noted however 
that 0.4M sucrose is a very severe treatment to use to inhibit internalisation and it 
therefore may not be as specific as hoped in interrupting only the clathrin pathway.
Many other mechanisms of internalisation have been documented which do 
not require the use of clathrin vesicles. One such pathway involves vesicles 
composed of lipids, proteins and chiefly caveolin, a 21-24kDa integral membrane 
protein. Caveolae are small vesicles 50-1 OOnm in size that can be defined by their 
unique morphology as viewed by electron microscopy (Parton, 1996 and Schlegel et 
al., 1998). Caveolae are abundant in cell types such as endothelial cells, adipocytes, 
cardiac smooth and striated myocytes and have so far been shown to be involved in 
vesicular transport (Severs, 1988), potocytosis (Anderson, 1993) and signal 
transduction (Okamoto et al., 1998 and Engelmann et al., 1998). To determine if  the 
A3AR required association with caveolae to undergo internalisation, CHO cells 
stably expressing A3AR-GFP were plated onto coverslips and treated with or without
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IpM (R)-PIA over a 30 minute time period. Cells were then fixed, permeabilised as 
described in the Methods and stained with anti-caveolin primary antibody followed 
by Alexa-tagged anti mouse secondary antibody (red). Confocal microscopy 
revealed that prior to agonist stimulation, A3 AR-GFP (green) and caveolin (red) were 
both localised at the membrane (Fig. 4.29, 0 minutes) with very little co-localisation 
(yellow). Agonist treatment led to internalisation of A3 AR-GFP but the caveolin 
staining did not progress from the membrane suggesting that the endocytic 
mechanism employing caveolae was not involved in A3AR internalisation.
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Figure 4.1 Co-localisation of internalised VSV-TRHR-GFP
with Alexa-labelled Transferrin (Tfn)
HEK 293 cells transiently expressing VSV-TRHR-GFP were treated with Alexa-Tfii 
for 30 minutes prior to stimulation with lOpM TRH over a 30 minute time period. 
TRH induced translocation of VSV-TRHR-GFP (green) from the membrane to 
distinct, punctate vesicles within the cytoplasm. These vesicles can be seen to 
overlap with internalised Alexa-Tfii (red) to give a distinct yellow staining when the 
red and green images are merged (merge, 30 minutes). The images shown opposite 
are representatives of multiple experiments showing similar results.
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Figure 4.2 Co-localisation of internalised A3AR-GFP with
Alexa-labelled Transferrin (Tfn)
HEK 293 cells transiently expressing A3 AR-GFP were treated with Alexa-Tfh for 30 
minutes prior to stimulation with IpM (R)-PIA over a 30 minute time period. 
Agonist induced translocation of A3AR-GFP (green) from the membrane to distinct 
vesicles within the cytoplasm. These vesicles can be seen to overlap with 
internalised Alexa-Tfii (red) to give a distinct yellow staining upon merging of the 
red and green images (merge, 15 minutes). The images shown opposite are 
representatives of multiple experiments showing similar results.
1 2 0

Figure 4.3 Distribution of WT AiAR-GFP and Alexa-labelled
transferrin (Tfn)
HEK 293 cells transiently expressing WT A, AR-GFP were treated with Alexa-Tfh 
for 30 minutes prior to stimulation with IpM (R)-PIA over a 30 minute time period. 
Addition of agonist produced no noticeable translocation of WT Ai AR-GFP (green) 
from the membrane over the time course investigated. Alexa-Tfh (red) was 
distributed throughout the cytoplasm The images shown opposite are representatives 
of multiple experiments showing similar results.
121

Figure 4.4 Co-localisation of internalised (C-A)A3AR-GFP
with Alexa-labelled Transferrin (Tfn)
HEK 293 cells transiently expressing (C-A)A3AR-GFP were treated with Alexa-Tfh 
for 30 minutes prior to stimulation with IpM (R)-PIA over a 30 minute time period. 
Agonist induced translocation of (C-A)A3AR-GFP (green) from the membrane to 
distinct vesicles within the cytoplasm. These vesicles can be seen to overlap with 
internalised Alexa-Tfii (red) to give a distinct yellow when the red and green images 
are merged (merge, 10 minutes). The images shown opposite are representatives of 
multiple experiments showing similar results.
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Figure 4,5 Co-localisation of internalised AiCT3AR-GFP
with Alexa-labelled Transferrin (Tfn)
HEK 293 cells transiently expressing AiCT3AR-GFP were treated with Alexa-Tfh 
for 30 minutes prior to stimulation with IpM (R)-PIA over a 30 minute time period. 
Agonist induced translocation of AiCT3AR-GFP (green) from the membrane to 
distinct vesicles within the cytoplasm. These vesicles can be seen to overlap with 
internalised Alexa-Tfii (red) to give a distinct yellow staining when the red and green 
images are merged (merge, 15 minutes). The images shown opposite are 
representatives of multiple experiments showing similar results.
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Figure 4.6 Schematic representation of GPCR agonist-
mediated internalisation via the clathrin-coated 
vesicle pathway
Agonist stimulation promotes the phosphorylation and internalisation of many 
GPCRs via clatlirin-coated vesicles. Shown opposite is a simplified diagram of the 
major components of this internalisation pathway.
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Figure 4.7 Confocal microscopic analysis of arr2-GFP and
VSV-TRHR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with VSV-TRHR (red) and arr2-GFP 
(green) cDNA were stimulated with lOpM TRH over a 30 minute time period to 
induce TRHR internalisation. In unstimulated cells, VSV-TRHR was observed 
predominately at the membrane with aiT2-GFP present diffusely in the cytoplasm. 
Agonist activation led to re-location of arr3-GFP to distinct spots within the 
cytoplam and accumulation of internalised VSV-TRHR. Co-localisation (yellow) 
was observed upon merging of the red and green images, and sustained over the 
time-course investigated (yellow; merge, 30 minutes). The images shown opposite 
are representatives of multiple experiments showing similar results.
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Figure 4.8 Confocal microscopic analysis of arr3-GFP and
VSV-TRHR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with VSV-TRHR (red) and arr3-GFP 
(green) cDNA were stimulated with lOfrM TRH over a 30 minute time period to 
induce TRHR internalisation. In unstimulated cells, VSV-TRHR was observed 
predominately at the membrane with arr3-GFP present diffusely in the cytoplasm. 
Agonist activation led to the accumulation of internalised VSV-TRHR to distinct 
spots in the cytoplasm. A small amount of co-localisation was observed between 
VSV-TRHR and an*2-GFP upon merging of the red and green images (yellow; 
merge, 30 minutes). The images shown opposite are representative examples from 
multiple experiments.
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Figure 4.9 Confocal microscopic analysis of arr2-GFP and
HA-A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-A3AR (red) and arr2-GFP (green) 
cDNA were stimulated with 1|tM (R)-PIA over a 30 minute time period to induce 
A3AR internalisation. In unstimulated cells, HA-A3AR was observed predominately 
at the membrane with arr2-GFP present diffusely in the cytoplasm. Agonist 
activation led to the accumulation of internalised HA-A3AR to distinct spots in the 
cytoplasm. No co-localisation was observed between HA-A3AR and arr2-GFP upon 
merging of the red and green images (merge, 30 minutes). The images shown 
opposite are representatives of multiple experiments showing similar results.
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Figure 4.10 Confocal microscopic analysis of arr3-GFP and
HA-A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-A3AR (red) and arr3-GFP (green) 
cDNA were stimulated with l|rM  (R)-PIA over a 30 minute time period to induce 
A3AR internalisation. In unstimulated cells, HA-A3AR was observed predominately 
at the membrane with aiT3-GFP present diffusely in the cytoplasm. Agonist 
activation led to the accumulation of arr3-GFP to distinct spots within the cytoplasm 
and internalised HA-A3AR from the membrane. A transient co-localisation (yellow) 
of the two proteins was observed between 1 0  and 15 minutes when the red and green 
images were merged (yellow; merge, 10 minutes). The images shown opposite are 
representatives of multiple experiments showing similar results.
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Figure 4.11 Confocal microscopic analysis of arr3-GFP and
HA-A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-A3AR (red) and arr3-GFP (green) 
cDNA were stimulated with l)rM (R)-PIA over a 30 minute time period to induce 
AiAR internalisation. In unstimulated cells, HA-A3AR was observed predominately 
at the membrane with arr3-GFP present diffusely in the cytoplasm. Agonist 
activation induced internalisation of HA-A3AR from the membrane and led to the 
accumulation of arr3-GFP to distinct spots within the cytoplasm and at the plasma 
membrane (agonist-treated, green). No co-localisation of the two tagged proteins 
was observed upon merging of the red and green images (merge, 15 minutes). The 
images shown opposite are representatives of multiple experiments showing similar 
results.
129

Figure 4.12 Confocal microscopic analysis of arr2-GFP and
HA-(C-A)A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells ti'ansiently co-transfected with HA-(C-A)A3AR (red) and arr2-GFP 
(green) cDNA were stimulated with IjuiM (R)-PIA over a 30 minute time period to 
induce (C-A)A3AR internalisation. In unstimulated cells, HA-(C-A)A3AR was 
obseiwed predominately at the membrane with arr2-GFP present diffusely in the 
cytoplasm. Agonist activation induced internalisation of HA-(C-A)A3AR to distinct 
spots within the cytoplasm. No co-localisation was observed between HA-(C- 
A)A3AR and arr2-GFP when the red and green images were merged (merge, 4 
minutes). The images shown opposite are representatives of multiple experiments 
showing similar results.
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Figure 4.13 Confocal microscopic analysis of arr3-GFP and
HA-(C-A)A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-(C-A)A3AR (red) and arr3-GFP 
(green) cDNA were stimulated with ljuM (R)-PIA over a 30 minute time period to 
induce (C-A)A3AR internalisation. In unstimulated cells, HA-(C-A)A3AR was 
obseiwed predominately at the membrane with arr3-GFP present diffusely in the 
cytoplasm. Agonist activation led to the accumulation of aiT3-GFP to distinct spots 
within the cytoplasm and induced internalisation of HA-(C-A)A3AR from the 
membrane. A transient co-localisation (yellow) of the two proteins was observed 
between 4 and 10 minutes upon merging of the red and green images (merge, 4 
minutes). The images shown opposite are representatives of multiple experiments 
showing similar results.
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Figure 4.14 Confocal microscopic analysis of arr3-GFP and
HA-(C-A)A3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-(C-A)A]AR (red) and arr3-GFP 
(green) cDNA were stimulated with IpM (R)-PIA over a 30 minute time period to 
induce (C-A)A3AR internalisation. In unstimulated cells, HA-(C-A)A3AR was 
obsei'ved predominately at the membrane with arr3-GFP present diffusely in the 
cytoplasm. Agonist activation induced internalisation of HA-(C-A)A3AR from the 
membrane and led to the accumulation of arr3-GFP to distinct spots within the 
cytoplasm and at the plasma membrane (agonist-treated, green). No co-localisation 
of the two tagged proteins was observed upon merging of the red and green images 
(merge, 5 minutes). The images shown opposite are representatives of multiple 
experiments showing similar results.
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Figure 4.15 Confocal microscopic analysis of arr3-GFP and
HA-AiCT3AR cellular distribution in transiently
transfected HEK 293 cells
HEK 293 cells transiently co-transfected with HA-A]CT3AR (red) and arr3-GFP 
(green) cDNA were stimulated with IpM (R)-PIA over a 30 minute time period to 
induce AiCT3AR internalisation. In unstimulated cells, HA-AiCT3AR was 
observed predominately at the membrane with arr3-GFP present diffusely in the 
cytoplasm. Agonist activation induced internalisation of HA-AiCT3AR from the 
membrane and led to the accumulation of arr3-GFP to distinct spots within the 
cytoplasm and at the plasma membrane (agonist-treated, green). No co-localisation 
of the two tagged proteins was observed upon merging of the red and green images 
(merge, 15 minutes). The images shown opposite are representatives of multiple 
experiments showing similar results.
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Figure 4.16 Schematic representation of the inhibition of 
clathrin-mediated internalisation by mutant 
proteins involved in clathrin-mediated endocytosis
Over-expression of dominant-negative or mutated forms of GRK2 (GRK2[BK-CT]), 
aiTestiii2 (an‘2[319-418]) and dynamin (Dyn[K44E]) have been shovyn to inhibit the 
clathrin-mediated pathway of internalisation. The diagram opposite shows the sites 
of interaction of these mutants within the clathrin pathway.
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Figure 4.17 Immunodetection of increasing concentrations of 
WT and mutant bovine GRK2 in transiently 
transfected CHO cells
AsAR-expressing CHO cells were transiently transfected with increasing 
concentrations of WT bovine GRK2 (A) and GRK2[BK-CT] cDNAs (B) ranging in 
concentration from 0-2.0pg/well. Cells were solubilised and the resultant protein 
separated by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised 
by incubation with the GRK2-specific monoclonal antibody 3A10 followed by HRP- 
conjugated anti-mouse secondary antibody. Control sample used was lOOng of pure 
recombinant bovine GRK2. Typical data is shown from one of three experiments.
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Figure 4.18 Effect of increasing GRK2[BK-CT] expression on
agonist-stimulated A3AR phosphorylation
CHO cells stably expressing the A3AR were transiently transfected with increasing 
concenetrations of GRK2[BK-CT] cDNA ranging from 0-0.5pg/well and left to 
recover overnight. Cells were labelled with and vehicle or (R)-PIA (final 
concentration of lOpM) was added for 30 minutes. Reactions were terminated and 
receptors solubilised as previously described. Proteins were fractionated by SDS- 
PAGE, the gel dried and visualised by aautoradiography. The graph shown opposite 
was calculated from three autoradiographs and plotted as mean ± S.E. Receptor 
stimulation with agonist alone was set at 1 0 0 %
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Figure 4.19 Confocal microscopic analysis of A3AR-GFP
internalisation in the presence of the mutant
GRK2[BK-CT]
CHO cells stably expressing A3AR-GFP were transfected with GRK2[BK-CT] 
cDNA and treated with or without IpM (R)-PIA for 30 minutes. Cells were 
solubilised and stained with GRK2-specific primary antibody followed by Alexa- 
tagged anti-mouse secondary antibody. Cells were then visualised by confocal 
microscopy as describe din the Methods. Images (a) and (b) show cells expressing 
A3AR-GFP (green) alone with or without agonist, which were used as controls. 
Images (c) and (d) show A3AR-GFP cells expressing Alexa-labelled GRK2[BK-CT] 
(red) with or without agonist over a 30 minute time period. Comparison of the 
images shows that internalisation of A3AR-GFP appears to be unaffected by the 
presence of the GRK2 mutant. The images shown opposite are representative 
examples of multiple experiments.
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Figure 4.20 Immunodetection of increasing concentrations of 
the arrestin mutant arr2[319-418] in transiently 
transfected CHO cells
AsAR-expressing CHO cells were transiently transfected with increasing 
concentrations of arr2[319-418] cDNA ranging in concentration from 0-2.0pg/well. 
Cells were solubilised and the resultant protein separated by SDS-PAGE. Proteins 
were transfeiTed to nitrocellulose and visualised by incubation with the arrestin- 
specific monoclonal antibody p-arrestinl followed by HRP-conjugated anti-mouse 
secondary antibody. Typical data is shown from one of three experiments.
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Figure 4.21 Confocal microscopic analysis of A3AR-GFP
internalisation in the presence of the mutant
arr2 [319-418]
CHO cells stably expressing A3AR-GFP were transfected with arr2[319-418] cDNA 
and treated with or without IpM (R)-PIA for 30 minutes. Cells were solubilised and 
stained with anti-anestin primaiy antibody followed by Alexa-tagged anti-mouse 
secondary antibody as described in the Methods and visualised by confocal
microscopy. aiT2[319-418] (red) can be seen to be present in punctate spots
throughout the cytoplasm confirming its interaction with endogenous clathrin
molecules. Agonist stimulation can be seen to promote A3AR-GFP (green)
internalisation in the presence of the arr2 mutant. The images shown opposite are 
representative examples of multiple experiments.
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Figure 4.22 Confocal microscopic analysis of VSV-TRHR-
GFP internalisation in the presence of the mutant
arr2[319-418]
Plain CHO cells transiently co-expressing VSV-TRHR-GFP and arr2[319-418] were 
treated with or without 10p,M TRH for 30 minutes. Cells were solubilised and 
stained with anti-VSV primary antibody followed by Alexa-tagged anti-mouse 
secondary antibody as described in the Methods and visualised by confocal 
microscopy. arr2[319-418] (red) can be seen to be present in punctate spots 
throughout the cytoplasm confirming its interaction with endogenous clathrin 
molecules. Agonist stimulation can be seen to promote VSV-TRHR-GFP (green) 
internalisation in the presence of the arr2 mutant. The images shown opposite are
representative examples of multiple experiments.
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Figure 4.23 Confocal microscopic analysis of (C-A)A3AR-GFP
internalisation in the presence of the mutant
arr2[319-418]
CHO cells stably expressing (C~A)A3AR-GFP were transfected with arr2[319-418] 
cDNA and treated with or without IpM (R)-PIA for 30 minutes. Cells were 
solubilised and stained with anti-arrestin primary antibody followed by Alexa-tagged 
anti-mouse secondary antibody as described in the Methods and visualised by 
confocal microscopy. arr2[319-418] (red) can be seen to be present in punctate spots 
thi'oughout the cytoplasm confirming its interaction with endogenous clathrin 
molecules. Agonist stimulation can be seen to promote (C-A)A3AR-GFP (green) 
internalisation in the presence of the arr2 mutant. The images shown opposite are 
representative examples of multiple experiments.
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Figure 4.24 Immunodetection of increasing concentrations of
myc-tagged dynamin [K44E] in transiently
transfected CHO cells
A3AR-expressing CHO cells were transiently transfected with increasing 
concentrations of myc-tagged Dyamin[K44E] cDNA ranging from 0-2.0|ag/well. 
Cells were solubilised and the resultant proteins separated by SDS-PAGE. Proteins 
were transferred to nitrocellulose and visualised by incubation with the myc-specific 
antibody 9E10 followed by HRP-conjugated anti-mouse secondary antibody. 
Typical data is shown from one of three experiments.
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Figure 4.25 Confocal microscopic analysis of A3AR-GFP 
internalisation in the presence of WT myc- 
dynamin
CHO cells stably expressing A3AR-GFP were transfected with WT myc-Dyn cDNA 
and treated with or without IjuM (R)-PIA for 30 minutes. Cells were solubilised and 
stained with anti-myc primary antibody followed by Alexa-tagged anti-mouse 
secondary antibody as described in the Methods and visualised by confocal 
microscopy. Agonist stimulation can be seen to promote A3AR-GFP (green)
internalisation in the presence of the myc-Dyn (red). The images shown opposite are 
representative examples of multiple experiments.
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Figure 4.26 Confocal microscopic analysis of A3AR-GFP 
internalisation in the presence of the mutant myc- 
dyn[K44E]
CHO cells stably expressing A3AR-GFP were transfected with myc-Dyn[K44E] 
cDNA and treated with or without IjuM (R)-PIA for 30 minutes. Cells were 
solubilised and stained with anti-myc primary antibody followed by Alexa-tagged 
anti-mouse secondary antibody as described in the Methods and visualised by 
confocal microscopy. Agonist stimulation can be seen to promote A3AR-GFP 
(green) internalisation in the presence of the mutant dynamin (red). The images 
shown opposite are representative examples of multiple experiments.
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Figure 4.27 Confocal microscopic analysis of the effect of 0.4M
sucrose on Alexa-Tfn internalisation and recycling
HEK 293 cells were pre-labelled with Alexa-Tfii in the absence or presence of 0.4M 
sucrose for 30 minutes. Image (a) shows a normal distribution of Alexa-Tfh within 
the non-sucrose treated cells. Alexa-Tfii in the presence of 0.4M sucrose (b) was 
seen to eluster in large pools at the plasma membrane. The images shown opposite 
are representative examples of multiple experiments.
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Figure 4.28 Confocal microscopic analysis of the effect of
0.4M sucrose on A3AR-GFP internalisation
Cells stably expressing WT A3AR-GFP were treated in the absence or presence of 
0.4M sucrose for 30 minutes. Prior to agonist stimulation, images (a) and (b) show 
expression of A3AR-GFP at the plasma membrane in both the absence and presence 
of 0.4M sucrose. Stimulation with IpM (R)-PIA in the absence of sucrose (c) led to 
noimal A3AR-GFP internalisation. The presence of 0.4M sucrose was seen to inhibit 
agonist-mediated internalisation of A3AR-GFP as the receptor was retained at the 
plasma membrane (d). The images shown opposite are representative examples of 
multiple experiments.
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Figure 4.29 Confocal microscopic analysis of caveolin cellular
distribution in HEK 293 cells transiently
expressing A3AR-GFP
CHO cells stably expressing A3AR-GFP were subjected to internalisation with IpM 
(R)-PIA over a 30 minute period. Cells were fixed and solubilised as described in 
the Methods. Caveolin was detected by the use of anti-caveolin promary antibody 
followed by Alexa-tagged anti-mouse secondaiy antibody (red). Prior to agonist 
stimulation, A3AR-GFP (green) and caveolin (red) were observed to overlap 
predominately at the membrane with very little co-localisation (yellow). Agonist 
activation led to internalisation of A3AR-GFP to distinct spots in the cytoplasm with 
caveolin remaining at the plasma membrane. The images shown opposite are 
representative examples of multiple experiments.
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4.3 Discussion
GPCRs play a key role in controlling regulation of numerous second 
messenger pathways. However, upon agonist activation, most GPCRs lose their 
ability to respond to the signal, a process commonly known as desensitisation. 
Agonist-specific desensitisation appears to be mediated primarily by two protein 
families: GRKs and arrestins. GRKs specifically bind to agonist-occupied receptors, 
promoting receptor phosphorylation that leads to arrestin binding. Arrestin binding 
disrupts receptor-G-protein interaction leading to functional desensitisation. Many 
receptors are then removed from the membrane via clathrin-mediated endocytosis 
(Krupnick and Benovic, 1998).
Several studies have suggested that agonist-induced translocation of receptors 
such as the PaAd, mACh (Koenig and Edwardson, 1996), p and ô opioid (Keith et 
a l, 1996) and TRH (Drmota et a l, 1998) from the PM to intracellular vesicles occurs 
via the clathrin coated pit / endosomal pathway utilised by constitutively recycling 
receptors and growth factor receptors such as Tfn and epidermal growth factor 
receptor (EGER) (Wakshull et a l, 1985). Clathrin-coated pits are the primary PM 
specialisation involved in the uptake of a wide variety of molecules by receptor 
mediated endocytosis (Pearse and Crowther, 1987). Phosphorylation of receptors by 
GRKs serves to increase the affinity of GPCRs for arrestins, which in turn act as 
adapter-like molecules for receptor trafficking (Ferguson et a l, 1996). Recent 
studies have demonstrated that arrestins can both desensitise agonist-activated 
GPCRs and promote their sequestration by also interacting with clathrin, the major 
protein component of the clathrin-based endocytic machinery (Goodman et al, 
1996). With abundant data suggesting the clathrin pathway as the primary 
endocytosing mechanism by which GPCRs internalise, we investigated the possible 
involvement of this pathway in AgAR internalisation.
In an initial attempt to determine the nature of the vesicles into which A3AR- 
GFP was internalised, co-visualisation studies using Alexa-labelled Tfh were 
performed. These suggested that WT A3AR, (C-A)A3AR and AiCT3AR were 
internalising via a pathway similar to that of Tfh and TRH due to the distinct yellow 
staining obtained following agonist stimulation (Figs. 4.1 -  4.5). As both Tfh and 
TRH receptors have been shown to internalise via clathrin-mediated endocytosis 
(Nussenzveig et a l, 1993), it could be supposed that the ARs were being sequestered 
through a clathrin-containing pathway. However, in contrast to the TfhR, the A3AR
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is seen only to enter early endosomes upon agonist stimulation suggesting a possible 
interaction with other co-factors is required before internalisation can be initiated. It 
is not possible at this resolution to state categorically that this staining would indicate 
co-localisation in the same vesicles. However, it can be clearly seen that the vesicles 
containing the tagged proteins are at least in close proximity.
Agonist binding and subsequent internalisation of GPCRs via clathrin 
requires an auxiliary recruitment factor. In the case of the P2AdR (Barak et al., 
1997a), GnRH receptor (Vrecl et al., 1998) and TRHR (Groarke et al., 1999) this 
adapter has been shown to be arrestin. Phosphorylation of receptor following agonist 
stimulation promotes binding of arrestin which serves to uncouple the receptor from 
the G-protein and mobilise clathrin and other cytosolic proteins to the plasma 
membrane (Schmid, 1997; Fig. 4.6). Two ubiquitously expressed arrestins (arr2 and 
arr3) contain a region within their C-terminus that mediates binding to clathrin 
(Krupnick and Benovic, 1998). Arrestins 2 and 3 are 78% indentical in amino acid 
composition and widely expressed in tissues, but their expression level varies in a 
cell-type specific manner (Attramadal et a l, 1992; Steme-Marr et al, 1993). By 
utilising GFP-tagged chimeras of arr2 and arr3, we were able to visualise these 
proteins simultaneously with HA-tagged ARs and assess their involvement in 
agonist-mediated AR endocytosis. Agonist stimulation of P]AdR has been shown to 
promote a sustained translocation of arr2 to the plasma membrane (Lin et al, 1997). 
Agonist stimulation did not produce arrestin translocation in cells co-transfected with 
arr2-GFP and either HA-A3AR or HA-(C-A)A3AR (Fig. 4.9 and 4.12). This lack of 
observable interaction could be attributed to the receptors themselves and not 
experimental error as THRH co-expressed with arr3-GFP was seen to co-localise as 
previously documented (Groarke et a l, 1999). However, co-expression of arr3-GFP 
was seen to transiently co-localise with a small proportion of HA-tagged receptors in 
some cells, but more noticeable was the clustering of arr3-GFP at the plasma 
membrane without interaction with the receptors. This phenomenon of clustering 
has also been shown for arr2-GFP following stimulation of Mi muscarinic 
acetlycholine and somatostatin receptors (Mundell and Benovic, 2000). A common 
assumption is that arrestins do not dissociate fr'om desensitised receptors at the 
plasma membrane, but traffic with them into early endosomes (Ferguson et a l, 1996; 
Krupnick and Benovic, 1998). However, recent observations have demonstrated that 
the fate of GPCR-arrestin complexes can differ among receptors (Zhang et al, 1999).
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These data could suggest that ARs may internalise via an endosomal pathway that 
does not require arrestin or that interaction of arrestin with ARs is a rapid and 
transient process, therefore we do not see any interaction over the time-course 
investigated. One other possibility is that AR internalisation is mediated by a 
pathway not associated with arrestin such as caveolin or by a mechanism not yet 
defined.
To try to further establish any involvement of arrestins in AR sequestration, a 
mutant arrestin comprising of only the C-terminal tail was employed, arr2[319-418]. 
Previous studies have shown that the primary sites involved in arrestin interaction 
with phosphorylated GPCRs are localised to the NH]-terminal half of the molecule 
(Krupnick et al., 1997b; Gurevich et al., 1993, 1995(a), 1995(b)). Therefore by 
expressing only the region of arrestin involved in clathrin binding (Krupnick et al., 
1997b), it would be expected that internalisation of the ARs under investigation 
would be inhibited if they required arrestin proteins. As was seen in figures 4.21 and 
4.22, this mutant arrestin failed to inhibit both AR and TRHR internalisation. This is 
in contrast to Vrecl et al. (1998) who showed inhibition of GnRH and TRH receptor 
internalisation in the presence of arr2[319-418]. From data obtained from Western 
blotting, the maximum concentration detected in our system was O.Sjig/well and was 
therefore used in subsequent confocal microscopy experiments. One possibility 
could be that the concentration of arr2[319-418] transiently expressed in the cells 
was insufficient to overcome the action of endogenous arrestin so that no inhibition 
of internalisation was observed. It was noted by Krupnick et al. (1997a) that over 
expression of arr2[319-418] was shown to display a constitutively punctate 
appearance, indicating binding to clathrin, which was also observed in our system. 
Having shown no distinction between the effects of WT and mutant arrestin, the 
possibility that confocal microscopy may not be sensitive enough to detect subtle 
differences, such as a small decrease in receptor internalisation, becomes apparent. 
One possible way to detect inhibition in sequestration brought about by the presence 
of arr2[319-418] could be to express increasing concentrations of arr2[319-418] in 
cells stably transfected with A3 ARs. Biotin-labelling and immunoprécipitation 
would detect loss of cell surface receptors upon agonist stimulation. This can be 
supported by the fact that mutant GRK2 (GRK2[BK-CT]) was seen to inhibit AR 
phosphorylation in a concentration-dependent manner on Western blots but was not 
seen to have an effect on internalisation when observed confocally. It is also known
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that HEK 293 cells have a higher endogenous level of arrestin than, for example, 
COS cells. HEK 293 cells may require a higher concentration of mutant arrestin to 
inhibit the system (Ferguson et al., 1996 and Zhang et al., 1996) therefore another 
possibility would be to carry out this analysis in another cell type such as COS.
An essential step in many vesicle trafficking pathways is the release or 
budding of the vesicles from membranes. Substantial evidence suggests that 
dynamin oligomerisation around the necks of endocytosing vesicles and subsequent 
dynamin-catalysed GTP hydrolysis is responsible for membrane fission (Takei et al., 
1999; Sweitzer and Hinshaw, 1998). Previous studies have indicated that expression 
of this mutant in HEK 293 cells stably transfected with 8 -opioid receptor can inhibit 
agonist-induced internalisation by clathrin coated pits (Herskovits et al., 1993; van 
der Bliek et al., 1993 and Chu et al., 1997). In contrast to this, when co-expressed 
transiently with VSV-TRHR-GFP (not shown) or A3AR-GFP, myc-Dyn[K44E] was 
not seen to inhibit agonist-mediated internalisation of either receptor (Fig. 4.24). 
This phenomenon could again be due to an insufficient level of myc-Dyn[K44E] 
being expressed in the cells, but it could also be possible that agonist-activated 
receptors are internalising via a different pathway when their primary route of 
internalisation is disrupted.
The clathrin-mediated pathway of internalisation did not appear to be 
inhibited by the use of dominant-negative or truncated mutants of proteins shown 
previously to be involved in clathrin-coated pit internalisation (Figs. 4.19, 4.21 -  
4.23). Following from these data, a less subtle approach to inhibition of 
internalisation was taken. Daukas and Zigmond (1985) first showed that exposure of 
leukocytes to medium containing 0.4M sucrose caused rapid and reversible inhibition 
of receptor-mediated internalisation, suggesting that coated-pit function could be 
inhibited by hypertonicity. This effect has been shown for other receptor types 
including LDLR (Heuser and Anderson, 1989) and TRFIR (Drmota et al., 1998). As 
such, there was a possibility that sucrose could also inhibit the AR system as WT and 
mutant A3ARS had previously been shown to internalise to endosomes along with 
receptors such as Tfn which are known to internalise via clathrin coated vesicles 
(Figs. 4.2, 4.4 and 4.5). Sucrose inhibits the formation of clathrin pits by disrupting 
the interaction of clathrin triskelions. Control cells expressing only Alexa-Tfn 
showed inhibition of internalisation and recycling in the presence of 0.4 M sucrose 
(Fig. 4.27). CHO cells stably transfected with WT A3AR-GFP (Fig. 4.28) also
151
showed an inhibition in internalisation in the presence of sucrose, suggesting that this 
receptor did in fact use the CCV pathway for sequestration upon agonist activation.
One other possibility is the involvement of other vesicular pathways that 
could be employed by the A3AR upon agonist activation. One such pathway 
invloves the interaction of the activated receptors with caveolin. As stated before, 
caveolae are small vesicles known to be involved in the endocytosis of many 
different molecules. However, dual imaging of A3AR-GFP and endogenous caveolin 
by confocal microscopy did not show an interaction of these two proteins either 
before or after agonist stimulation suggesting that caveolin plays no role in AR 
sequestration (Fig. 4.29). Recent work by Okamoto et al. (1998) has determined a 
caveolin binding motif that is present in most caveolae-associated proteins (Couet et 
al. 1997) such as receptors, Ga subunits and kinase domains of many protein kinases. 
There is no comparable site within the A3AR, supporting the lack of interaction 
between the receptor and caveolin.
These data alone are inconclusive concerning the involvement of CCVs in 
AR internalisation, however, when taken together, these data collected thus far 
suggests that agonist-mediated AR sequestration is an arrestin-independent but 
clathrin-dependent mechanism.
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Chapter 5
Study of Agonist-mediated A3AR Down-Regulation
5.1 Introduction
Agonist stimulation leads to the desensitisation of GPCR function by three 
temporally distinct mechanisms: phosphorylation, internalisation and down- 
regulation (Gagnon et al., 1998). Down-regulation is defined as an overall decrease 
in receptor number in response to prolonged receptor stimulation, and can occur as a 
consequence of either increased lysosomal degradation of pre-existing receptors 
and/or reduced mRNA and receptor protein synthesis (Bouvier et al., 1989).
As can be seen in Fig. 5.1, four main pathways determine the intracellular 
distribution of GPCRs. Upon synthesis, new receptors are delivered from the Golgi 
complex to the cell surface where, in the absence of agonist, there is a slow rate of 
endocytosis from the membrane into endosomes. Agonist stimulation dramatically 
increases the rate of receptor internalisation. Upon accumulation in the endosomes, 
receptors such as the p2AdR become dissociated from their ligand, dephosphorylated 
and recycled back to the plasma membrane for another round of agonist stimulation 
(Trejo and Coughlin, 1999). Following sustained agonist exposure, some receptors 
can be routed to lysosomes where they are degraded. Trafficking of GPCRs from 
endosomes to lysosomes leading to down-regulation has been described for several 
GPCRs, including those for thrombin (protease-activated receptor, PARI) (Hein et 
al., 1994), thyrotropin (Petrou and Tashjian, 1995) and cholecystokinin (Tarasova et 
al., 1997).
The aim of the following experiments was to assess the consequences of 
chronic treatment of AsARs with agonist to determine whether or not this receptor 
follows the down-regulation pathway cited above.
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5.2 Results
Firstly, to determine if prolonged agonist treatment induced down-regulation 
of the A3AR, CHO cells stably expressing HA-A3ARS were seeded into 6 -well plates 
and treated with or without agonist over a 24 hour period. Solubilised cell extracts 
were analysed by immunoblotting with an anti-HA-specific antibody as described in 
the Methods. In the presence of lOpM NECA, HA-A3AR protein levels were 
reduced by 90 ± 2% compared to non-stimulated controls (p<0.05) indicating a 
down-regulation of the total number of cellular receptors present in the cells (Fig.
5.2). To assess any effect of the GFP tag on receptor down-regulation, the same 
experiment was carried out using A3AR-GFP expressing CHO cells in which they 
were treated in the absence or presence of IpM (R)-PIA over a 24 hour period. Cell 
extracts were analysed by immunoblotting using an anti-GFP-specific antibody as 
previously described. Compared to non-stimulated receptors, the protein levels of 
agonist treated A3AR-GFP expressing cells was reduced by 64 ± 11% (p<0.05; Fig.
5.3). Although less of the GFP-tagged receptor was down-regulated overall, both 
sets of data showed a significant difference in the levels of receptor protein in the 
absence and presence of agonist. GFP-tagged constructs were used in subsequent 
experiments for two reasons. Firstly, the antibody against GFP bound with higher 
affinity and greater sensitivity than the HA-specific antibody, thus requiring less 
protein per assay. Secondly, it was not possible to assay receptor down-regulation 
via ligand binding as receptor-ligand interactions are relatively unstable therefore we 
would not be detecting receptor down-regulation, more receptor-ligand uncoupling.
Having shown the A3AR-GFP to be down-regulated in the continued 
presence of agonist over 24 hours, we explored the effects of increasing agonist 
concentration on receptor down-regulation. A3AR-GFP expressing CHO cells were 
seeded into 6 -well plates and treated with agonist at the concentrations indicated 
(Fig. 5.4). Quantitation of the blots revealed maximal receptor down-regulation ( 8 6  
± 5%, p<0.05) to be obtained at approximately 0.5pM. This gave an IC50 value for 
A3AR-GFP down-regulation in the range of 0.05 to 0.5pM. When treated with low 
nanomolar concentrations of agonist (5nM), it was observed that there was a small, 
reproducible yet non-significant increase in the total amount of A3AR-GFP protein 
detected in the cells (p>0.05, N.S.). A similar phenomenon had been observed 
previously when investigating the effect of increasing agonist concentration on
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receptor internalisation (Chapter 3). The effect of prolonged agonist exposure on 
A3AR-GFP was further investigated by exploring the time-course of this down- 
regulation over 24 hours. CHO cells expressing A3AR-GFP were plated onto 6  well 
plates as described previously and left to recover overnight. The following day, cells 
were treated with or without agonist at the time points indicated and solubilised cell 
extracts analysed by immunoblotting as before. The greatest loss of receptor was 
detected between 4-12 hours of agonist exposure with a for internalisation 
occurring at approximately SVi hours (Fig. 5.5). Maximal down-regulation was 
obtained by 12 hours of agonist exposure (87 ± 4%, p<0.05). Further time-course 
experiments narrowed this window to between 8-12 hours (Fig. 5.6).
Having detected a significant loss of overall A3AR-GFP number in 
chronically agonist treated cells, we attempted to visualise this phenomenon in intact 
cells by confocal microscopy. A3AR-GFP expressing cells were plated onto 
coverslips as described previously and treated in the presence or absence of IpM 
(R)-PIA over a 24 hour period. Cells were then fixed and their subcellular 
distribution visualised as described in the Methods. Consistent with immunoblotting 
data, computational analysis that quantitatively measured the total fluorescence in 
selected areas containing multiple cells, confirmed that treated cells compared to 
untreated did in fact show a significant level of down-regulation (Fig. 5.7). This 
reduction in receptor levels was calculated to be 46 ± 8 % (p<0.05) compared to 
untreated controls.
Once internalised, many membrane receptors and transporters including ETb 
(Abe et al., 2000) and human dopamine transporter (hDAT; Daniels and Amara, 
1999) transit through the endosomal/lysosomal pathway and are ultimately degraded 
(Chpt. 2, section 1.4.3a). Having shown that A3AR-GFP was down-regulated in 
response to agonist, the next step was to try to characterise the degradation pathway 
utilised. Thus, CHO cells stably expressing A3AR-GFP were seeded onto coverslips 
and pre-incubated for 30 minutes with LysoTracker^wRed, a fluorescently labelled 
acidotropic probe which specifically labels acidic lysosomes (Anderson and Orci, 
1988). LysoTracker was removed, the cells washed once and subsequently treated in 
the presence or absence of IpM (R)-PIA over 24 hours. Cells were then fixed and 
visualised as described in the Methods. Confocal microscopy revealed A3AR-GFP 
to be present predominantly at the plasma membrane prior to agonist treatment, with
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LysoTrackeri^Red labelling distinct spots within the cytoplasm (Fig. 5.8, 0 minutes, 
merge). Following a 24 hour incubation with IpM  (R)-PIA, A3AR-GFP had 
translocated from the plasma membrane to spots within the cytoplasm that were 
distinct from those vesicles labelled with LysoTracker’''^  (Fig. 5.8, 24hrs, merge), 
signifying no accumulation of A3AR-GFP with lysosomes at this time point. 
Immunoblotting experiments showed agonist-induced down-regulation of A3AR- 
GFP between 8-12 hours. Consequently the time-course of agonist treatment in the 
presence of LysoTracker^"^ was reduced to a maximum of 16 hours. Cells were 
treated as described previously and visualised by confocal microscopy. In the 
absence of agonist treatment, A3AR-GFP was observed at the membrane with 
distinct lysosomal staining within the cytoplasm (Fig. 5.9, 0 minutes, merge). 
Agonist treatment over 16 hours failed to show co-localisation of A3AR-GFP with 
lysosomes (Fig. 5.9, time points, merge).
Given the apparent lack of interaction between receptors and lysosomes, we 
investigated the possibility that another pathway for down-regulation was being 
utilised. The ubiquitin system of protein degradation controls the abundance of 
many critical regulatory proteins, membrane receptors, transporters and channels 
(Rotin et al., 2000). Protein degradation by the ubiquitin system involves two 
distinct and successive steps: 1) covalent attachment of a 76 amino acid polypeptide, 
ubiquitin, or a multi-ubiquitin chain to the end of the target protein and 2 ) 
degradation of the tagged protein by the 26S proteosome (Ciechanover, 1998). The 
proteosome is an essential component of the ATP-dependent proteolytic pathway in 
eukaryotic cells (Coux et al., 1996). The 26S proteosome (2000 kDa) is composed of 
a main core protease-catalytic complex (20S) flanked on both sides by 19S 
regulatory complexes composed of multiple ATPases. Together, this complex 
recognises specific ubiquitinated proteins and targets them for degradation. L%iquitin 
activating enzyme (El) catalyses the activation of ubiquitin in an ATP-dependent 
reaction by formation of a high-energy thiolester intermediate with ubiquitin 
involving an internal Cys residue. The activated ubiquitin is then transferred to a 
Cys residue of ubiquitin conjugating or E2 enzyme, generating another thiolester 
intermediate. In most cases, an E2 transfers ubiquitin to several substrate-specific E3 
enzymes. E3 or ubiquitin-protein ligase enzymes link ubiquitin by its C-terminus to 
an E-amino group of the substrate protein’s Lys residues or with a polyubiquitin
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chain already anchored to it. Formation of a substrate-E3 complex and synthesis of a 
substrate-anchored polyubiquitin chain causes binding of the polyubiquitinated 
substrate to the ubiquitin receptor subunit present in the 19S complex of the 26S 
proteosome. The protein is then degraded into short polypeptides by the 20S 
complex and the ubiquitin is recycled (Ciechanover, 1998; Hershko and 
Chiechanover, 1998).
To investigate any interaction between the A3AR and down-regulation via the 
ubiquitin pathway, A3AR-GFP~expressing CHO cells were seeded into 6 -well plates 
and subjected to a 30 minute incubation with proteosomal (MG-132; lOpM) or 
lysosomal (chloroquine; 45pM and NH4CI; 15mM) inhibitors in the presence of 
ADA. Cells were then treated in the absence or presence of IpM  (R)-PIA for 24 
hours in the continued presence of the inhibitors and ADA. Following agonist 
treatment, the cells were solubilised and receptor levels analysed by immunoblotting 
with anti-GFP antibody as previously described. The blots obtained showed that (R)- 
PIA-mediated down-regulation of A3AR-GFP was reduced to 6  ± 5% by MG-132 
and 19 ± 9% by chloroquine (Fig. 5.10). Treatment with NH4CI did not appear to 
inhibit down-regulation as the extent of receptor down-regulation was not different 
from that of cells treated only with ADA and agonist (59 ± 11% vs 57 ± 13% 
respectively; p>0.05, N.S.). The differences of inhibition observed between MG-132 
and chloroquine treated cells were found to be statistically insignificant ( 6  ± 5% vs 
19 ± 9%; p>0.05, N.S.), suggesting that MG-132 and chloroquine inhibit agonist- 
mediated down-regulation equally.
Down-regulation is defined as a net loss of receptor protein following agonist 
stimulation. This suggests that recovery from down-regulation requires new protein 
synthesis (Doss et al., 1981). Newly synthesised receptor proceeds from the ER to 
the Golgi apparatus from where it is transported to the plasma membrane. In an 
attempt to detect synthesis of new receptor following agonist-mediated down- 
regulation, A3AR-GFP expressing cells were plated onto coverslips and left to 
recover overnight. The following day, the cells were treated with 1 pM (R)-PIA for a 
24 hour period. Cells were then fixed, solubilised and stained using Alexa^ "^^ - 
concanavalin A, a lectin that binds to a-mannopyranosyl and a-glucopyranosyl 
residues in the ER, or a polyclonal antibody against GM-130, a 130kDa matrix 
protein that has an immunogenic C-terminal that interacts with the Golgi membranes.
157
Cells labelled with anti-GM-130 were subsequently labelled with Alexa^ "^ -^ 
conjugated anti-mouse secondary antibody as described in the Methods to allow 
visualisation via confocal microscopy. The initial images obtained did not show any 
co-localisation between A3AR-GFP and either ER (Fig. 5.11) or Golgi (Fig. 5.12). 
The possibility that receptor synthesis was taking place only after the signal to down- 
regulate had been removed was investigated by plating A3AR-GFP-expressing CHO 
onto coverslips and treating in the presence or absence of IpM  (R)-PIA over a 24 
hour period. The following day, the medium containing agonist was replaced with 
fresh medium for a time course ranging from 30 minutes to 3 hours. Cells were 
fixed, solubilised and fluorescently labelled as previously described. From the 
preliminary images obtained, it was not possible to detect co-localisation of the GFP- 
tagged A3AR with the ER over the time course investigated. It was observed that 
green fluorescence was located around the nucleus at approximately Ihr 30 minutes 
following agonist removal (Fig. 5.13). Comparison with the cells stained for Golgi, 
the green fluorescence was observed in the nuclear area along with the red Golgi 
marker at the 1 hour time-point (Fig. 5.14). These two stains were seen to overlap 
and give yellow staining in the images taken from the 1 - 1 . 5  hour time points, 
suggesting that new receptor was being synthesised.
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Figure 5.1 Schematic representation of the pathways
determining GPCR subcellular distribution
Newly synthesised receptors are subject to trafficking from the endoplasmic 
reticulum to the Golgi apparatus from where they are targeted to the plasma 
membrane in preparation for agonist activation. Upon binding of agonist, many 
GPCRs undergo desensitisation and subsequent sequestration into clathrin coated 
vesicles. Once internalised, the receptors can be dephosphorylated and recycled to 
the plasma membrane for another round of agonist activation or targeted for 
proteolytic degradation.
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Figure 5.2 Agonist-mediated down-regulation of HA-A3AR
expressed in CHO cells
CHO cells stably expressing HA-A3AR were treated in the presence or absence of 
lOpM NECA over 24 hours. Cells were solubilised and the resultant protein 
separated by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised 
by incubation with an anti-HA-specific antibody followed by HRP-conjugated anti­
mouse secondary antibody. Blots were quantified by densitometric scanning and 
values represent mean ± S.E. for three experiments. The total cellular level of 
receptor in the absence of agonist is set at 1 0 0 %.
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Figure 5.3 Agonist-mediated down-regulation of A3AR-GFP
expressed in CHO cells
CHO cells stably expressing A3AR-GFP were treated in the presence or absence of 
IpM (R)-PIA over 24 hours. Cells were solubilised and the resultant protein 
separated by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised 
by incubation with an anti-GFP-specific antibody followed by HRP-conjugated anti­
sheep secondary antibody. Blots were quantified by densitometric scanning and 
values represent mean ± S.E. for three experiments. The total cellular level of 
receptor in the absence of agonist is set at 1 0 0 %,
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Figure 5.4 Effect of increasing agonist concentration on
A3AR-GFP down-regulation
A3 AR-GFP expressing CHO cells were incubated with (R)-PIA at the concentrations 
indicated for 24 hours at 37°C. Cells were then solubilised and separated by SDS- 
PAGE before transfer to nitrocellulose. Visualisation was by incubation with anti- 
GFP-specific antibody followed by HRP-conjugated anti sheep secondary antibody. 
Blots obtained fiom tluee experiments were quantitated by densitometric scanning. 
The levels of cell-surface receptors in untreated cells were set at 100% and those 
treated only with agonist at 0%. The total levels of receptor in the agonist treated 
samples were normalised with respect to these limits. The figures are representative 
of tliree experiments that produced similar results.
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Figure 5.5 Time-course of agonist-mediated A3AR-GFP
down-regulation
CHO cells stably expressing A3 AR-GFP were treated in the presence or absence of 
1 pM (R)-PIA for the times indicated. Cells were solubilised and the resultant protein 
separated by SDS-PAGE. Proteins were transferred to nitrocellulose and visualised 
by incubation with an anti-GFP-specific antibody as described previously. Blots were 
quantified by densitometric scanning and values represent mean ± S.E. for three 
experiments. The total cellular level of receptor in the absence of agonist is set at 
100%.
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Fig. 5.6 Time-course of agonist-mediated A3AR-GFP
down-regulation
A3AR-GFP expressing CHO cells were treated with or without IpM (R)-PIA for the 
times indicated. Cells were then solubilised and separated by SDS-PAGE as 
previously described before transfer to nitrocellulose. Visualisation was by 
incubation with an anti-GFP-speeific antibody followed by HRP-conjugated anti­
sheep secondary antibody. Typical data is shown hom one of three experiments.
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Fig. 5.7 Confocal microscopic analysis of (R)-PIA-
mediated A3AR-GFP down-regulation
CHO ceils stably expressing A3AR-GFP were plated onto coverslips and treated with 
or without IpM (R)-PIA over 24 hours. Cells were then fixed and visualised by 
confocal microscopy as described in the Methods. The images represent of one of 
tliree experiments showing identical results.
The total levels of grey in each image were calculated using MetaMorph Imaging 
software. The total cellular level of receptor in the absence of agonist is set at 100%. 
Values represent mean ± S.E. for three experiments showing comparable results.
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Fig. 5.8 Confocal microscopic analysis of A3AR-GFP and
lysosomal cellular distribution following agonist 
stimulation
CHO cells stably expressing A3AR-GFP were plated onto coverslips and labelled 
with LysoTracker'''^Red for 30 minutes prior to treatment with or without IpM  (R)- 
PIA over a 24 hour period. Cells were fixed and visualised by confocal microscopy 
as described in the Methods. Agonist stimulation can be seen to promote the 
internalisation of A3AR-GFP to spots within the cytoplasm distinct from those 
labelled with LysoTracker. Images shown represent results from three experiments 
showing similar results.
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Fig. 5.9 Confocal microscopic analysis of A3AR-GFP and
lysosomal cellular distribution following agonist
stimulation over 16 hours
CHO cells stably expressing A3AR-GFP were plated onto coverslips and labelled 
with LysoTracker^'^R.ed for 30 minutes prior to treatment with or without IpM  (R)- 
PIA over a 16 hour period. Cells were fixed and visualised by confocal microscopy 
as described in the methods. Agonist stimulation can be seen to promote the 
internalisation of A3AR-GFP to spots within the cytoplasm distinct from those 
labelled with LysoTracker.
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Fig. 5.10 Effects of inhibitors of proteosomal and lysosomal
degradation on A3AR-GFP down-regulation
CHO cells stably expressing A3AR-GFP were treated with or without 1 pM (R)-PIA 
in the presence of either proteosomal (MG-132) or lysosomal (chloroquine and 
NH4CI) inliibitors and ADA over a 24 hour period. Cells were solubilised and the 
resultant protein separated by SDS-PAGE. Proteins were transferred to 
nitrocellulose and visualised by incubation of the membrane with GFP-specific 
antibody followed by HRP-conjugated anti-sheep secondary antibody. Blots were 
quantified by densitometric scanning and values represent mean ± S.E. for three 
experiments. The level of receptor in the absence of agonist is set at 100%.
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Fig. 5.11 Confocal microscopic anlaysis of A3 AR-GFP
cellular distribution in the presence of Alexa^ *^ -
concanavalin A
A3AR-GFP expressing CHO cells were plated onto coverslips and treated with or 
without IpM (R)-PIA over a 24 hour period. Cells were then fixed, solubilised and 
the endoplasmic reticulum stained using Alexa^^"^-conjugated concanavalinA. 
Visualisation of the cells by eonfocal microscopy showed no overlay of A3AR-GFP 
with the ER following agonist stimulation. Shown opposite are representative 
images fi'om tliree experiments showing the same results.
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Fig. 5.12 Confocal microscopic anlaysis of A3 AR-GFP
cellular distribution in the presence of the Golgi 
marker GM-130
A3AR-GFP expressing CHO cells were plated onto coverslips and treated with or 
without 1 pM (R)-PIA over a 24 hour period. Cells were then fixed, solubilised and 
the Golgi apparatus stained using anti-GM-130 antibody followed by Alexa^ "^ -^ 
conjugated anti-mouse secondary antibody. Visualisation of the cells by confocal 
microscopy showed no overlay of A3AR-GFP with the Golgi following agonist 
stimulation. The images are representative of three experiments showing the same 
results.
170

Fig. 5.13 Time course of A3 AR-GFP resynthesis from the
ER following 24 hour agonist treatment and 
removal over 3 hours
A3AR-GFP expressing CHO eells were plated onto coverslips and treated with or 
without agonist over 24 hours. The following day, medium containing agonist was 
removed over a 3 hour period and replaced with fresh medium. The cells were then 
fixed and stained for ER using Alexa^^"^-conjugated concanavalin A as described in 
the Methods. Removal of agonist led to redistribution of A3AR-GFP although no 
colocalisation was observed with the ER stain.
Shown opposite are representative examples of confocal microscopic images 
obtained from two experiments that showed similar results.
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Fig. 5.14 Time course of A3AR-GFP resynthesis from the
Golgi apparatus following 24 hour agonist 
treatment and removal over 3 hours
A3AR-GFP expressing CHO cells were plated onto coverslips and treated with or 
without agonist over 24 hours. The following day, medium eontaining agonist was 
removed over a 3 hour period and replaced with fresh medium. The cells were then 
fixed and stained for Golgi using GM-130 followed by Alexa^^"*-conjugated anti­
mouse secondary antibody as described in the Methods. Colocalisation of A3 AR- 
GFP with the Golgi was observed between 1-1.5 hours following agonist removal. 
Shown opposite are representative examples of confocal microscopic images 
obtained fr om two experiments that showed similar results.
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5.3 Discussion
Down-regulation is defined as a reduction in the number of ligand binding 
sites detected in a total membrane fraction, which is generally induced by repeated or 
prolonged activation of receptors (Tsao and von Zastrow, 2000a). GPCRs regulate 
their physiological effects by interaction with heterotrimeric G-proteins, the duration 
of which is controlled by multiple processes including receptor desensitisation, 
sequestration and down-regulation. So far (Chpts. 3 and 4), we have shown that 
AsARs undergo desensitisation via phosphorylation by GRKs, and subsequent 
sequestration via an endosomal pathway in response to short-term agonist exposure. 
In an attempt to complete the characterisation of the A3AR, investigation into 
receptor down-regulation was required.
A chronic agonist treatment (24 hours, Figs. 5.2 and 5.3) determined that the 
A3AR undergoes down-regulation and that the level of degradation is elevated in 
response to increasing agonist eoncentration (Fig.5.4). It was also concluded that 
this degradation of A3AR became more apparent between 8-12 hours following 
agonist treatment (Fig. 5.6). One question to be answered is how then are A3ARS 
down-regulated? Debate still surrounds the process of GPCR down-regulation. 
Over-expression of dominant-negative arrestins that inhibit sequestration has been 
shown to reduce the rate of PzAdR down-regulation (Gagnon et al., 1998). Mutation 
studies have also identified receptor mutants of the (3 2AdR that do not sequester, but 
down-regulate more efficiently (Barak et al., 1994) as well as receptors that sequester 
normally but do not down-regulate (Campbell et al., 1991). Previous studies of the 
V2 vasopressin receptor have also demonstrated that this receptor undergoes ligand- 
induced endoproteolytic cleavage by a plasma membrane-associated metalloprotease 
(Kojro and Fahrenholz, 1995). Many GPCRs undergo ligand-induced endocytosis 
via clathrin-coated pits, a process mediated by interaction of the receptors with 
arrestin molecules (Goodman et al., 1998). Distinct GPCRs are significantly 
different in their abilities to undergo endocytosis with evidence for receptor-specific 
and cell-type-specific differences in the precise mechanisms used (Goodman et al., 
1998; Roettger, et al., 1995; Vickery and von Zastrow, 1999). However, such 
diversity in the early stages of the endocytie pathway may not control the targeting of 
receptors to lysosomes as D] and D2 receptors have been shown to exhibit similar 
rates of proteolytic degradation despite entering the eells via distinctly different
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mechanisms (Vickery and von Zastrow, 1999). How then is sorting and targeting for 
down-regulation initiated and regulated?
Comparison of two structurally distinct GPCRs ((3 2 Ad and 5-opioid) by Tsao 
and von Zastrow (2000b) concluded that the opioid receptor was held in a different 
population of vesicles to the p2 receptor upon sequestration and that this subset of 
endocytie vesicles was distinct from those found in the conserved recycling pathway 
utilised by Tfn. They also showed that p2 receptors could be recycled to the 
membrane upon removal of agonist, whereas the 5-opioid receptors were retained 
within the vesicles (< 50% returned). This same phenomenon has been shown with 
the (C-A)AgAR (Chpt. 3) suggesting that the ability of AgARs to be retained 
intracellularly, and possibly targeted for degradation following agonist removal is 
dependent upon the integrity of its C-terminal domain. In addition, A3AR-GFP was 
seen to be retained in vesicles distinct from those labelled with lysosomal marker, 
possibly indicating that the pathway of down-regulation of the A3ARS does not 
involve transfer to lysosomes (Figs. 5.8 and 5.9).
The concept of ARs being degraded by a pathway other than lysosomes was 
investigated by treating A3AR-GFP-expressing cells with agonist in the presence of 
proteosomal and lysosomal inhibitors. Statistical analysis of the blots obtained 
revealed that the inhibition of receptor down-regulation in the presence of MG-132 
and chloroquine was not significantly different from each other (Fig. 5.10). If down- 
regulation were taking place via both proteosomal and lysosomal pathways, it would 
then be expected that the second lysosomal inhibitor, NH4CI, would have a similar 
effect to that observed with chloroquine. However, this was not the case as NH4CI 
failed to inhibit down-regulation to any extent above only agonist treated cells. In 
contrast to MG-132, which is a specific proteosomal inhibitor, chloroquine and 
NH4CI have a very broad method of action. Both of these inhibitors produce their 
effects by raising the pH within the lysosomes causing a neutralising effect. One 
possible explanation for the divergent effects of NH4CI and chloroquine is that 
chloroquine may interfere with lysosomal and proteosomal degradation. Evidence to 
support the lack of specificity or general mechanism of action of chloroquine could 
be taken from its use to treat a wide range of medical conditions including malaria, 
leprosy and rheumatoid arthritis (Barduagni et ah, 1999; Razaek and Zahra, 1981; 
Fox, 1993). If this suggestion holds true, this could be one explanation as to why no
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colocalisation of A3AR-GFP with Alexa-labelled lysosomes was observed. One way 
of investigating this further would be to co-transfect non-receptor expressing cells 
with A3AR-GFP and an HA-tagged ubiquitin protein and agonist treat in the absence 
and presence of MG-132. Any interaction of these two proteins, receptor and 
ubiquitin, could be detected by immunoblotting. Further analysis would involve 
more specific ubiquitination experiments on the A3AR.
The colocalisation of A3AR-GFP with Golgi marker (GM-130) following 
agonist removal fi'om chronically treated cells suggests that new receptor is being 
synthesised through the Golgi apparatus back to the plasma membrane (Fig. 5.14). 
The possibility that receptor resynthesis is taking place within 1 hour of agonist 
removal could explain why no colocalisation was seen between A3AR-GFP and the 
ER stain (Alexa^^^^-concanavalin A, Fig. 5.13). Further confocal analysis over 
shorter periods of time is required to allow any further conclusions to be drawn fi'om 
these initial data.
In this chapter, we have shown that AsARs are down-regulated in response to 
prolonged agonist exposure and have presented initial images suggesting that 
removal of this stimulus causes new or recycled receptor to be transported back to 
the plasma membrane. However, it is currently impossible to determine whether the 
down-regulation pathway utilised by AsARs is similar to those employed by other 
GPCRs including psAdR, PARI and ETgR (Kallal et al., 1998; Trejo and Coughlin, 
1999; Oksche et al., 2000).
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Chapter 6
Conclusions and Perspectives
The results of each individual chapter have been discussed at length 
elsewhere. Therefore this final discussion aims to combine the conclusions reached 
and consider possible therapeutic strategies that could be developed from the data 
obtained.
In chapter 3 it was shown that A3AR phosphorylation and sequestration were 
initiated by the presence of agonist and that these phenomena were controlled 
primarily by the integrity of the C-terminal region. In contrast to the A3AR, the 
AiAR did not undergo significant phosphorylation and was only seen to internalise 
after a prolonged period of agonist treatment. Work by Liang and Jacobson (1998) 
showed that Ai and A3ARS produced cardioprotective effects within isolated cardiac 
ventricular cells, determined by quantitation of the percentage of cells killed and the 
amount of creatine kinase released into the media following stimulated ischaemia. It 
was established that the Ai and A3ARS produced a cardioprotective effect both 
individually and in combination, with the effect of the A3AR being prolonged over 
that of A] ARs. The eardioprotective effects of each individual receptor were blocked 
by receptor-selective antagonists suggesting that the Ai and A3ARS convey their 
effects via distinct, and as yet undesignated pathways.
Both Ai and A3AR8 signal through G,- but produce very different effects. One 
reason for the effects of the Ai AR being so short-lived may be due to its inability to 
undergo phosphorylation and subsequently internalise following agonist activation. 
This lack of internalisation leaves the receptor at the membrane, possibly limiting its 
interaction with signalling molecules to those that are close to or membrane-bound 
e.g. AC and PLC. It has been suggested that GPCRs gain access to Ras-dependent 
signalling pathways by modulating the activity of receptor tryrosine kinases (RTKs) 
such as EGF and IGF-1 (Lin et al., 1998). This leads to the formation of a 
membrane-associated Ras activation complex that serves as a scaffold to recruit non­
receptor tyrosine kinases required for down-stream signalling. Such a mechanism 
may explain how the non-intemalising AiAR exerts its cardioprotective effects. In 
contrast, the A3AR is able to sequester into the cells, a process inhibited by 
dominant-negative forms of arrestin and dynamin. Treatment with these inhibitory 
molecules not only blocked receptor internalisation, but also had a marked effect on 
the MAPK signalling cascade (Daaka et al., 1998). It was found that signal 
transduction proceeded only as far as Raf activation, suggesting that the 
internalisation process is required for efficient phosphorylation of up-stream
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activators of MAPK. Some GPCRs, upon agonist activation, recruit arrestin 
molecules to the plasma membrane leading to a functional desensitisation of 
receptors by uncoupling them from the G protein. In the case of the P2AdR, this 
translocation of arrestin functions as an adapter protein that brings activated c-Src to 
the agonist-occupied receptor and targets both receptor and Src to clathrin-coated 
pits. Both Src binding and clathrin targeting are required for P%AdR activation of 
MAPK, suggesting that receptor internalisation is required to produce a ‘second 
wave’ of signal transduction (Luttrell et al., 1999).
From the data obtained in chapter 3, this may suggest that the prolonged 
cardioprotective effects of the A3AR are a consequence of its ability to undergo 
phosphorylation and internalisation. It may therefore be of advantage to prolong the 
activation of the AiARs during an ischaemic episode. To determine the requirement 
of phosphorylation in prolonged cardioprotection, cardiac cells could be transfected 
with either the loss of function (T-A)A3AR mutant or the gain of function AiCTSAR 
chimera and the protective effects measured as described by Liang and Jacobson 
(1998). Prolonging the activity of the AiARs could increase the protective effects of 
adenosine leading to a decrease in the size of the infarcted area with subsequent 
periods of ischaemic injury.
We have shown that mutation of the GRK phosphorylation sites in the A3AR 
renders the receptor resistant to agonist-mediated phosphorylation and internalisation 
and that A3AR internalisation kinetics can be conveyed to the non-phosphorylated 
A]AR purely by exchange of the C-terminal tails. Investigation into the ultimate 
effects of these mutations on down-stream signalling events was not examined. 
Further studies of these mutations may prove detrimental to the overall system of 
cardioprotection. It should be noted that the restoration of blood flow to ischaemic 
tissue although supplying oxygen and nutrients, initiates a cascade of inflammatory- 
like processes that leads to expression of critical adhesion molecules in endothelial 
cells. This process brings about release of oxidants and proteases that result in 
damage to or death of the coronary endothelium (Jordan et al., 1999).
As with many other GPCRs, A3ARS were shown to be desensitised in 
response to agonist exposure, with results from chapter 4 indicating A3AR 
sequestration to follow an arrestin independent/clathrin-dependent endosomal 
pathway. Using the mutants described in chapter 3, it was shown that the 
trafficking route utilised was not altered by mutation of the receptor’s predicted
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palmitoylation site and that the slow-intemalising AiAR could be driven through the 
same pathway as WT AsARs, again by exchange of the C-terminal tails. There is a 
possibility that the initial and ensuing duration of activation of these systems is a 
consequence of the receptor’s ability to internalise. Gene transfer of the A]CT3AR 
could alter internalisation kinetics of the AiAR. Although this may increase the 
duration of cardioprotection by AiAR activation, the consequent expression of 
AiCT3AR may dampen the initial AiAR response by decreasing the chances of 
adenosine binding to endogenous AiARs. Conversely, while expression of the (C- 
A)AsAR may increase onset of As-mediated cardioprotection, decreasing the period 
of time the activated receptor is present at the membrane may diminish G protein- 
mediated effects. We must therefore consider the advantages and disadvantages for 
applications of direct receptor mutation versus manipulation of existing signalling 
pathways with substrate-specific compounds.
Chapter 5 discussed the down-regulation of AsARs following prolonged 
exposure to agonist. We concluded that down-regulation occurred over an 8-12 hour 
period but from the data obtained, could not determine which system, lysosomal or 
proteosomal, was predominant. It was suggested that the C-terminal tail region 
directs targeting of receptors for down-regulation (Trejo and Coughlin, 1999). 
Down-regulation of GPCRs can occur as a consequence of either increased 
degradation of pre-existing receptors and/or reduced mRNA and receptor protein 
synthesis. This process is required in part for the regulation of GPCR signalling, it 
may be possible to manipulate it such that direct inhibition or activation alters the 
extent of down-regulation. This would have great impact on therapeutic strategies 
that could control the trigger that targets receptors for down-regulation thereby 
altering the extent to which receptors interact with ligands.
The A3AR is the newest receptor in the adenosine family yet its presence has 
already been implicated in several debilitating diseases. Activation of these 
receptors in many cases requires a high level of adenosine (pM), concentrations that 
are only produced under stress conditions suggesting specificity for activation of 
these receptors. The mutant receptors investigated in this work may not be useful 
directly as regulators of A3AR signalling, although having characterised the main 
regulatory functions for this specific AR, it may be possible to use this knowledge to 
build on the therapies already in place. Many positive therapeutic responses to 
adenosine have come from the inhibition of adenosine metabolism and degradation,
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strategies that are currently being used in the treatment of cardiac and brain 
ischaemia. Prolonging the action of adenosine by inhibiting its uptake and 
metabolism has been documented to reduce the size of infarcted tissue and aids in 
recovery of cardiac function (Van Belle et al, 1993). It has also been shown to have 
a neuroprotective effect in the ischaemic brain, although the effects in this situation 
are less well documented (Ogini et ah, 1997). In contrast, immune responses caused 
by the activation of ARs would not benefit from a prolonged presence of the 
causative agent. Therefore we must examine alternative therapies.
Our data have confirmed that the A3AR undergoes agonist-mediated 
phosphorylation, internalisation and down-regulation over distinct time courses. If 
we then examine the consequence of manipulating these processes either individually 
or in concert with the therapies already in use, we may be able to modify the 
activation of specific receptors to respond to the surrounding physiological 
conditions. One strategy would be to carry out gene transfer of mutated receptors to 
the affected areas. Cardioprotection and neuroprotection are enhanced via a 
prolonged exposure of ARs to agonist. Transfer of adenovirus expressing receptors 
such as (T-A)A3AR which is phosphorylation deficient, or treating with inhibitors of 
GRK-mediated phosphorylation (e.g. GRK2[BK-CT]) would inhibit receptor 
internalisation and extend the length of time that the receptor has to interact with its 
ligand therefore increasing its cardioprotective effects. Again the cardioprotective 
effects of these therapies could be determined by expressing the constructs in cardiac 
cells as described by Liang and Jacobson (1998). These strategies could also be 
coupled with ADA and adenosine kinase inhibitors to further lengthen the half-life of 
adenosine itself.
Allergic reactions consist of an initial response that triggers the degranulation 
of mast cells leading to the release of a range of chemicals that cause inflammation. 
This has grave consequences on the lungs where it causes constriction of the 
bronchiolar smooth muscle and in the heart where reperfusion after ischaemia can 
lead to inflammatory tissue damage. The principal site of action must therefore be 
inhibition of mast cell degranulation. Mast cells are found in most organs of the 
body, but it may be possible to administer AR antagonists to counteract the effects of 
increasing adenosine levels. Although only receptor-selective and not specific, 
antagonistic actions could be restricted to areas with increased adenosine levels. In 
the case of reperfusion injury, activation of A2aARs has been shown to reduce
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infarction size following ischaemia, therefore it may be of advantage to inhibit 
A2aAR sequestration and down-regulation as well as prolonging agonist activation 
via inhibitors of adenosine metabolism. The actions of A3ARS in the pathology of 
human disease are still, to a certain extent, undefined. The aim of these data was to 
determine how A3ARS are regulated and the possible implications for their 
manipulation in disease states. Although important in themselves, ARs interact with 
a variety of other systems to bring about their effects and any direct manipulations of 
these receptors may well produce both positive and negative consequences.
These data presented here have characterised only a small area of A3AR 
regulation but provide a foundation for subsequent investigations. Having 
constructed mutant Ai and A3ARS that show altered regulation compared to WT, it is 
essential that we determine any variation in their ability to initiate intracellular 
signalling such as the inhibition of AC and activation of MAPK. Due to the changes 
in cell shape during agonist treatment (chapter 3), it would also be of interest to 
investigate the interaction of these receptors with other small G-proteins involved in 
the control of the actin cytoskeleton. Activation of Rho could be examined in cells 
co-expressing WT or mutant ARs and Rho by using GST-fused C21 (aa7-l 13 of 
rhotekin). This construct, which binds only to activated Rho, may be used in a pull­
down assay to detect AR-mediated activation of Rho.
We failed to detect inhibition of receptor internalisation by the addition of 
dominant-negative forms of proteins involved in clathrin-mediated endocytosis 
although a decrease in receptor phosphorylation was detected in the presence of a 
mutant form of GRK2 (chapter 4). Further investigation of these mutants by means 
of immunoblotting and sensitive array scan technology using the GFP-tagged form of 
the WT A3 AR, may be able to detect any reduction or slowing of internalisation over 
time.
Down-regulation has been described for many GPCRs with the pathway 
utilised by the A3AR still undetermined (chapter 5). Further characterisation of this 
pathway requires control experiments using receptors whose pathway of down- 
regulation has already been determined e.g. ô-opioid receptor that down-regulates via 
a lysosomal pathway (Tsao and von Zastrow, 2000). A consequence of down- 
regulation is that synthesis of new receptor and subsequent trafficking to the plasma 
membrane is required. Preliminary data showed that this phenomenon of receptor 
trafficking could be detected in cells that had undergone down-regulation then
1 8 0
agonist removal over a controlled time period (chapter 5). In order to detect 
synthesis of new receptor, cells must be examined at earlier time-points, again in the 
presence of a positive control. Ideally, the data obtained so far and any future work 
should be carried out in a cell line that endogenously expresses the A3AR. Such cell 
lines have been cultured (RBL-2H3) and initial investigations are underway.
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Appendix 1
Sample calculation for Bj
Bmax = nM = 0.03407
Molarity = moles
V
/. moles = Molarity (M) x volume (L)
= (0.03407 X 10'^) X (250 x lO *^) 
= 8.5175 fmol
Actual protein conc. = 0.500
14 (dilution factor)
-  35.7ug/ml
0.15ml membranes added/tube = 0.15 x 35.7
= 5.355mg/tube
.5175fmol in 5.355mg protein = 8.5175
5.355
= 1.59 fmol/|rg [ = pmol/mg]
Appendix 2
Cheng-Prusoff Equation
Ki =  EC50
1 + TLigandl 
Kd
